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Abstract 
Introduction: The rise in emergency department admissions for chest pain necessitates a quicker 
and more specific test for the different acute coronary syndromes. For a non-ST elevated myocardial 
infarction (NSTEMI) diagnosis, the current Gold Standard requires at least one cTn (cTn) value above 
the 99th percentile of a reference population across 12h of serial testing. Current research suggests 
serum levels of monomeric C-reactive protein (mCRP) and ultra-high-sensitive cTn assays may rule 
out NSTEMI more rapidly. 
Aims: To develop a novel immunoassay for mCRP for use on clinical samples to assess its diagnostic 
accuracy for NSTEMI. The Singulex Clarity and the Abbott iSTAT point of care hs-cTnI assays were 
assessed against the standard laboratory assay from Roche® Diagnostics hs-cTnT assay for NSTEMI 
diagnosis using non-kinetic (0h, 3h and max values) and kinetic (Δabsolute, %Δbaseline and %Δmean) values 
and in combination with H-FABP and ECG ischaemia.  
Methods: A competitive immunoassay for mCRP was optimised, which became an ELISA with a 
commercial anti-CRP detection antibody. Diagnostic tests calculated the clinical sensitivity, 
specificity, positive predictive value and negative predictive value for non-kinetic and kinetic values 
with the aim of creating the highest clinical sensitivity possible for NSTEMI rule out. Patients were 
grouped into 3 risk groups and cut-offs were optimised for each group. Predictor composites of 0h 
cTn, cTn deltas, ECG ischaemia and H-FABP were used for NSTEMI diagnosis and prediction of 3 
different composite outcomes at 30 days. Cox regression assessed the assays’ and risk factors’ utility 
in 30-day MACE prediction. 
Results: The mCRP immunoassay was not sensitive enough for physiological mCRP concentrations 
(LoD 2 µg/ml) and the inter-assay imprecision was too great to be clinically useful. The Roche and 
Singulex assays showed 100% sensitivity and NPV for kinetic values in intermediate risk groups and 
predictor composites. The Singulex assay had 100% sensitivity for non-kinetic values also but the 
iSTAT assay did not perform well as a rule out diagnosis tool. Singulex Δabsolute and prior angina were 
independent predictors for 30-day MACE. 
Discussion: The mCRP immunoassay had problems because the antibody was not commercially 
produced, had to be used at high concentrations and therefore is not suitable for a competitive 
immunoassay. The Singulex assay could be used for early rule out but its variability could limit its 
clinical utility. The iSTAT assay is a useful tool for identifying high-risk patients quickly and all assays 
performed better when patients were split into risk groups by 0h cTn levels. Multi-faceted diagnostic 
tools are becoming more prominent for NSTEMI diagnosis and rule out. 
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1.1 Introduction 
With the number of people admitted to the emergency department (ED) in the UK 
increasing and many present with chest pain, there is a call to differentiate those in 
need of immediate attention and those who are not at significant risk of acute 
coronary syndrome (ACS). As many as 85% of patients who present to the ED do not 
suffer an acute myocardial infarction and are needlessly kept in the ED waiting for 
an acute myocardial infarction (AMI) exclusion or, perhaps worse, delaying 
diagnosis of another syndrome or disease. Currently, when a patient presents with 
chest pain an electrocardiogram (ECG) is taken immediately to confirm or role out 
an ST-elevation myocardial infarction (STEMI). However, absence of ST segment 
elevation is not sufficient to rule out ACS.  
In the case of a negative ECG, a blood test is used to assess the likelihood of a non-
STEMI (NSTEMI). The Gold Standard biomarker is currently cardiac troponin (cTn) to 
diagnose AMI (7, 8). The rise and fall in cTn is used as an indicator of AMI but is 
insufficiently sensitive to safely rule out AMI until 12 hours after presentation. An 
AMI is diagnosed if serum cardiac cTn concentration is above the 99th percentile in 
at least one of the measurements taken over the 6-12 hour hospital stay. However, 
this does not take into account conditions that cause a chronic rise in serum cTn 
such as heart failure and hypertrophic cardiomyopathy. Even new thinking of using 
an absolute or relative rise in cTn over a shorter period of time causes problems as 
non-ischaemic disease such as pericarditis and myocarditis cause an acute rise in 
cTn (9). This is because cTn is a marker of cardiac cell death instead of direct marker 
of an infarct. 
2 
 
Moreover, as cTn is a measure of an event that has already happened, its use as an 
ACS predictor has been limited thus far. The problem lies with the cause of cTn 
release, which is that it is only released due to cardiac necrosis. Another possible 
approach would be to measure markers that rise earlier such as those involved in 
vascular inflammation or plaque rupture, such as monomeric C-reactive protein 
(mCRP) and human fatty acid binding protein (h-FABP), and use them in 
combination with cTn. Their benefits have been noted by earlier studies but their 
use in conjunction with clinical risk stratification of an unselected group of patients 
have not. 
The development of ACS is the outcome of progressive atherosclerosis, which in 
itself is an inflammatory process. Instead of focusing on the outcome of a 
myocardial infarct, attention has now turned to markers that cause plaque rupture 
and therefore AMI. One such marker is C-reactive protein (CRP), which in a recent 
meta-analysis was shown be a predictor of long-term cardiovascular mortality 72 
hours post-event (10). CRP is a pentraxin consisting of five identical non-covalently 
linked subunits in its pentameric form, pCRP, but its monomeric form, mCRP, arises 
by pCRP dissociating on circulating microparticles (MPs) and activated platelets 
under flow (11). The isoforms have already been shown to rise in AMI and unstable 
angina pectoris (UAP). Due to the opposing roles pCRP and mCRP take part in 
vascular inflammation, a pCRP:mCRP ratio may have greater utility. 
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1.2 Atherosclerosis and its role in the development of ACS 
The primary cause of ACS is ischaemia at rest from a lack of adequate blood flow to 
the myocardium. Although there can be many causes of this ischaemia, such as 
acute coronary vasospasm, the vast majority of patients suffer with atherosclerosis-
related ACS such as STEMI (30%), NSTEMI (25%) and unstable angina (38%) (12). 
Atherosclerosis causes a thickening of the arteries and a change in cellular 
composition resulting from lipid accumulation, cell proliferation and transformation 
over a number of years (13). Normally a gradual process, ruptures cause a large and 
rapid transformation of the atheroma. The centre of the plaque has no or very 
restricted blood flow, which leads to the development of a necrotic core. Plaque 
rupture exposes the necrotic core to the blood that initiates the clotting cascade 
and a thrombus develops. Repair of plaques develops its size by enveloping the 
thrombus and inward remodelling of the artery into the lumen restricts blood flow, 
which is when symptoms begin to occur. If a thrombus is present in a coronary 
artery and large enough, ACS will develop, a medical emergency that requires 
immediate treatment to prevent further necrosis to the myocardium. 
1.2.1 Atherosclerosis as an inflammatory disease 
The initiation of atherosclerosis is not well understood. In the first instance, an 
inflammatory response is required to begin atherosclerosis and the association of 
low-density lipoprotein (LDL) to the vessel wall either initiates or propagates this 
response of the endothelium (14). This, as well as high sheer stress, causes 
endothelial activation and more LDL is allowed into the tunica intima of the 
affected site creating a burden on the vascular smooth muscle cells (vSMCs) in the 
tunica media, which causes the wall to become less compliant through oxLDL-
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mediated vSMC transformation (15). Along with the loss of function of the 
endothelium and cell transformation, the increased inflammatory profile of the 
area causes an increase in blood flow and cell number and leukocyte infiltration. A 
number of cardiovascular risk factors, such as hypertension, hyperlipidaemia, 
oxidative stress and diabetes, increase LOX-1 expression in the endothelial cells that 
further increases the LDL uptake (16). This process is upregulated by the binding of 
CRP to LOX-1, further increasing oxLDL uptake, a process that increases endothelial 
upregulation of CRP expression creating a strong local positive feedback loop (17). 
To compound this process, anti-atherogenic endothelial nitric oxide synthase 
(eNOS) and nitric oxide (NO), a powerful vasodilator, are downregulated by LDL, a 
decrease in sheer stress, cytokines and CRP. 
Although the decrease in sheer stress does not conform with the traditional 
cardiovascular risk factor of hypertension, the shape of an atheroma allows low 
sheer stress to occur downstream of the plaque with the endothelium upstream of 
the plaque experiencing high levels of sheer stress (18) as seen in figure 1.2.1.1. Its 
own remodelling initiating further plaque progression in different areas of the 
artery due to high sheer stress (19). However, the role of high sheer stress is 
debated and is considered now as possible cardioprotective except at sites of 
inflammation but oscillating shear stress could 
Figure 1.2.1.1 Diagram of 
shear stress changes around 
atheromas. The blood flow 
is restricted by the imposing 
atheroma increasing wall 
sheer stress experienced at  
and upstream of the 
atheroma. The re-expansion 
of the lumen downstream 
causes oscillatory shear 
stress (2). 
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downregulated PI16, an endothelial cell migration inhibitor (20). This increases the 
inflammatory profile of the atheroma further. 
The migration of endothelial cells is important for leukocyte infiltration through the 
endothelium and into the intima (21). As seen in figure 1.2.1.2, a product of 
endothelial dysfunction is the expression of leukocyte receptors P- and E-selectins, 
which has been found to be upregulated by the presence of leukocytes themselves 
along with endothelial-derived chemoattractants (22) that attract more leukocytes. 
The selectins cause a loose association between the endothelium and the L-selectin 
and PSGL on leukocytes, which begin to roll and slow along the apical surface of the 
endothelium. At this point, the leukocytes undergo a slight conformational change 
due to the rolling and become flatter, increasing their surface area. The increased 
blood flow prevents the shearing force from dragging leukocytes into the middle of 
the blood flow. Both these actions allow firmer adhesion to the endothelium and 
binding to vascular cell adhesion molecule (VCAM)-1 and intercellular adhesion 
molecule (ICAM)-1. Monocytes have specific receptors for binding such as CXCL1, 
Figure 1.2.1.2 Diagram of leukocyte infiltration through the vascular endothelium. Matrix 
metalloproteinases (MMPs) degrade the basement membrane and leukocytes can enter the 
tunica intima proper (2). 
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CXCL4, CXCL7 and CCL5. Transmigration is complete by the movement of leukocytes 
through the endothelium in areas where gap junctions have been weakened 
because of changes to VE-cadherin and dimerization of JAM-1 increases endothelial 
permeability (23). 
Once in the intima of the endothelium, the monocytes differentiate into 
macrophages that uptake LDL and release cytokines, as seen in figure 1.2.1.3. The 
migration of vSMC from the media to the intima is induced through the interleukin 
(IL)-6/interferon (IFN)-γ pathway. Here, the JAK/STAT pathway (24) and CD36 and 
TLR4-mediated oxLDL downregulation of contractile proteins initiates the vSMCs’ 
transition from a contractile to a reparatory phenotype (25) and TNF-α-promoted 
vSMC proliferation increases atheroma size further. PDGFs, FGFs and TGFs 
promotes extracellular matrix synthesis that includes collagen, which initiates the 
Figure 1.2.1.3 Diagram of monocyte infiltration into the vascular tunica intima and 
vSMC migration from the tunica media into the intima(1).  
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thrombin/thromboxane platelet aggregation pathway (26), leading to thrombosis 
and possible artery occlusion. 
If the resulting thrombosis is asymptomatic and no treatment occurs then the 
thrombosis is repaired and is added to the atheroma. This results in a stronger 
atheroma overall but is the cause of inward remodelling, which leads to stenosis. 
Even though stenosis reduces blood flow by narrowing the lumen, the thicker 
fibrous cap generated by multiple rupture-repair cycles protects the atheroma from 
further rupture. An unstable plaque has a thin fibrous cap, a large lipid-laden 
necrotic core with many macrophages and foam cells, and vasa-vasorum 
neovascularisation leading to intra-plaque haemorrhage (27, 28). Stable plaques 
have more stabilising smooth muscle cells, a thick fibrous cap and a smaller lipid 
core (figure 1.2.1.4). The differences between stable and unstable plaque 
conformation mean that even though stable plaques lower blood flow leading to 
stable angina, the rupture risk of unstable plaques leading to more unstable angina 
and 
AMI 
(16, 
29). 
 
 
 
    
Figure 1.2.1.4 Stable and unstable plaque conformation. 
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1.3 mCRP as a causative Biomarkers for ACS 
As mentioned above, in order to risk stratify patients into high- and low-risk groups 
attention has turned to factors that promote plaque destabilisation and possible 
rupture. The different biomarkers that have been identified target different parts of 
the atheroma cause its destabilisation, see figure 1.3.1. The dysfunctional 
endothelium causes an influx of monocytes and release inflammatory chemokines, 
cytokines and growth factors in the plaques as macrophages. Placental growth 
factor (PIGF) causes smooth muscle cells to migrate from the tunica media, into the 
intima and change from a protective, elastic phenotype to a collagen-producing cell 
(30).  Pregnancy-associated plasma protein A (PAPP-A) promotes degradation of the 
fibrous cap via IGF-1 signalling (31) and has been shown to be an ACS predictor 
independent from CRP (32).  Myeloperoxidase (MPO) appears to activate matrix 
Figure 1.3.1 Atheroma development from foam cell infiltration through to plaque rupture. 
Rupture is not an inevitability but the presence of these proteins could cause rupture. Their 
presence is increased by inflammation, increased blood pressure. Picture from (5) 
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metalloproteinases (MMPs) and impair MMP inhibitors (33, 34) which is deleterious 
for plaque stability as MMPs themselves promote extracellular matrix degradation 
(35) and it has been shown that an increase in MMP-9 is associated with future CV 
death (36). An increase in monocyte infiltration can cause instability and this is 
promoted by monocyte chemoattractant protein-1 (MCP-1), which has been shown 
to be increased in patients who have a higher risk of cardiac death but is not an 
independent predictor of coronary heart disease events (37). Recently, a small 
study showed that mCRP is elevated in AMI patient, but not angina patients (38), 
which means it might be of use as a clinical decision tool. 
 
1.3.1 CRP 
CRP is principally produced and released from the liver in response to infection, 
inflammation and tissue injury. The protein is formed of 5 identical subunits 
covalently bonded around a central pore. Higher serum CRP concentration has been 
attributed to a higher cardiovascular disease and myocardial infarction risk (39). 
Primarily synthesised in hepatocytes in response to IL-6 and IL-1, pCRP forms part of 
the innate immune system (6) and interacts with the classical complement pathway 
(4). Raised CRP was found to be the best indicator for future adverse cardiovascular 
events in healthy, asymptomatic individuals (6, 39, 40). It has also been shown to be 
released from damaged endothelium (41). However, since this was before CRP was 
categorised into distinct forms, there may be discrepancy between which isoform 
was released from plaques. Therefore, there has been a growing body of research 
investigating the nature of mCRP production, its differences to pCRP and how mCRP 
may be used as a clinical decision algorithm for ACS, all of which will be discussed. 
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1.3.2 Dissociation from pCRP to mCRP 
The dissociation process of CRP provides information on its function, where mCRP is 
most likely to affect and its possible role in ACS. As more data is published, it is 
becoming clear that dissociation allows the potential pro-inflammatory action of 
CRP to be released in the form of mCRP. Understanding the dissociation process will 
allow us to understand where, how and why mCRP is formed and crucially what this 
means for ACS diagnosis. 
In fact, recent data have shown that it is the dissociated monomeric form that is 
active in the atheromas and produces the biggest changes to the endothelium in 
atherosclerotic progression (42, 43). However, in contrast to pCRP, mCRP is not 
found in the general circulation in healthy individuals as it is localised to sites of 
inflammation and has much slower solubility than pCRP (44). The facilitators for 
dissociation are activated platelets (11, 45), MPs (46) and endothelium (47). mCRP 
Figure 1.3.2.1 The 
mechanism that leads to 
pCRP dissociation creating 
mCRP. pCRP is pictured as 
the yellow, 5-disk shape; 
mCRP as a single yellow 
disk. The green and blue 
platelet is shown to be 
adherent to the 
endothelium and facilitating 
pCRP dissociation in its 
active state. The platelet-
mCRP deposit on the 
endothelium attracts and 
stimulates passing 
monocytes leading to their 
incorporation into the 
plaque. The mCRP will 
remain adhered to the 
monocyte when entering 
the plaque, which explains 
the presence of mCRP in 
damaged intima (6). 
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might not be readily detected in the systemic circulation because it is such a strong 
localiser of the inflammatory process it will continue binding to the facilitator and 
promote atherosclerosis and thrombus generation. Figure 1.3.2.1 depicts the 
process surrounding atheromas. 
Mechanisms of dissociation differ between platelets and MPs. On activated 
platelets, the dissociation of pCRP relies on a specific receptor that is expressed on 
the cell surface. Glycoprotein IIb-IIIa binds pCRP and promotes mCRP generation 
(48). However, this has not been the only proposed cell-surface receptor. Lipid rafts 
have also been considered and there is evidence to suggest that the proposition is 
accurate. By disturbing lipid raft conformation in human aortic endothelial cells 
with either methyl-β cyclodextrin or nystatin the amount of IL-8 release was 
decreased (49). Again, this is evidence of a positive feedback loop concerning 
mCRP. In the interaction between mCRP and lipid raft, the interaction between 
cholesterol and amino acids 35-47 were of greatest importance (49). In pCRP, this 
motif is hidden in its core and is only exposed when dissociated into mCRP (49) and 
therefore could be central to mCRP signalling. 
MPs facilitate dissociation through pCRP binding to lysophosphatidylcholine (LPS) in 
the lipid membrane. Habersberger et al (46) showed this by incubating MPs derived 
from THP-1 cells and human umbilical vein endothelial cells (HUVECs) with pCRP 
that produced mCRP. This action was inhibited pCRP membrane-binding by pre-
treating the protein with 1,6 bis-phosphocholine, which binds to the pCRP 
phosphocholine binding site. The group also observed that the mCRP-containing 
MPs binding and releasing mCRP to activated HUVECs by specific staining. By 
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comparison with platelets, their functions are similar in that both cause dissociation 
and deliverance of mCRP but the mechanisms differ. Whether the difference in 
mechanisms provides a difference in mCRP function remains to be seen. 
Understanding the differences could provide information concerning how best to 
diagnose ACS using mCRP. 
Evidence that CRP is released from endothelial cells when stimulated with 
inflammatory cytokines displays a possible mechanism for a self-perpetuating cycle 
of increasing inflammation and atherosclerosis in a specific area (47). Especially as 
IL-6 and MCP-1 expression both increased, together increasing the plaque’s size 
further and IL-6 promoting CRP expression. The infiltration of more monocytes into 
the plaque causes it to destabilise increasing the likelihood of rupture. Since mCRP 
associates with the membrane and causes and increase in VCAM-1 expression (46), 
it can be said that a higher mCRP presence could cause plaque rupture and 
infarction. 
Furthermore, dissociation is increased during hypoxia, for instance during an AMI or 
stroke (50). The hypoxic environment provides a local area where hypoxic-reactive 
species can induce mechanisms that oppose the negative effects of oxygen 
depletion. One of these mechanisms is angiogenesis of neovessels. mCRP has been 
shown to stimulate cell migration and tube formation in endothelial cells (47) that, 
when occurring within plaques, destabilises atheroma cores leading to more MACEs 
(51-53). The small, fragile neovessels may haemorrhage introducing lipid-rich red 
blood cells into the plaque that will increase its necrotic core and pro-inflammatory 
profile from within (28, 54). These factors have a negative impact on the stability of 
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the core, which combined with increased monocyte infiltration could further 
rupture risk. 
The dissociation is fuelled by intermolecular electrostatic forces becoming greater 
than intramolecular forces when pCRP is clustered on a lipid monolayer, as shown 
by Wang et al (55). The comparably weak intramolecular forces are overcome by 
intermolecular forces when the pentamers aggregate and are in close proximity. 
The salt bridges holding the pentamer together are broken creating a dimeric and 
trimeric isoform from the native molecule. The lipid surface allows this close 
proximity and perhaps a secondary catalyst to break down pCRP is not necessary. 
However, the interaction between pentamers has been shown to be stable at 
physiologically similar salt levels and does not induce spontaneous dissociation (56). 
Dissociation is not an instantaneous process but with 30-40% of pCRP dissociating 
within 1-2 hours of contact with the cell membrane, it is still a fast progression (57). 
It is this speed of dissociation that leads the thinking that mCRP might be a good 
biomarker not only for AMI but for risk stratification of patients who do not 
experience AMI upon presentation at the ED. Also, if it is proved to be a causative 
factor, detection in AMI would be earlier and risk stratification would be more 
reliable than biomarkers that assess myocardial damage. 
1.3.3 Different effects of pCRP & mCRP 
Before the knowledge that CRP had 2 distinct isoforms with opposing functions, any 
findings surrounding the isoforms were attributed to CRP as a singly functioning 
protein, which produced conflicting accounts on its activity. One of the activities 
that was falsely attributed to pCRP was that it was deposited in atherosclerotic 
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plaques (58) when in fact it was the dissociated form that was found in the 
damaged intima (47, 59). The failure to differentiate the two isoforms meant that 
pCRP was viewed as actively involved in atherosclerosis progression and as it is 
found in the general circulation, it was postulated that CRP could be accelerating or 
creating atheroma growth. This implied that pCRP has many more functions than in 
reality and from this inaccurate prognostic data would be inferred. In fact, it is the 
dissociation of pCRP to mCRP that exposes proinflammatory binding sites and 
allows association between mCRP and downstream proinflammatory effectors (54). 
For instance, it has now been found that mCRP resides on the endothelium of the 
area of an infarct and on at risk areas of the endothelium (60). A myocardial 
ischaemia-reperfusion injury model was conducted in rats in the left anterior 
descending coronary artery to assess the effect of this model on mCRP deposition. 
Not only did the infarct area of the group with mCRP included in the injection group 
increase more than the sham-operated group, there was no increase in RNA 
expression of mCRP implying the CRP would arrive from the circulation and not 
from the cells’ response to the reperfusion post-ischaemia. 
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The different functions of the 2 isoforms have been detailed in table 1.3.3.1. As 
previously mentioned, exposure to mCRP will increase IL-8 and MCP-1 release from 
the endothelium will, as its name suggests, attract monocytes to the activated 
endothelium, and the adhesion molecules will cause an increase in monocyte 
infiltration and weaken the atheroma (42, 47). A much longer incubation period is 
required – 24 hours instead of 4 hours – for these proinflammatory effects are 
observed by pCRP on the endothelium suggesting that the pCRP is dissociating into 
pCRP mCRP 
Increase in IL-8 secretion in monocytes (61) Increase in IL-8 and MCP-1 secretion in 
neutrophils and coronary artery endothelial 
cells (43, 50) 
Increase in monocyte-endothelium 
interaction in human aorta and umbilical vein 
cells (62) 
Increase in neutrophil-endothelium 
interaction (43) 
Increase in apoptosis in endothelial 
progenitor cells (63, 64) 
Delayed apoptosis of neutrophils (65) 
Released from endothelium of vulnerable 
plaques (41) 
Propagates platelet activation and thrombus 
growth (11) 
Co-localises with macrophages, oxidised low-
density lipoprotein (66) 
Increases platelet-neutrophil interactions 
(43) and platelet-endothelium interactions 
(67) 
Strong pro-inflammatory action (68) Signals through classical complement 
pathway on necrotic cells (69) 
Delayed plaque formation (70) Increase in expression of adhesion molecules 
E-selectin, ICAM-1 and VCAM-1 (43) 
 Increase in angiogenesis within atheromas 
leading to haemorrhage (50, 71) 
Table 1.3.3.1 The different functions of pCPR and mCRP in inflammation. Some of the effects appear 
to be contradictory especially concerning pCRP. These are due to a lack of distinction between pCRP 
and mCRP in earlier papers, an obstacle that has now been overcome with the understanding that the 
isoforms are different. 
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mCRP. As activated platelets and MPs are proinflammatory and are significant 
factors in mCRP generation, this localises mCRP action and further increases 
monocyte infiltration and platelet activation to a specific site in the endothelium 
(72). 
The delay in apoptosis of neutrophils by mCRP (65) may serve to protect the cardiac 
tissue post-infarction but may accentuate apoptosis and increase degradation of 
the extracellular matrix by a continued inflammatory response resulting in further 
cardiac remodelling (73). However, differing effects in the complement cascade in 
necrotic cells by mCRP may yet prove to be cardioprotective (69). Nevertheless, the 
recruitment of monocytes and neutrophils to the endothelium will only cause a 
larger thrombus to form when the atheroma does rupture possibly leading to more 
complications (68). 
Another factor contributing to this might be tissue factor (TF), which is exposed 
when a plaque is disrupted and is believed to initiate thrombus formation (74). 
Through confocal microscopy, it has been shown that HUVECs incubated with mCRP 
increase expression of TF and the initial fibrin monolayer in clot formation is denser 
than that formed when incubated with pCRP (75). mCRP also promotes intra-plaque 
angiogenesis through the PI3K/Akt pathway (76) that causes haemorrhaging 
worsening thrombus formation upon plaque rupture. This along with inducing 
platelet activation and aggregation (11, 67) points towards a multi-causative role 
for mCRP in thrombus growth. 
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The problems surrounding the overlapping functions of mCRP and pCRP could be 
caused by the difficulty in preventing spontaneous pCRP dissociation in vitro, which 
may produce effects that only occur in the presence of mCRP. As seen in table 1, 
Meuwissen et al (66) reported through immunohistological staining that CRP was 
found within the plaques of stable angina (SA) and UA patients and MI patients. It 
was assumed that the CRP found was pCRP as the antibody used was not tested for 
specificity and the CRP found in the plaque could be mCRP. This seems likely 
considering plaques in cerebral arteries of stroke patients were found to contain 
mCRP, but not pCRP, by using validated antibodies that were specific for pCRP and 
mCRP (47). 
Peisajovich et al (4) displayed that pCRP has overlapping binding sites for 
C1q of the complement system and FcγRs, as seen in figure 1.3.3.2. In addition, it 
has been suggested that the role of mCRP as a complement effector changes 
depending on its state. mCRP has reduced solubility compared to pCRP (44). mCRP 
Figure 1.3.3.2 Space-filling 
model of the 2 faces of 
pCRP. (A) This face shows 
the receptor binding face 
of CRP with the ridge helix 
binding site in red. The 
binding sites for Cq1 and 
FcγRs overlap meaning 
interaction with one will 
inhibit binding with the 
other. Taking the size of 
Cq1 and CRP into 
consideration, it appears 
that only 1 globular head 
binds to the pore. (B) The B 
face of the pentamer is 
shown with the positions 
of the binding sites for 2 
calcium ions (green) and 
for phosphocholine (blue) 
(4).  
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is most effective at activating the complement cascade via C1q when bound to LDLs 
or ox-LDLs. In fluid phase, mCRP binds to C1q and inhibits downstream signalling 
and therefore the complement cascade (50). This evidence indicates that the role of 
mCRP in complement is more complex and is dependent on other factors outside 
the cascade itself. 
Alluding to the pores for calcium binding (figure 1.3.3.2), the existing knowledge on 
calcium-dependent binding to lysophosphaditylcholine (LPC) is being challenged 
(77). The binding to LPC is the facilitator for pCRP to mCRP dissociation and 
arguably the increase of its inflammatory properties. Previous studies reported that 
calcium was absolutely necessary for the binding of CRP (78, 79) and therefore the 
understanding of mCRP and its role in the complement cascade must be reviewed. 
Even though it is known that mCRP can attach to lipid rafts in the plasma 
membrane in a calcium independent manner (49), this new study shows the 
importance of understanding conformation and pH on the function of mCRP and 
hence its complex interactions with the complement cascade (80, 81). 
1.3.4 mCRP in ACS diagnosis 
This information could be of great value in the use of mCRP as a clinical decision 
tool. Obradovic et al (82) have proposed that only when CRP and oxLDL are 
measured and both are elevated can ACS be prognosed. The rationale behind this 
was that pCRP blocked LDL binding to monocytes via the LOX-1 receptor and 
therefore attenuated the pro-atherogenic effects of the LDL. However, these 
effects did not occur when mCRP was dissociated from pCRP. In our aims, it is 
hypothesised that the ratio between pCRP and mCRP would provide a good clinical 
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decision tool for ACS. This ratio overcomes the pCRP-oxLDL association problem by 
virtue of mCRP opposing effects on LDL and its receptors. 
Concerning mCRP detection alone, there have been studies that have linked more 
mCRP with MI (38, 44). With larger cohorts, it could be decided whether mCRP is a 
suitable addition to the diagnosis of ACS, particularly NSTEMI, and in prognosis of 
patients for developing major adverse coronary events (MACE) within the 
subsequent 30-days. The evidence above suggests that mCRP is the local effector of 
the CRP isoforms and could be used a specific biomarker because of this. Its 
specificity and sensitivity in ACS diagnosis is yet to be seen but if is effective, it 
would be of great value to add a causative biomarker to ACS diagnostics. 
Above it has been shown how mCRP is formed and that its local formation is vital to 
its function. It also increases monocyte and neutrophil infiltration, thins the fibrous 
cap, increases thrombus size and intra-plaque haemorrhage that increase plaque 
vulnerability leading to ACS. In the next section, how AMI is currently diagnosed will 
be introduced along with the role that cTn plays in those diagnoses. 
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1.4 Current AMI diagnosis 
The condition of NSTE-ACS is a pressure-based chest pain that lasts for 10 or more 
minutes with possible associated pain in either arms, neck or jaw. Pain in these 
areas independent of chest pain can also indicate NSTE-ACS. Typical symptoms that 
are present alongside chest pain are diaphoresis, dyspnea, abdominal pain, nausea 
and syncope. Less commonly, patients may present without chest pain but with 
nausea, vomiting, unexplained fatigue, syncope and diaphoresis (83). For these 
patients, their history and the clinical judgement of the physicians may be enough 
to consider these more uncommon symptoms as a possible NSTE-ACS. High risk 
groups include the elderly (≤ 75 years old), male sex, presence of peripheral artery 
disease, positive family history of coronary artery disease, renal insufficiency, 
diabetes mellitus, prior MI and percutaneous coronary intervention (PCI) (84, 85). In 
these groups, atypical symptoms are more likely than other groups and can include 
epigastric pain, indigestion, and stabbing or pleuritic pain (86). 
1.4.1 Risk stratification 
NSTEMI needs to be separated from unstable angina diagnosis as the treatments 
are different but symptoms are very similar. In addition, the prognosis of NSTEMI is 
worse than that of unstable angina (UA) and at 6 months, mortality rates are equal 
or greater than those of STEMI patients (87). Furthermore, early interventions can 
provide short-term treatments but may lead to worse prognoses (88). At initial 
presentation, different risk factors in the patient’s history such as sex, age, 
symptoms and a history of coronary artery disease (CAD), are used in combination 
with traditional symptoms of angina to assess how likely the prolonged chest pain is 
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due to stable chronic or acute ischaemia, instead of an alternative aetiology (89, 
90). 
The use of clinical risk scores can provide invaluable information on a patient’s 
prognosis by using these risk factors to stratify patients by scoring certain factors 
(91). These include the Thrombolysis In Myocardial Infarction (TIMI) score, the 
HEART score and the Manchester Acute Coronary Syndromes (MACS) decision rule. 
The HEART score is more general and is useful to make accurate diagnostic 
stratifications without validation or invasive procedures (92, 93). TIMI also is non-
invasive but has more focus on ischaemia than the HEART score (94). These aim to 
provide clinicians with a guide to how likely the patient is to experience MACE 
within a certain time. 
A recent National Institute for Health and Care Excellence (NICE) strategy (95) has 
suggested to clinicians to use a validated tool, such as those mentioned above, to 
assess risk of MI and that if patients fall into the low-risk group that a single cTn test 
below the limit of detection (LoD) is sufficient to rule a patient out of NSTEMI. 
Observational studies have shown that using a sample at presentation may be a 
safe rule out tool when using the LoD of a hs-cTn assay (7, 96-102) and have 
significantly higher sensitivities and negative predictive values (NPVs) than the 
traditional cut-off at the 99th percentile when compared directly (103). 
1.5 Molecular characteristics of cTn 
cTn is a complex found in skeletal and cardiac muscle but not smooth muscle. It is 
bound to tropomyosin in between actin filaments in the muscle’s sarcomeres and is 
vital to muscle contraction (104). In its relaxed state, tropomyosin will block the 
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attachment of the myosin cross bridge on the actin filaments by covering the 
binding sites preventing contraction (104). Action potentials stimulate the Ca2+ 
channels to open in the sarcoplasmic membrane and the Ca2+ ions bind to cTn 
changing its shape exposing its myosin binding sites (105). This causes myosin to 
bind to actin and, by releasing the ADP and Pi, induces a contraction stroke in the 
filament. The myosin head detaches once a new ATP molecule binds and the 
muscle is relaxed once more. 
There are three forms of cTn, cTn C (TnC), cTn T (TnT) and cTn I (TnI) (106, 107). TnC 
is 18kDa (108) and binds to Ca2+ ions causing a conformational change to TnI (109, 
110). TnT, 37 kDa (111), binds tropomyosin to form a cTn-tropomyosin complex and 
TnI at 23kDa (112) binds to actin to hold the complex in place on the thin filament. 
Only TnT and TnI have cardiac-specific forms and therefore useful as a cardiac 
biomarker (113) but TnC has no cardiac-specific isoform. There is only one cardiac 
isoform of TnI (106), cTnI, whereas there are several cTnT isoforms but only one is 
expressed in a healthy heart (114). Even though cTnT is cardiac-specific, in cases of 
chronic skeletal muscle injuries or renal disease cTnT can be expressed in skeletal 
muscle (115-118) lowering its utility as a cardiac biomarker somewhat. 
1.5.1 cTn immunoassays 
The specificity of cTnI can be alluded to the expression pattern of cTnI and cTnT in 
foetal development. Skeletal forms of cTn are expressed in the foetal heart until 
late in development when cTnI and cTnT replace them (119, 120). cTnI is never 
expressed in other tissues during development (121) and it can be assumed that 
cells other than the myocardium cannot produce cTnI. In the case of cTnT, its four 
isoforms have significant cross reactivity with skeletal muscle TnT (skTnT), which 
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caused non-specific antibodies for use in assays to be created (122). Early cTn 
assays were not sensitive or specific enough to outperform CK-MB diagnosis and 
could only identify patients with AMI 6 hours after event (123, 124).  The problem 
was solved by developing a highly specific monoclonal antibody that finds its 
epitope on the N-terminal of cTnT (125). 
The development of the antibodies allowed the assays to become more and more 
sensitive to circulating cTn, which had exceeded CK-MB as the superior marker for 
AMI diagnosis (126, 127). Moreover, the consensus document released in 2000 of 
the Joint European Society of Cardiology and American College of Cardiology 
Committee to redefine MI (128) acknowledged the importance of biomarkers in the 
diagnosis of AMI as depending on ECG alone will result in a significant number of 
missed diagnoses. The combined use of ECG, CK-MB and cTn allowed faster 
diagnoses and options if differential diagnosis proves difficult. One such problem is 
an elevated serum cTn level at presentation meaning the rise and fall pattern may 
not be as clear as a patient whose cTn level is relatively low. By combining with the 
ECG, it is possible to ascertain if the patient is experiencing an ischaemic attack, for 
example ACS, or a non-ischaemic condition such as myocarditis (129). 
1.5.2 cTn in ACS diagnosis 
It was recommended that cTn be the preferred MI biomarker due to its higher 
specificity for myocardial necrosis with CK-MB becoming a support marker for early 
diagnosis as it rises faster than cTn (128, 130), and it was later suggested that CK-
MB does not add value to the diagnosis (131). Furthermore, the longer half-life of 
the cTns results in elevated cTn levels over a longer period of time (132, 133), which 
allows more patients to be identified as high-risk for subsequent MACE in 
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comparison to CK-MB (134-137). The increased clinical sensitivity of cTn is 
correlated to a higher concentration of cTn than CK-MB in the blood (138) meaning 
absolute increases in cTn are more marked. In addition, the normal reference range 
for cTn is much smaller than CK-MB as cTn is not detected in healthy patients and 
therefore any detected cTn in patients is regarded with clinical suspicion. 
The utility of cTn in ACS prediction 
may be because it is a specific 
measure of myocardial necrosis but 
why this aids in predicting future 
adverse cardiac events is still 
uncertain. It has been postulated 
that the low levels of cTn seen is as 
a result of thrombotic activity 
surrounding vulnerable plaques 
and the subsequent associated 
emboli characterise areas of the coronary vasculature likely to rupture and 
therefore identify high-risk patients (139-143). It has been established that in 
unstable angina patients, sporadic necrosis in coronary arteries leads to higher risk 
of sudden cardiac death (144, 145). 
As cTn was outperforming CK-MB and myoglobin in diagnosis, focus was changing 
from whether cTn was a more accurate biomarker to what cut-off would be best to 
implement. The consensus brought the 99th percentile as a recommendation to 
diagnose AMI in a healthy population (128) and the <10% CV was proposed as an 
Box 1: Definitions for cTn assays 
 Limit of detection: lowest detectable 
concentration that is above zero. A 
more sensitive assay will have a lower 
limit of detection. 
 Upper limit of normal: for most 
assays, the upper limit of normal is 
set at the 95th percentile of the 
reference population (mean ± 2 SDs). 
For cTn assays, the cut off was set at 
99th percentile (mean ± 3 SDs). 
 Coefficient of variation: measures 
variability as a ratio between SD and 
mean in percent. Cut offs for cTn 
assays must have a CV < 10%. 
 Precision profile: Used to determine 
at which concentration the 10% CV 
limit is reached. 
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alternative (146). Imprecision profiles of assays available at the time yielded CVs 
lower than 10% at the 99th percentile or lower concentrations (147).  The 99th 
percentile was useful for early rule out of AMI due to its low cut-off but yielded 
small PPVs (131) but conversely imprecision greater than 10% around the 99th 
percentile presents increased risk of misdiagnoses. 
There are now many high-sensitivity cTn (hs-cTn) assays, all of which have different 
precision profiles, LoDs and 99th percentile cut-offs hence why guidelines for MI 
diagnosis are quoted as above and not at specific concentrations. hs-cTn assays are 
named as such if cTn can be detected in 50% of the population. The differences 
arise from the array of antibodies used in separate assays that have epitopes on 
diverse fragments of the circulating cTnI and cTnT (148-152). Each fragment will 
have different half-lives in the plasma, antibody-fragment affinity will differ (151) 
and the components of the assays will cause differing amounts of matrix effects in 
each (153, 154). The heterogeneity of the factors will affect the percentage 
recovery of the proteins in the plasma and the degree of detection by the 
antibodies causing each assay and its parameters to be particular to that assay. 
It is for this reason that it is difficult to compare the performance of assays directly 
and for their diagnostic accuracies to be assessed individually, clinical sensitivity, 
specificity, positive predictive value (PPV) and NPV based on specific diagnostic cut-
offs must be calculated. This allows the number of patients who will be identified 
correctly by a test to be quantified but these clinical parameters allow flexibility in 
how cut-offs are used in diagnosis. 
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1.5.3 Kinetic and non-kinetic cTn values in ACS diagnosis 
For ACS diagnosis, a rule out diagnosis is a useful tool and is becoming more 
popular now with more sensitive hs-cTn 
assays because they allow detection of 
very small concentrations of cTn (155). 
Until the advent of hs-cTn assays, a 
patient with negative cTn could be 
confidently ruled out of AMI but a 
positive hs-cTn can now be found in 50% 
of the population. The concentration at 
which cTn is considered safe for 
different assays still remains up for 
debate (7, 99, 100, 131, 156-162). Sampling at presentation allows for the 
possibility of immediate AMI rule out and time between serial sampling has been 
recommended to be reduced from 6h to 3h (163). 
As well as non-kinetic values of cTn, changes between two cTn samples, or cTn 
deltas, have been proposed to assess what degree of change constitutes an AMI 
has occurred, as per international guidelines (164). Deltas allow the distinction 
between acute and chronic causes of cTn rise, e.g. between AMI and chronic heart 
failure (CHF) (165) Therefore, raised cTn is not specific enough to for it to be used 
alone to diagnose AMI. Consequently, the rise and fall pattern must be observed 
but how these increases and decreases apply to AMI diagnosis is debated (166-
169). 
Box 2: Definitions for diagnostic tests 
(3) 
 Sensitivity: proportion of 
patients with the disease who 
are correctly identified by the 
test 
 Specificity: proportion of 
patients without the disease 
who are correctly identified by 
the test 
 Positive predictive value: 
Proportion of patients with a 
positive test who are correctly 
diagnosed as disease positive 
 Negative predictive value: 
Proportion of patients with a 
negative test who are correctly 
diagnosed as being disease free 
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There are two main methods, the absolute delta, which is the change between two 
cTn samples expressed as an absolute value, or the relative delta, which is 
expressed as a percentage change. The later method can utilised in different ways, 
e.g. the change relative to the baseline cTn value, to the mean of the cTn values, to 
the minimum or maximum of the cTn values, and has been the delta tool of choice. 
However, with the advent of ever more analytically sensitive cTn assays, the 
absolute delta has been found to be more accurate for lower cTn levels, such as 
those cTn values found in NSTEMI (160). 
1.6 Molecular characteristics of h-FABP 
h-FABP is a small 15 kDa cytoplasmic protein released from cardiomyocytes in 
ischaemic conditions (170). It is involved in long chain fatty acid transportation and 
metabolism by moving fatty acids from the plasma membrane to the mitochondria 
for oxidation (171). h-FABP is found to be highly specific to the cardiomyocytes 
(172) and in only low levels in the skeletal muscle, small intestine, liver and kidneys 
(173, 174). It has been shown that it is 20 times more specific to the heart than 
myoglobin (172). In addition, it is very soluble, stable and has a low molecular 
weight (175, 176), all of which contribute to its rapid increase in systemic 
concentration (177), which has been reported to increase 30 minutes post-event 
(178) and returns to the reference population values within 24h (179). 
The diagnostic utility for AMI diagnosis of h-FABP has previously been shown 
especially concerning early detection of h-FABP (180-187). The combination of h-
FABP with cTn concentration, ECG ischaemia and cTn deltas has not yet been 
explored for the diagnosis of AMI and the prediction of MACE. As h-FABP is released 
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earlier into the bloodstream than cTn, it may allow faster diagnosis of AMI with 
early presenters and prevent more false negatives. 
1.7 Project Aims 
The aim of this project is to assess if mCRP and different cTn measurements can be 
used to rule in/rule out ACS. 
The primary objective is to address the following research questions: 
 In patients with suspected ACS, serial measurement of the ratio of mCRP to 
pCRP, cTn in addition to routine clinical and laboratory investigations, 
identify: 
o Patients at sufficiently low risk of AMI or MACEs within 30 days to 
enable safe early discharge, rule out and 
o Patients at high risk of AMI or MACE within 30 days that the 
diagnosis of ACS should be ruled in 
 Our secondary objective is: 
o To derive and validate a clinical decision algorithm incorporating 
serial measurements of the above markers for the identification of 
patients at low and high risk of MACE within 30 days, including 
identifying optimal critical difference 
The above aims will be achieved as detailed below. 
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1.7.1 Assay development 
Method 
mCRP concentration will be determined in patients’ blood via a new immunoassay 
developed into a competitive format with a colorimetric testing step. Initial 
validation will determine antibody titre and assay linear range. Further validation 
will utilise industry standard guidelines for the validation of the immunoassay. 
1.7.2 mCRP Clinical Study 
Method 
We will conduct a prospective diagnostic cohort study in patients presenting with 
possible ACS warranting hospital admission for further investigation. Patients must 
be >25 years of age and presenting with suspected cardiac chest pain that has 
occurred within 24 of coming to the ED. Patients with unequivocal evidence of 
STEMI who will be transferred for immediate percutaneous coronary intervention 
will be excluded. Also excluded will be those with renal failure requiring dialysis, 
suspected myocardial contusion or another medical condition requiring hospital 
admission. Comprehensive clinical, ECG and biochemical data will be recorded at 
the time of presentation using a custom designed case report form. We will collect 
whole blood samples for the measurement of mCRP/pCRP ratio by immunoassay. 
As part of routine clinical care, all patients will undergo diagnostic testing 
(reference testing) using a laboratory based cTn assay on arrival and at least 12 
hours after symptom onset. A positive result will be any cTn level >99th percentile 
of a reference population. Patients will be followed up throughout their inpatient 
stay and after 30 days. The primary endpoint will be a composite of AMI and MACE 
within 30 days. We will determine the diagnostic accuracy of serial measurements 
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of mCRP/pCRP and cTn by calculating sensitivity, specificity, positive and negative 
predictive value. In addition we will derive and validate a clinical decision algorithm 
to rule out and rule in AMI. This analysis will include clinical findings in addition to 
data from mCRP, pCRP, the mCRP/pCRP ratio and cTn to define a clinical decision 
rule to determine short and long-term risks of AMI and/or MACE. 
1.7.3 cTn Clinical Study 
For the following analyses, the fifth-generation Elecsys, Roche Diagnostics hs-cTnT 
assay, the Singulex Clarity™ cTnI assay and the Abbott Point of Care iSTAT cTnI 
assay will be assessed as tools for rule in and rule out of ACS. This will be explored 
in diagnosis and 30-day MACE prediction by: 
 Using the 10% CV of each assay as cut-offs at presentation and 3h to assess 
utility as quick rule in or rule out  
 Calculating the deltas between presentation and 3h samples as absolute 
deltas, relative to baseline deltas and relative to mean deltas, that will allow 
100% sensitivity for rule out 
 Using the baseline cTn concentrations to divide the cohort into high-, 
intermediate and low-risk groups and create group-specific cut-offs to 
assess if grouped improves diagnostic accuracy 
 Using a novel risk score, which includes predictor variables of cTn, cTn 
deltas, ECG ischaemia and H-FABP 
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Chapter 2: Materials and Methods  
Chapter 2: Materials and Methods 
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2.1 Materials 
2.1.1 Immunoassay development materials 
This section details the different reagents and equipment used in the immunoassay 
development. Any changes will be included in the results section. 
CRP purchased from mybiosource.com (catalogue # MBS318375) in its native, 
pentameric form. mCRP obtained via urea chelation stored in a CRP buffer (140 mM 
NaCl, 20mM Tris-HCl, 2mM CaCl2, pH 7.5). 
Plates used are Nunc-Immuno™ MicroWell™ Polysorp® flat bottom 96 well solid 
plates (catalogue # M0661-1CS, Sigma Aldrich). 
mCRP antibody clone 8C10 was kindly gifted from Dr Potempa (47). 
Mouse monoclonal anti-C reactive protein antibody [C6], HRP conjugated (ab24462, 
Abcam). 
Goat polyclonal anti-C reactive protein antibody, HRP conjugated (ab19175, 
Abcam). 
The mCRP-biotin conjugate was made as per the instructions using Lightning-Link® 
Biotin Conjugation Kit (Type A*), 1-2mg scale (catalogue # 704-0015, Innova 
Biosciences). 
Bovine serum albumin (BSA) was in the form of lyophilised powder, crystallised 
≥96.0% (catalogue # A4503-100G, Sigma Aldrich). 
Monster Block™ (obtained from ImmnuoChemistry Technologies, catalogue # 
6295). 
ImmunoPure® Streptavidin-HRP conjugated 5 mg (Prod # 29994, ThermoScientific). 
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3,3’,5,5’-tetramethyl benzidine (TMB) 0.4g/L in aqueous solution (Prod #1854050, 
ThermoScientific) and peroxide solution, 0.02% in buffer (Prod #1854060). 
 
2.2 Methods 
2.2.1 Immunoassay development methods 
This section details the different reagents and equipment used in the immunoassay 
development. Any changes or additional materials will be included in the results 
section. 
2.2.2 Competitive immunoassay development 
A competitive immunoassay was in development first, a diagram of the basic 
principles is provided in figure 2.2.2. 
 
2.2.2.1 First competitive immunoassay protocol 
The plates were coated with the antibody overnight at 4oC at concentration 1:10 
and 1:20 in CRP buffer. After aspirating, 3 x 5 minute washes with CRP buffer were 
conducted. Dilutions were made immediately before usage and diluted using CRP 
Figure 2.2.2. Diagram of the mCRP competitive immunoassay. The capture antibody, mCRP 
antibody clone 8C10, was coated on the wells. The mCRP and mCRP-biotin are added to the 
wells, then the streptavidin –HRP is added and binds to the biotin. TMB is added and the HRP 
changes the colour of the TMB from colourless to blue. The amount of colour change is 
measured by absorbance at 450 nm. The mCRP and mCRP-biotin compete to bind with available 
antibodies and therefore a higher mCRP concentration will result in a smaller absorbance 
reading. An array of standards was used per immunoassay to produce standard curves. 
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buffer. 80 µl of CRP buffer was added to each well, and 10 µl of mCRP-biotin at 
concentrations 0-300 µg/ml. mCRP standards at 0-500 µg/ml were added 
immediately in triplicate and incubated overnight at 4oC. The solution was aspirated 
and 5 x 3 minute washes with CRP buffer were conducted. 0.1 µg/ml avidin-HRP 
was added and incubated for 30 minutes at room temperature. The solution was 
aspirated and wells washed as above. TMB and peroxide solutions were added and 
the reaction stopped after 10 minutes with 2M sulphuric acid. The plates were read 
by Synergy HT Microplate reader (BioTek). 
2.2.2.2 Immunoassay with competition from mCRP removed 
The plates were coated with the antibody overnight at 4oC at concentrations 1:10, 
1:20, 1:30, 1:40, 1:50, 1:100 and 1:200 in CRP buffer. After aspirating, 3 x 5 minute 
washes with CRP buffer were conducted. Dilutions were made immediately before 
usage and diluted using CRP buffer. 80 µl of CRP buffer was added to each well, and 
10 µl of mCRP-biotin at concentrations 0-200 µg/ml in triplicate and incubated 
overnight at 4oC. The solution was aspirated and 5 x 3 minute washes with CRP 
buffer were conducted. 0.1 µg/ml avidin-HRP was added and incubated for 30 
minutes at room temperature. The solution was aspirated and wells washed as 
above. TMB and peroxide solutions were added and the reaction stopped after 10 
minutes with 2M sulphuric acid. The plates were read by Synergy HT Microplate 
reader (BioTek). 
2.2.2.3 No competition introduced with alternative mCRP-biotin concentrations 
Protocol as previous but with mCRP-biotin concentrations 0-150 µg/ml. 
2.2.2.4 Addition of 0.05% Tween to wash buffer 
Protocol as previous but with 0.05% Tween in CRP buffer as wash buffer. Capture 
antibody concentration at 1:20. 
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2.2.2.5 Reduction in range of mCRP-biotin standards to below 60 µg/ml 
Protocol as previous but with mCRP-biotin standards at 0-60 µg/ml. 
2.2.2.6 Addition of BSA as blocking buffer 
The plates were coated with the antibody overnight at 4oC at concentration 1:10 
and 1:20 in CRP buffer. After aspirating, 3 x 5 minute washes with CRP buffer were 
conducted and 300 µl BSA at 0%, 0.5% and 2% added to the plate for 1 hour. BSA 
was aspirated and plates washed 3 x 5minutes with 0.05% Tween. Dilutions were 
made immediately before usage and diluted using CRP buffer. 80 µl of CRP buffer 
was added to each well, and 10 µl of mCRP-biotin at concentrations 0-160 µg/ml 
were added in triplicate and incubated overnight at 4oC. The solution was aspirated 
and 5 x 3 minute washes with 0.05% Tween in CRP buffer were conducted. 0.1 
µg/ml avidin-HRP was added and incubated for 30 minutes at room temperature. 
The solution was aspirated and wells washed as above. TMB and peroxide solutions 
were added and the reaction stopped after 10 minutes with 2M sulphuric acid. The 
plates were read by Synergy HT Microplate reader (BioTek). 
 
2.2.2.7 Possible BSA-mCRP interaction 
Plates were incubated with CRP buffer overnight at 4oC. After aspirating, 3 x 5 
minute washes with 0.05% Tween were conducted before adding 100 µl BSA in CRP 
buffer at concentrations of 0%, 0.5% and 2% in quadruplicate incubated at room 
temperature for 2 hours. After aspiring, washes were performed as above. mCRP-
biotin concentrations of 0, 5, 10, 15, 20, 25, 30, 40 µg/ml were diluted with CRP 
buffer and made with serial dilutions. 90 µl CRP buffer was placed into each well 
with 10µl of mCRP-biotin and incubated overnight at 4oC. The solutions were 
aspirated and wells washed as above. 0.1, 0.05, 0.025 and 0 µg/ml Streptavidin-HRP 
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was added in duplicate and incubated for 30 minutes at room temperature. The 
solution was aspirated and wells washed as above. 80 µl of the mixed TMB and 
peroxide solution was added and the reaction stopped after 10 minutes with 2M 
sulphuric acid. The plates were read by Synergy HT Microplate reader (BioTek). The 
experiment was performed twice. 
2.2.2.8 Antibody-avidin and plate-avidin non-specific binding 
Plates were coated with 80 µl of antibody in an array of concentrations (1:40-1:500) 
diluted with CRP buffer incubated overnight at 4oC. 3 x 5 minute washes of 0.05% 
Tween before adding 100 µl BSA at concentrations 0%, 0.5% and 2% in 
quadruplicate incubated at room temperature for 2 hours. Plates were washed as 
above. 80 µl of avidin at concentrations at 0.1, 0.05, 0.025, 0 µg/ml were added to 
the plates for 30 minutes at room temperature. 80 µl of the mixed TMB and 
peroxide solution was added and the reaction stopped after 10 minutes with 2M 
sulphuric acid. The plates were read by Synergy HT Microplate reader (BioTek). The 
experiment was performed twice. 
2.2.2.9 Milk protein vs BSA as blocking agent 
Plates were coated with 80 µl antibody at concentrations 1:100, 1:200 or 1:400 and 
incubated at 4°C overnight. 3 x 5 minute 0.05% Tween washes were performed. 80 
µl of 2% BSA and 5% and 10% milk were added and incubated for 2 hours at room 
temperature. Washes were performed as above. 10 µl of  mCRP-biotin at 
concentrations 0-160 µg/ml and 90 µl of CRP buffer were added in duplicate and 
incubated overnight at 4°C and then washed as above. 80 µl of 0.1 µg/ml avidin 
were added to the plates for 30 minutes at room temperature. . 80 µl of the mixed 
TMB and peroxide solution was added and the reaction stopped after 10 minutes 
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with 2M sulphuric acid. The plates were read by Synergy HT Microplate reader 
(BioTek). The experiment was performed twice. 
2.2.2.10 Using antibody coating buffer and Monster Block™ 
Plates were coated with 80 µl of either 1:200 antibody diluted in either antibody 
coating buffer or CRP buffer and incubated overnight at 4°C. Another plate was 
coated with 1:50 antibody with the antibody coating buffer and incubated as above. 
3 x 5 minutes 0.05% Tween washes were performed and 300 µl of Monster Block™ 
was added to each well and incubated for 24 hours at room temperature. Washes 
were performed as above. 10 µl of mCRP-biotin of concentrations 0-160 µg/ml 
were added as 6 replicates to 90 µl of CRP buffer in wells and incubated overnight 
at 4°C on the plates of 1:200 antibody. The plate with 1:50 antibody had mCRP-
biotin concentrations of 0-640 µg/ml and incubated as above. Washes were 
performed as above. 80 µl of 0.1 µg/ml avidin were added to the plates for 30 
minutes at room temperature. 80 µl of the mixed TMB and peroxide solution was 
added and the reaction stopped after 10 minutes with 2M sulphuric acid. The plates 
were read by Synergy HT Microplate reader (BioTek). The experiment was 
performed twice. 
2.2.2.11 Possible interaction between mCRP and Monster Block™ 
The plates were coated with Antibody coating buffer™ containing no antibody and 
incubated overnight at 4°C. After aspirating, 3 x 5 minute washes with 0.05% Tween 
were conducted before adding 300 µl Monster Block™ at 0%, 50% and 100% 
concentration (100% as concentration bought) for 24h at room temperature. 
Dilutions were made immediately before usage and diluted using CRP buffer. 80 µl 
of CRP buffer was added to each well, and 10 µl of mCRP-biotin at concentrations 0 
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µg/ml, 80 µg/ml and 120 µg/ml. mCRP standards at 0-80 µg/ml were added 
immediately in triplicate and incubated overnight at 4oC. The solution was aspirated 
and 5 x 3 minute washes with 0.05% Tween were conducted. 0.1 µg/ml avidin-HRP 
was added and incubated for 30 minutes at room temperature. The solution was 
aspirated and wells washed as above. TMB and peroxide solutions were added and 
the reaction stopped after 20 minutes with 2M sulphuric acid. The plates were read 
by Synergy HT Microplate reader (BioTek). The experiment was performed twice. 
2.2.2.12 mCRP-biotin conjugates competing for antibody availability with non-labelled mCRP 
standards 
The plates were coated with the antibody overnight at 4oC at concentration 1:50 in 
Antibody coating buffer. After aspirating, 3 x 5 minute washes with 0.05% Tween 
were conducted before adding 300 µl Monster Block™ for 24h at room 
temperature. Dilutions were made immediately before usage and diluted using CRP 
buffer. 80 µl of CRP buffer was added to each well, and 10 µl of mCRP-biotin at 
concentrations 0-200 µg/ml. mCRP standards at 0-70 µg/ml were added 
immediately in triplicate and incubated overnight at 4oC. The solution was aspirated 
and 5 x 3 minute washes with 0.05% Tween were conducted. 0.1 µg/ml avidin-HRP 
was added and incubated for 30 minutes at room temperature. The solution was 
aspirated and wells washed as above. TMB and peroxide solutions were added and 
the reaction stopped in half the wells after 10 minutes and 16 minutes in the other 
half with 2M sulphuric acid. The plates were read by Synergy HT Microplate reader 
(BioTek). The experiment was performed twice. 
2.2.2.13 Experimentation of mCRP incubation time at 24h and 48h at room temperature 
The plates were coated with the antibody overnight at 4oC at concentration 1:50 in 
Antibody coating buffer. After aspirating, 3 x 5 minute washes with 0.05% Tween 
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were conducted before adding 300 µl Monster Block™ for 24h at room 
temperature. Dilutions were made immediately before usage and diluted using CRP 
buffer. 80 µl of CRP buffer was added to each well, and 10 µl of mCRP-biotin at 
concentrations 0-160 µg/ml. mCRP standards at 0-40 µg/ml were added 
immediately in triplicate and incubated for 24h or 48h at 4oC or at room 
temperature to make 4 plates in total. The solution was aspirated and 3 x 5 minute 
washes with 0.05% Tween were conducted. 0.1 µg/ml avidin-HRP was added and 
incubated for 30 minutes at room temperature. The solution was aspirated and 
wells washed as above. TMB and peroxide solutions were added and the reaction 
stopped in half the wells after 10 minutes and 16 minutes in the other half with 2M 
sulphuric acid. The plates were read by Synergy HT Microplate reader (BioTek). 
2.2.2.14 Use of a prep plate to premix the mCRP-biotin and mCRP before adding to working 
plate 
Protocol as previous but mCRP-biotin and mCRP were premixed on a prep plate 
before being added to the working plate. The prep plate was washed and TMB 
added for 10 minutes to observe any residual mCRP-biotin. 
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2.2.3 Sandwich ELISA development 
The project moved onto developing an ELISA protocol, the basics of which are 
displayed in figure 2.2.3. 
 
 
2.2.3.1 ELISA with monoclonal detection antibody ab24462 
The plates were coated with the antibody overnight at 4oC at concentration 1:50 
and 1:200 in Antibody coating buffer. After aspirating, 3 x 5 minute washes with 
0.05% Tween were conducted before adding 300 µl Monster Block™ for 24h at 
room temperature. Dilutions were made immediately before usage and diluted 
using CRP buffer. 100 µmCRP standards at 0-32 µg/ml were added in triplicate and 
incubated for 2h at room temperature. The solution was aspirated and 3 x 5 minute 
washes with 0.05% Tween were conducted. 100 µl of detection antibody (ab24462) 
at 1:3000 and 1:6000 was added and incubated for 1h at room temperature. The 
solution was aspirated and wells washed as above. TMB and peroxide solutions 
were added and the reaction stopped after 10 minutes with 2M sulphuric acid. The 
plates were read by Synergy HT Microplate reader (BioTek). 
Figure 2.2.3 Diagram of the mCRP sandwich ELISA. The capture antibody, mCRP antibody clone 
8C10, was coated on the wells. The mCRP is added to the wells to bind to the capture antibody, 
and then the detection antibody is added to bind to the mCRP. TMB is added and the HRP 
changes the colour of the TMB from colourless to blue. The amount of colour change is 
measured by absorbance at 450 nm. The mCRP binds directly without competition to available 
antibodies and therefore a higher mCRP concentration will result in a larger absorbance 
reading. An array of standards was used per immunoassay to produce standard curves. 
41 
 
2.2.3.2 ELISA with monoclonal detection antibody ab19175 
Protocol as previous but with capture antibody only at 1:50, ab19175 as the 
detection antibody and mCRP standards at 0-100 µg/ml.  
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2.2.4 Diagnostic and prognostic analysis of three contemporary assays 
As hs-cTn detects cTn in 50% of the population, using any detectable Tn as the 
rationale for further Tn testing is no longer useful. An alternative is to measure the 
amount of change observed in patients. The aim of these analyses to identify what 
change can diagnose AMI. 
2.2.4.1 Cohort & Samples 
The prospective cohort study recruited patients who presented to the ED with chest 
pain from 5 sites (Manchester Royal Infirmary, annual ED consensus 145,000) as a 
part of the BEST study (NHS ethical approval: 14/NW/1344). Patients were over 25 
and had chest pain within the last 24h, which the initial treating physician believed 
was cardiac in nature. Exclusion criteria are as follows: renal failure requiring 
dialysis, suspected myocardial contusion, another medical condition requiring 
hospital admission or if they did not consent to have their blood taken for the 
study. 
Blood was drawn at time of ED presentation and at 3h and immediately 
centrifuged. Plasma was drawn off and frozen at -20⁰C for up to 48h and -70⁰C 
thereafter. The samples were analysed with the high-sensitivity cardiac cTn (hs-
cTnT) assay from Roche® Diagnostics by hospital laboratory staff as part of routine 
diagnostics. The assay had a cTn concentration in the 99th percentile of a reference 
population of 14 pg/ml and CoV of 10% at 5.03 pg/ml. The samples were analysed 
for hs-cTnI with the ultra-sensitive Singulex Clarity automated analyser (99th 
percentile < 8.67 pg/ml, CV of 10% at 0.53 pg/ml). The assay uses a one-step 
immunoassay with single molecule counting to measure cTnI very sensitively in 90 
minutes (188). The analysis was done at CityLabs 2.0, Manchester, by laboratory 
staff who were blinded to patient outcomes. Testing for Singulex was completed in 
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May-June 2017. The handheld point of care device, Abbott iSTAT® cTnI test (99th 
percentile 80 pg/ml, CV of 10% at 100 pg/ml) obtained results within 10 minutes at 
the patient’s bedside. The Abbott iSTAT® system uses single-use cartridges to which 
a small amount of blood is applied to chemically sensitive biomarkers and inserted 
into the device for quantification. The device has cartridges for many analytes for 
different clinical tests but cTnI cartridges were used for these analyses (189). 
Follow-up was at 30 days using the National Health Service Strategic Tracing Service 
database to check for mortality data. Cause of death was retrieved for all deceased 
patients. The electronic hospital records then were reviewed for every patient, 
including all subsequent ED attendances, hospital admissions, out-patient clinic 
appointments and all investigations requested and undertaken. All living patients 
were contacted by telephone and in the event the patient could not be reached 
their GP was contacted. Copies of records were retrieved if the patient was 
hospitalised during the follow-up period. 
2.2.4.2 Outcomes 
The primary outcome was AMI; two independent investigators who had all the 
clinical, laboratory and imaging data available for review but who were blinded to 
the hs-cTnT levels adjudicated final diagnosis. AMI was diagnosed in accordance 
with the universal definition of AMI, one of the following symptoms plus a rise of 
hs-cTnT above the 99th percentile of the reference population. Secondary outcome 
included death and AMI within the next 30 days. Three composite 30-day prognosis 
endpoints were devised. Composite MACE consisted of all-cause mortality, AMI, 
revascularisation, PCI, coronary artery bypass graft (CABG), stenosis, tests for heart 
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disease, cardiac arrest, arrhythmia and acute heart failure. Adverse events 1 (AV1) 
included all-cause mortality, AMI, revascularisation, PCI, CABG and stenosis and  
 2 (AV2) included cardiac arrest, arrhythmia and acute heart failure. 
2.2.4.3 Statistical analysis 
Data was tested for normality using Kolmogorov-Smirnov test and if data was found 
to be not normally distributed and non-parametric tests were used to analyse the 
data. Means are presented as mean ± SD, ± 95% confidence intervals (CI) for 
normally distributed data and median ± 95% CI for non-normally distributed data. 
Categorical variables were compared with the χ2 test and degrees of change 
between paired categorical variables were compared with McNemar’s test. 
Receiver operating characteristic (ROC) curves were made for cTn values at 0h, 3h, 
the maximum value of 0h or 3h (max values), absolute change or delta (Δabsolute), 
relative to baseline delta (%Δbaseline) and relative to mean delta (%Δmean). Values 
quoted in the diagnostic tests are absolute to assess magnitude of change instead 
of direction of change and quoted as 2-tailed significance. The delta values were 
calculated as Pretorius et al (190): 
∆𝑎𝑏𝑠𝑜𝑙𝑢𝑡𝑒 = 0ℎ − 3ℎ  
%∆𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 =
3ℎ−0ℎ
0ℎ
 × 100  
%∆𝑚𝑒𝑎𝑛 =  
(3ℎ−0ℎ)
0.5 ×(3ℎ+0ℎ)
 × 100  
Cut-offs were derived from ROC curve analysis to find the highest sensitivity 
possible and quoted as pg/ml. If the cut-off found by ROC curve analysis was below 
the concentration at which the assay exhibits a CV of 10%, the cut-off was set at 
10% CV, as specified by the manufacturers. This was done as this is the accepted 
limit of the functional sensitivity (FS) for assays (146, 191). For the Roche assay, this 
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concentration was 5.03 pg/ml, for the Singulex assay was 0.53 pg/ml and for the 
iSTAT assay was 100 pg/ml (details for iSTAT as found in Appendix II). The LoDs for 
the assays were considered as cut-offs, as explored previously (99), but the 
confidence in the CV of the Singulex assay at its LoD of 0.08 pg/ml was low as the 
precision measurements only tested to 1 pg/ml. The precision profile of the assay is 
shown in figures 2.2.4.3.1 and 2.2.4.3.2 and has been constructed from data 
provided from Singulex (from raw data in manual found in Appendix I). Sensitivities, 
specificities, PPVs and NPVs for diagnosis and prognosis were calculated using 
MedCalc diagnostic test evaluation calculator. 
To calculate at which minimum cTn concentration the %Δbaseline and %Δmean cut-offs 
will surpass the FS in absolute terms, the lowest possible baseline cTn level for 
effective %Δ (cTnlow) was calculated. The calculation is based on the percentage 
equation: 
% =  
𝐹𝑆
𝑐𝑢𝑡−𝑜𝑓𝑓
 × 100   
 and was rearranged as: 
𝑐𝑇𝑛𝑙𝑜𝑤 =
100
𝑐𝑢𝑡−𝑜𝑓𝑓
 × 𝐹𝑆  
Patients were grouped into rule out, intermediate and rule in groups based on 0h 
cTn concentration to achieve the greatest sensitivity for the rule out group and the 
greatest specificity for the rule in group. The intermediate group were patients who 
were in between these groups. The above analysis was repeated on the individual 
groups to assess diagnostic accuracy. 
Predictor composites were made from 0h cTn values, cTn deltas (all composites 
including deltas as a variable will be calculated for diagnostic and prognostic 
accuracy with Δabsolute, %Δbaseline and %Δmean individually), evidence of ischaemia by 
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ECG (ECG) and H-FABP. All predictors in composites used the same cut-offs as 
detailed above and converted to categorical variables. The ECG and H-FABP 
predictors were provided as categorical variables, ECG as a positive or negative for 
ischaemia and H-FABP as a semi-qualitative test but quoted as positive or negative 
for the presence of H-FABP. 
Figure 2.2.4.3.1 Mean single site repeatability %CV of cTnI Singulex assay. Repeatability of cTnI 
measurements over 20 days by 2 operators at one site with a 10-point standard curve, 1-10,000 pg/ml, 
using 3 lots of reagents. For this graph, the 3 lots were averaged before plotting. Dotted line indicates 
linear trend line with supporting equation included on chart. 
Figure 2.2.4.3.2 Mean multi-site repeatability %CV of cTnI Singulex assay. Repeatability of measuring 
cTnI by two operators at each of the three sites over 5 days using a10-point standard curve, 1-10,000 
pg/ml, in triplicate with a single lot of reagents. The results from the three sites were averaged before 
plotting. 
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Chapter 3: Immunoassay development 
  
Chapter 3: Immunoassay development 
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3.1 Competitive immunoassay development 
3.1.1 Preliminary competitive immunoassay 
The first competitive immunoassays run are shown in figure 3.1.1. mCRP-biotin was 
used in an array of concentrations to assess which had the best fitting standard 
curve against the increasing concentrations of competing mCRP. As the signal-
producing mCRP-biotin is in competition with biotinylated mCRP, it would be 
expected for the signal to decrease with increasing mCRP concentration (x-axis). 
This did not occur and no discernible pattern can be observed from any mCRP-
biotin concentration. Values have not been zeroed to show the variability even at 0 
concentrations. 
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Figure 3.1.1 Preliminary competitive immunoassay for the determination of mCRP concentration 
in serum. A) had plates coated with 1:10 8c10 mCRP antibody b) had plates coated with 1:20 
8c10 antibody. The standard curve is made of 8 points 0-500 ug/ml. Each data series is one 
mCRP-biotin concentration. 
B 
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3.1.2 Immunoassay with competition from mCRP removed 
As the competition may have caused the large variability within the first assay, as 
seen in figure 3.1.1, it was decided that competition would be removed to assess 
which antibody dilution yielded the best fitting standard curve. For figure 3.1.2, the 
values have been zeroed. This experiment was to determine the correct antibody 
and mCRP-biotin concentration to use. 
There is a general trend of increasing signal with increasing antibody concentration 
but the stronger signal of the 100 ug/ml mCRP-biotin compared with 200 ug/ml 
introduces uncertainty. In addition, a high antibody concentration used but 
resulting absorbance is low. 
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Figure 3.1.2 Association between antibody concentrations, mCRP-biotin concentrations and 
absorbance. Antibody concentration is quoted as ratios on the x-axis and the legend denotes 
the mCRP-biotin concentration in ug/ml. 
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3.1.3 No competition introduced with alternative mCRP-biotin concentrations 
Alternative mCRP-biotin concentrations were used to assess their viability as a 
possible standard for a standard curve. Figure 3.1.3 below also shows the effort to 
try to determine the best antibody concentration to use.  
Again, the concentrations have no pattern and the lowest concentrated mCRP-
biotin produced the highest two signal points overall. Also, note how there are no 
patterns emerging between any of the assays with respect to variability or 
individual antibody titres between assays.  
 
  
-0.3
-0.2
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
0 200 100 50 40 30 20 10
A
b
so
rb
an
ce
 (
4
5
0
n
m
)
Antibody concentration (1:)
70
90
110
130
150
Figure 3.1.3 Association between antibody concentrations with alternative mCRP-biotin 
concentrations and absorbance. Antibody concentration (1:200 – 1:10) is quoted as ratios on the x- 
and the legend denotes the mCRP-biotin concentration in ug/ml. 
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3.1.4 Addition of 0.05% Tween to wash buffer 
The large variation was partly attributed to the wash cycles, which had only 
contained CRP buffer. Addition of 0.05% Tween would wash away unbound mCRP 
that could have been causing the variation. Antibody concentration was set at 1:20. 
The reduction in overall absorbance shows that the 0.05% Tween did wash away 
excess mCRP-biotin that was binding non-specifically to the plate. The outliers 
between 80 – 120 µg/ml can be explained by unusually high background from the 0 
antibody negative control wells and slightly low reading from these 1:20 antibody 
wells. However, the three could be affected by pipetting errors. By discounting the 
outliers, there appears to be a plateau at around 60 µg/ml suggesting saturation of 
antibody. 
 
  
Figure 3.1.4 The effect of 0.05% Tween in CRP buffer as a wash buffer. Antibody 
concentration was set at 1:20 and mCRP-biotin standards were 0-160 µg/ml. 
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3.1.5 Reduction in range of mCRP-biotin standards to below 60 µg/ml 
As the signal was seen to rise most between 0-40 µg/ml, the range of standards was 
reduced. Tween 0.05% in CRP buffer was still used as a wash buffer. 
As displayed in figure 3.1.5, there was close agreement between the different 
antibody concentrations with regards to mCRP-biotin signal strength. However, 
there remained much variation as the concentrations increased and the antibody 
concentration has no bearing on signal strength. 
   
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
0 10 15 20 25 30 40
A
b
so
rb
an
ce
 (
4
5
0
 n
m
)
mCRP-biotin (ug/ml)
1,40 1,50 1,100 1,200 1,300 1,400 1,500
Figure 3.1.5 Smaller range of mCRP-biotin concentrations in an immunoassay without 
competition to determine where rises in absorbance occur. Each data series represents a 
different antibody concentration, expressed as a ratio in the legend. mCRP-biotin standards are 
0-40 µg/ml. 
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3.1.6 Addition of BSA as blocking buffer 
Different BSA concentrations were used to assess if there was any impact of the 
blocking buffer on the variability. 
The addition of Tween appeared to limit variability but the standard curves, after an 
initial rise, are now flat with a slight rise at 160 ug/ml for 2% BSA, displayed in figure 
3.1.6. As a blocking buffer, it would be expected that a higher BSA concentration 
would weaken the signal but this was not observed. Instead, the two BSA 
concentrations are very similar (p = 0.997). 
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Figure 3.1.6 Use of 0.05% Tween in CRP buffer for wash cycles and the effect of varying BSA 
concentrations 
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3.1.7 BSA-mCRP interaction  
The results of adding BSA as a blocking buffer (figure 3.1.6) was not as expected and 
therefore its role in the immunoassay and any interactions were explored further. 
Figure 3.1.7 shows the effect of different BSA concentrations on signal strength and 
capture antibody coating with increasing concentrations of biotinylated mCRP. No 
competition was introduced to the plate in the form of free mCRP in order to assess 
BSA-mCRP interaction alone. 
BSA was first assessed as a potential blocking buffer to reduce non-specific binding. 
Figures 3.1.7A-C show that avidin associates to biotinylated mCRP in a dose-
dependent manner and there is very little difference in absorbance as biotinylated 
mCRP concentration increases from 5-40 µg/ml. As it was observed that as BSA 
concentration increases, absorbance increases as seen in figure 3.1.7D, a graph was 
plotted to directly compare 0%, 0.5% and 2% BSA and the effect on absorbance. 
The absorbance at 0% BSA is only a tenth of that at 2% BSA.  
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Figure 3.1.7 Graphs displaying possible BSA-mCRP interaction by using different BSA 
concentrations. Legends in A-C display avidin concentration (µg/ml). In A, BSA concentration is 
2%; in B, BSA concentration is 0.5%; in C BSA concentration is 0%. D compares the different BSA 
concentrations at one avidin concentration – 0.1 µg/ml. Error bars display standard error. There 
were significant differences between the different BSA concentrations in D (p < 0.001). 
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3.1.8 Possible antibody-avidin and plate-avidin non-specific binding 
For the analyses presented in figure 3.1.8, antibody was coated on the plate as 
specified on the x-axes and no mCRP or biotinylated mCRP was added to the plate 
to assess any avidin-antibody interactions. 
In in figures 3.1.8A-C, there is no significant difference between absorbance at 1:40 
antibody concentration and 0 antibody concentration across all BSA concentration 
ranges but there are significant differences between different avidin concentrations 
(p > 0.001, p = 0.020 and p > 0.001, for 2%, 0.5%, 0% BSA, respectively). Figure 
3.1.8D compares absorbance at different BSA concentrations at 0.1 µg/ml, there 
was no significant effect of BSA concentration on absorbance (p = 0.50). The 
absorbance values in figure 3.1.8 is not as great as in figure 3.1.7 and the magnitude 
of difference between each of the values is also less. In figure 3.1.8.1, there is a 
slight but not significant association between in plate-avidin binding and increasing 
avidin concentration (p = 0.21). There is an association between BSA concentration 
and avidin-plate binding (p> 0.001). 
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Figure 5 Assessing possible antibody-avidin non-specific binding. Data from graphs A, B and C were 
blocked with 2%, 0.5% and 0% BSA, respectfully. Legends in A-C display avidin concentration 
(µg/ml). D compares the different BSA concentrations at one avidin concentration – 0.1 µg/ml. 
Error bars display standard error. Ab: antibody 
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3.1.9 Milk protein vs BSA as blocking buffer 
The 3.1.7 experiment was repeated by comparing BSA and milk proteins directly 
over a wider range of mCRP concentrations. This was to assess if milk protein was a 
more appropriate blocking agent than BSA and if the association between mCRP 
and BSA was mammalian in nature. The plates were coated with 1:100, 1:200 and 
1:400 antibody concentrations. BSA was made to 2% for each experiment, milk 
protein was made to 5% and 10% concentrations. Each blocking concentration was 
tested with each mCRP and antibody concentration. 
In figure 3.1.9A, the BSA retains a higher signal than milk protein by comparing the 
same concentration antibodies between the two blocking agents. The distinction 
between data series and the variability displayed is still poor even when 0.05% 
Tween washes were used. This demonstrates a problem with repeatability. 
When using 10% milk protein to block plates, there is no significant difference 
between the three antibody concentrations used (p = 0.77). In figure 3.1.7B, milk 
protein concentration has an effect on absorbance. At antibody concentration 
1:100, 10% milk produces a significantly higher signal than 5% milk (p < 0.01). There 
are significant differences in absorbance between BSA and milk protein when 
comparing corresponding antibody concentrations (all p > 0.001).  
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Figure 3.1.9 Comparing milk protein and BSA as blocking buffers. A) BSA and milk as blocking 
buffers with antibody concentrations at 1,100, 1,200 and 1,400. B) shows a repeat of the A) but 
with different concentrations of milk protein and legend shows antibody concentration (1,100; 
1,200; 1,400) and BSA, 10% milk and 5% milk. Error bars represent standard error. 
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3.1.10 Antibody coating buffer™ and Monster Block™ 
Figure 3.1.10 shows the difference in absorbance between using antibody diluted in 
distilled water to that in Antibody coating buffer™. Antibody coating buffer™ was 
used as directed by the manufacturer. In figure 3.1.10, a steeper curve is observed 
between 0-60 µg/ml and a stronger signal overall when using the coating buffer. 
There is 4 times the signal when using the coating buffer compared to dH2O (p < 
0.001). Figure 3.1.10B shows the correlation between exponential mCRP 
concentrations and absorbance. R2 is higher than both R2 values in figure 3.1.10A. 
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Figure 3.1.10 Comparison between coating plates with antibody with and without Antibody 
Coating Buffer™ and possible interaction between mCRP and Monster Block™. (A) is coated with 
1:200 antibody and (B) with 1:50 antibody. Error bars represent standard error. 
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3.1.11 Possible interaction between mCRP and Monster Block™ 
The results from the milk and BSA experiments show a possible affinity between 
mCRP and mammalian proteins; therefore, a non-mammalian block was found to 
assess this hypothesis. The same procedure that was done for BSA-mCRP was done 
for mCRP-Monster Block™ association. However, no antibody was present for these 
experiments and there was competing mCRP to the mCRP-biotin to make a 
rudimentary competitive immunoassay. Monster Block™ was used neat (100%) and 
diluted in dH2O to 50% and to 0%. As seen in figure 3.1.11, higher concentration of 
Monster Block™ produces lower signal. There are significant differences between 
all Monster Block™ concentrations at 80 µg/ml and 120 µg/ml when competing 
mCRP standard concentration is 0 µg/ml and across data sets (p < 0.001). 
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Figure 3.1.11 Assessing mCRP-Monster Block™ interaction with no antibody present. The different data 
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3.1.12 mCRP-biotin conjugate competing with non-labelled mCRP standards 
By using the Monster Block, the results looked more linear than with the 
mammalian blocks and therefore competing mCRP standards were reintroduced to 
form a competitive assay once more. Figure 3.1.12A shows the use of mCRP from 
an existing CRP lot and figure 3.1.12B was from a new CRP lot. It was though that 
mCRP may degrade even at 4°C and the variation in concentration seen between 
lots of CRP may also contribute to variation. It was therefore decided to test this 
hypothesis. 
After introducing mCRP standard concentrations, the higher mCRP-biotin 
concentrations continue yield the highest absorbance values (figure 3.1.12A). There 
is no trend of decreasing absorbance from 0-70 µg/ml and the intermediate values 
are not linear. 
The same was witnessed for the data in figure 3.1.12B. TMB incubation time was 
assessed as a potential variable and therefore its incubation time was changed. The 
longer TMB incubations times did increase signal strength only at higher mCRP-
biotin concentrations (both 160 µg/ml and 120 µg/ml 10 mins vs 16 mins p < 0.001; 
80 µg/ml 10 mins vs 16 mins p = 0.840). 
The analytical sensitivity under the conditions of figure 3.1.12B was calculated using 
the theoretical equivalent of two standard deviations above the zero calibrator of 
10 replicates of a zero concentration sample and was found to be 0.22 units of 
absorbance. The within-assay imprecision was too great to estimate to which 
concentration this refers. 
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error. 
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3.1.13 Experimentation of mCRP incubation time at 24h and 48h at room 
temperature 
As the difference in TMB incubation made a significant difference to the results of 
the competitive immunoassay, the incubation times for the competing mCRP were 
increased to 24h and 48h at room temperature. The hypothesis behind this was to 
allow the mCRP and the mCRP-biotin to equilibrate to produce a linear, less variable 
curve. The results in figure 3.1.13 show that the mCRP began to degraded as the 
signal strength was decreased after 24h and 48h at room temperature. 
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Figure 3.1.13 Competitive immunoassay with 24h and 48h mCRP incubation time at 
room temperature. A) shows 24h incubation and B) shows 48h incubation times. 
mCRP-biotin are shown in the legend and each data series represents one mCRP-biotin 
concentration. 
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3.1.14 Experimentation of mCRP incubation time at 24h and 48h at 4°C 
It appeared the mCRP was degrading in the immunoassay at room temperature. 
Therefore, to allow equilibration to take place but to preserve the integrity of the 
mCRP, the incubation of the competing mCRP was conducted at 4°C. 
At 24h (figure 3.1.14A) the integrity of the mCRP remained somewhat intact. 
However, there is a general increasing trend with increasing mCRP concentration, 
which is opposed to the theory of the assay. It could be that the equilibration stage 
has allowed the mCRP and mCRP-biotin to associate instead of compete and the 
unbound mCRP-biotin could associate with antibody-bound unlabelled mCRP. This 
also could suggest the biotinylation of mCRP may affect its binding properties if 
unlabelled mCRP is binding to the antibodies and then mCRP-biotin associates to 
the antibody indirectly through the unlabelled mCRP. The biotinylation kit does 
quench the biotinylation reaction to prevent further unwanted biotinylation. 
Therefore, the error would not come from the kit but this may point to the 
hydrophobicity of mCRP and its affinity for any species but water. 
Figure 3.1.14B shows the result after 48h incubation at 4°C. The pattern of 
degradation is similar to that of the room temperature incubations (figure 3.1.13). 
This points to mCRP as not stable outside its specific pH and solute conditions and 
as the immunoassay would create a different physical chemistry conditions, mCRP 
is liable to degrade even at low temperatures.  
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Figure 3.1.14 Competitive immunoassay with 24h and 48h mCRP incubation time at 4°C. A) 
shows 24h incubation and B) shows 48h incubation times. mCRP-biotin are shown in the 
legend and each data series represents one mCRP-biotin concentration. 
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3.1.15 Using a mixing plate to pre-equilibrate the mCRP-biotin and competing mCRP 
The equilibration of mCRP-biotin and competing mCRP therefore pre-mixing the 
two solutions in an antibody-free prep plate before adding to the experimental 
plate was done. TMB of the prep plate was also applied to assess mCRP-plate 
binding. The mCRP-biotin would only be present in the plate for a maximum of 5 
minutes before application to the experimental plate that had already been coated 
with antibody. Monster Block™ was used as a blocking agent on the experimental 
plate. 
Similar results (figure 3.1.15) were seen as previously without pre-mixing. The prep 
plate had very high absorbance considering there was no antibody and therefore no 
specific binding site for the mCRP-biotin to bind. 
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Figure 3.1.15 Pre-
mixing of mCRP-
biotin and mCRP 
and the effect of 
absorbance on the 
mixing plate. A) 
Legend shows 
mCRP-biotin 
concentrations and 
x-axis shows 
competing mCRP 
concentrations. B) 
mCRP-biotin was in 
contact with these 
wells for a 
maximum of 5 
minutes and 
without antibody. 
The comparison 
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without BSA (figure 
…) is that the prep 
plate has over 4 
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71 
 
3.2 Sandwich ELISA for the determination of mCRP concentration 
3.2.1 Monoclonal anti-human CRP antibody ab24462 as detection antibody 
A new approach of developing a sandwich ELISA was considered. The 8C10 mCRP 
antibody was still used, as the lack of sensitivity displayed in previous analyses may 
be overcome by the addition of a sensitive detection antibody. As Wang et al., (38) 
showed success with monoclonal antibody ab24462 but a different source of 
capture antibody, a novel ELISA using the 8C10 clone was proposed for 
development. 
Figure 3.2.1A shows that no signal was achieved by using this antibody pairing as 
absorbances for all standards (0-32 µg/ml) fall either side of the zero. The 
experiment was repeated with a greater range of mCRP standards (0-160 µg/ml) 
but still no signal was achieved. It was concluded that the two antibodies shared 
the same or very close epitopes with the capture antibody, 8C10 hiding the epitope 
from the detection antibody, ab24462. From this evidence, it was decided that a 
polyclonal antibody would be a btter option because a polyclonal would recognise 
many different epitopes around the pCRP, and therefore mCRP, molecule and 
would produce a signal. 
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Figure 3.2.1 Development of sandwich ELISA for mCRP concentration determination using 
monoclonal antibody ab24462. A) shows the first experiment with a small range of standards (0 
– 32 µg/ml) and B) shows a wider range of standards (0 – 160 µg/ml). The legends display the 
antibody concentrations in the conformation of 8C10; abcam24462. 8C10 was used at 
concentrations 0, 1:50 and 1:200; abcam24462 was used at 1:3000 and 1:6000. Each 
concentration was tested with each other to produce 6 data series.  
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3.2.2 Polyclonal anti-human CRP antibody ab19175 as detection antibody 
As previously, the assay was conducted with and without capture antibody present. 
As seen in figure 3.2.2, the antibody was used at 0 and 1:50 concentration, as 
denoted by the first number of each line in the legend. The detection antibody was 
used at 1:3000, as recommended by the manufacturer, and 1:6000. Concentrations 
from both antibodies were tested together to produce the data series seen in the 
figure. 
The 1:50 capture antibody concentrations are significantly different from their 0 
antibody concentration counterparts (1:3000, p < 0.001; 1:6000, p < 0.001). There is 
an outlier at 1 µg/ml for 0 + 1:6000, however due to the apparent random nature of 
mCRP behaviour, this was not considered representative. However, this curve was 
not repeatable to the same strength of absorbance nor to the same linearity in 
following experimentation. 
Line equation for 1:50 + 1:3000
y = 0.0538x2 - 0.2189x + 0.1723
R² = 0.9967
Line equation for 1:50 + 1:6000
y = 0.0609x2 - 0.2621x + 0.2189
R² = 0.9748
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Figure 3.2.2 Sandwich ELISA for the determination of mCRP concentration. Two concentrations 
were used for each antibody creating 4 lines in the figure. Capture antibody concentrations 
were at 0 and 1:50 and detection antibody concentrations were at 1:3000 and 1:6000. Two 
polynomial trendlines were created for the 1:50 capture antibody for mCRP determination in 
unknown samples. 
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3.2.3 Non-repeatability of the sandwich ELISA with polyclonal anti-human CRP 
antibody ab19175 
The attempts to repeat the standard curves in figure 3.2.2 are displayed below and 
in order of when the plates were run. There appeared to be degradation of signal 
and the strongest signals varied between 0 antibody and antibody presence. pCRP 
was measured alongside mCRP shown in figure 3.2.3, and no significant differences 
were found between p/mCRP standard curves (1:50 antibody p = 0.535; 0 antibody 
p= 0.092).  
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Figure 3.2.3 Poor repeatability of the mCRP ELISA with ab19175. A), B) and C) all show the 
same protocol repeated on three separate days in consecutive weeks. Legends denote capture 
antibody and detection antibody concentrations, respectively. D) shows cross-reactivity 
between pCRP and the 8C10 mCRP antibody. The curves also have a clear downward trend as 
the standard concentrations increase. Legend denotes CRP isoform; 8C10 antibody 
concentration, respectively. 
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3.3 Summary of the immunoassay development 
The above analyses show the attempt at immunoassay development for the 
determination of mCRP in serum.  The aim was to create an immunoassay 
analytically sensitive enough to use in clinical diagnoses. A competitive 
immunoassay was first developed, which was not sensitive or reliable enough to be 
used in diagnoses. Therefore, it was decided that an ELISA would be attempted as 
its design allows higher sensitivity. However, the same problems remained and the 
major theme for the assay was high intra- and interassay variability that rendered 
the assay clinically unusable. This is hypothesised to be down to: 
 Poor antibody source 
 The hydrophobicity and short half-life of mCRP outside of high pH 
 mCRP’s association with: 
o BSA 
o Milk protein 
o ELISA plate wells 
o Other mCRP monomers 
From the evidence shown, the most limiting factor was the poor antibody. The 
assumed functional sensitivity of 2 µg/ml is far above concentrations found 
systemically and it became clear that any adaptation to the assay, apart from a 
more sensitive antibody, would not improve the assay’s performance. Therefore, 
the development was discontinued. 
 
  
78 
 
Chapter 4: Diagnosis of NSTEMI with non-kinetic cTn values 
  
Chapter 4: Diagnosis of NSTEMI with non-
kinetic cTn values 
79 
 
4.1 Baseline characteristics of included patients 
The baseline characteristics of the 724 patients included in the study are displayed 
in Table 4.1. AMI was the adjudicated diagnosis in 75 patients (10%). The average 
time between symptom onset and assessment was 4.5h. After a follow-up period of 
42 days there were 6 (0.8%) deaths, 3 (4%) in the group adjudicated with AMI (all 3 
of AMI) and 3 (0.4%) in the group who were not adjudicated with AMI (1 of 
carcinomatosis from the lung, 1 of colon cancer and 1 not recorded).  
 
Table 4.1 Baseline characteristics of the patients 
Variable Total (n = 724) AMI (n = 75) No AMI (n = 
645) 
p value 
Age (mean, 95% 
CI) 
 
55.5 (54.4 – 
56.7) 
62.3 (59.0 – 
65.6) 
54.7 (53.5 – 
55.8) 
< 0.001 
Sex, male (%) 
 
439 (60.6) 49 (65.3) 388 (645) 0.385 
Prior myocardial 
infarction (%) 
 
175 (24.2) 22 (29.3) 152 (23.6) 0.269 
Previous angina 
(%) 
 
193 (26.7) 22 (29.3) 169 (26.2) 0.561 
Prior coronary 
intervention (%)  
 
141(19.5) 16 (21.3) 124 (19.2) 0.662 
Previous 
hypertension (%) 
325 (44.8) 43 (57.3) 281 (43.6) 0.023 
Previous 
hyperlipidaemia 
(%) 
 
264 (36.5) 42 (56) 222 (34.4) < 0.001 
Current smoker 
(%) 
 
157 (21.7) 25 (33.3) 132 (20.5) 0.011 
ECG ischaemia (%) 
 
58 (8.1) 10 (13.3) 48 (7.4) 0.076 
Prior CABG (%) 
 
46 (6.4) 6 (8) 38 (5.9) 0.471 
Diabetes mellitus 
(%) 
 
9 (1.2) 2 (2.7) 7 (1.1) 0.245 
Chronic kidney 
disease (%) 
 
26 (3.6) 9 (12) 16 (2.2) < 0.001 
H-FABP positive 
(%) 
88 (12.2) 12 (16.0) 63 (9.8) 0.291 
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4.2 Baseline cTn levels of AMI and no AMI groups 
Baseline levels of cTn were higher in patients adjudicated with AMI than those who 
were not as shown in Figure 4.2. In the AMI group, baseline cTn concentrations for 
the Roche, Singulex and iSTAT assays were 201.92 pg/ml± 46.9 (95% CI 121.1 – 
305.3), 523.61 pg/ml ±206.1 (95% CI 196.4 – 995.9) and 452.4 pg/ml ± 132.8 (CI 
95% 243.8 – 738.6), respectively. Baseline cTn concentrations of patients without 
AMI for the Roche, iSTAT and Singulex assays were 8.00 pg/ml  ±10.1 (95% CI 7.2 – 
8.8), 38.6 pg/ml  ±438.4 (95% CI 12.3 – 76.6) and 73.44 pg/ml ±1550.4 (95% CI 18.3 
– 2680.2), respectively. At baseline, the mean difference between these groups for 
the Roche assay was 193.92 pg/ml ±47.0 (95% CI 100.2 – 287.6; p > 0.001) for the 
Singulex assay was 484.92 pg/ml ±215.9 (95% 54.6 – 915.2; p = 0.028) and for the 
iSTAT was 377.4 pg/ml ±145.8 (95% CI 88.5 – 666.3; p = 0.011). 
  
Figure 4.2 Mean baseline cTn concentrations 
according to the Roche, Singulex and iSTAT 
assays. Bars are clustered by whether an 
outcome has occurred or not occurred (AMI and 
no AMI). Bars include results from one assay, as 
specified by the legends and are assorted by 
colours. The y-axis shows mean baseline cTn in 
pg/ml. Error bars indicate 95% CI. 
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4.3 Distribution of cTn 0h and 3h values 
For the Roche assay (figure 4.3), the majority of the 0h no AMI samples are to be 
found between 0 – 100 pg/ml (99.8%) with very little spread across 100 – 1000 
pg/ml (0.2% 100 – 200 pg/ml). The majority of the AMI 0h samples are also found in 
the 0 – 100 pg/ml group but not to the same degree (65.7%) and the frequencies in 
other groups is higher (19.4% in 100 – 200 pg/ml; 10.4% in 200 – 300 pg/ml; 4.5% at 
≥ 300 pg/ml). A similar pattern is visible in the 3h samples (0 – 100 pg/ml, 99.8% for 
no AMI, 67.7% for AMI) but with more spread in the AMI group as more consistent 
frequencies are seen at higher concentrations (12.3% in 100 – 200 pg/ml; 4.6% 200 
– 300 pg/ml; 1.5% for each bin thereafter apart from 800-900 pg/ml, binned every 
100 pg/ml).  
As with the Roche assay, the majority of the 0h samples according to the Singulex 
assay (figure 4.3) are found in the lowest concentration bin of 0 – 100 pg/ml  (no 
AMI 98%; AMI 72.1%). There are more consistent frequencies of samples above 100 
pg/ml for the 0h AMI samples (7.5% in 100 – 200 pg/ml; 6% in 200 – 300 pg/ml and 
3% each in 400 – 500, 500 – 600 and 600 - 700 pg/ml). The 3h no AMI include 99.1% 
< 100 pg/ml and AMI samples have more patients with higher concentrations, 
65.6% at < 100 pg/ml 7.8% in 100 – 200 pg/ml, 3.2% in 200 – 300 pg/ml, 9.4% in 400 
– 500 pg/ml and 4.7% in 600 – 700 pg/ml. 
The iSTAT assay (figure 4.3) also follows the pattern on the two assays above. For 
the 0h no AMI and AMI groups there measured 100% and 65.7% < 100 pg/ml .The 
AMI group showed consistent frequencies from 100 pg/ml onwards (5.9% in 100 – 
200 pg/ml; 4.4% in 200 – 300 pg/ml; 2.9% in 300 – 400 pg/ml; 7.3% in 400 – 700 
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pg/ml and 1.5% in 900 – 1000 pg/ml). This was not seen in the 3h samples where all 
samples were included < 100 pg/ml. 
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Figure 4.3 Distribution in histograms of cTn values in AMI and no AMI groups according to the Roche, 
Singulex and iSTAT assays. A) Roche 0h B) Roche 3h C) Singulex 0h D) Singulex 3h E) iSTAT 0h F) iSTAT 3h. 
AMI groups (left) are in blue and no AMI groups (right) are shown in green. Distribution is shown as 
percentage cohort per 100 pg/ml from 0 – 1000 pg/ml. 
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4.4 Diagnostic accuracy of 0h, 3h and maximum values of cTn for AMI 
diagnosis 
The aim of these analyses was to determine a cut-off that produced 100% 
sensitivity for rule out diagnoses. The diagnostic accuracy of the iSTAT assay at 0h is 
higher than that of the Roche and Singulex assays (AUC 0.518, 95% CI 0.444 – 0.592 
for Roche assay; AUC 0.84, 95% CI 0.791 – 0.908 for the Singulex assay; AUC 0.890, 
95% 0.837 – 0.943 for the iSTAT) (figure 4.4). 
As seen in table 4.4, the 0h cut-offs for the Roche, Singulex and iSTAT assays at 
5.03, 0.8550 and 10 resulted in sensitivities of 48.5%, 100.0% and 46.0%, of which 
the Singulex was significantly more clinically sensitive (p < 0.001). The number of 
patients below the cut-off is higher when using the Roche or iSTAT assays but the 
clinical sensitivities of these assays are significantly lower in comparison to the 
Singulex assay (48.5%, 47.1%, 51.5%; 100.0%, 97.3%, 100.0%; 46.0%, 65.1%, 57.1%, 
all assays p < 0.001 for the 0h, 3h and max values of the Roche, Singulex and iSTAT, 
respectfully). 
The Singulex assay produced sensitivities and NPVs for 0h and max values at 100% 
but the 3h was lower at 97.3% (95% CI 90.6 – 100.0) and 96.4% (95% CI 86.8 – 99.0), 
respectively (0h vs 3h p = 0.542; 3h vs max p < 0.001). 
The iSTAT assay produced very high specificities (0h: 98.7%, 95% CI 97.2 – 99.5, 3h: 
99.2%, 95% CI 98.0 – 99.8, max values: 98.3%, 95% CI96.7 – 99.2) and with high 
PPVs (80.6%, 95% CI 65.4 – 90.1, 91.1%, 95% CI 79.2 – 96.5 and 80.0%, 95% CI 66.9 
– 88.8, respectively). 
Using the max cTn values from the baseline or 3h samples produced a higher cut-
off, 1.3450 pg/ml, with 30% of patients below cut-off with 100% sensitivity.  
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Figure 4.4 ROC curve of cTn 0h, 3h 
and max values according to the 
Roche, Singulex and iSTAT assays 
for 30-day composite MACE. Each 
graph represents the results from 
one assay. Each line within the 
graphs represents the ROC curve 
associated with either 0h, 3h or 
maximum values, as specified in the 
legends. A) Roche assay curves; B) 
Singulex assay curves; C) iSTAT assay 
curves. 0h: 0h cTn; 3h: 3h cTn; max: 
maximum value from 0h and 3h cTn 
samples. 
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Table 4.4 Diagnostic accuracy of 0h, 3h and max cTn values for AMI diagnosis 
 AUC 
(95% 
CI) 
P Cut-off 
(pg/ml) 
Patients 
below 
cut-off 
(%) 
Sensitivity Specificity PPV NPV 
Roche         
0h 0.518 
(0.444 – 
0.592) 
< 0.001 5.03 51 48.5 (36.2 
–61.0) 
51.9 (47.7 
– 56.0) 
10.8 
(8.5 – 
13.5) 
89.4 
(86.8 – 
91.5) 
3h 0.480 
(0.406 – 
0.554) 
< 0.001 5.03 52 47.1 (34.8 
– 59.6) 
49.0 (44.8 
– 53.2) 
10.0 
(7.8 – 
12.6) 
88.5 
(85.9 – 
90.8) 
Max 0.547 
(0.466 – 
0.628) 
< 0.001 5.03 49 51.5 (39.0 
– 63.9) 
46.0 (41.9 
– 50.2) 
10.3 
(8.2 – 
12.7) 
88.9 
(85.9 – 
91.1) 
Singulex         
0h 0.849 
(0.791 – 
0.908) 
< 0.001 0.8550* 21 100.0 
(95.3 – 
100.0) 
23.4 (20.2 
– 26.9) 
13.5 
(13.0 – 
14.0) 
100.0 
3h 0.853 
(0.790 – 
0.916) 
< 0.001 0.53 9 
 
97.3 (90.6 
– 100.0) 
9.0 (6.9 – 
11.7) 
11.9 
(11.4 – 
12.4) 
96.4 
(86.8 – 
99.0) 
Max 0.874 
(0.819 – 
0.928) 
< 0.001 1.3450* 30 100.0 
(95.1 – 
100.0) 
5.3 (3.6 – 
7.5) 
11.8 
(11.6 – 
12.0) 
100.0 
iSTAT         
0h 0.890 
(0.837 – 
0.943) 
< 0.001 100* 94 46.0 (33.4 
– 59.1) 
98.7 (97.2 
– 99.5) 
80.6 
(65.4 – 
90.1) 
93.8 
(92.3 – 
95.0) 
3h 0.918 
(0.868 – 
0.968) 
< 0.001 100* 92 65.1 (52.0 
– 76.7) 
99.2 (98.0 
– 99.8) 
91.1  
(79.2 – 
96.5) 
95.9 
(94.4 – 
97.0) 
Max 0.858 
(0.792 – 
0.923) 
< 0.001 100* 94 57.1 (44.1 
– 69.5) 
98.3 (96.7 
– 99.2) 
80.0 
(66.9 – 
88.8) 
95.0 
(93.4 – 
96.2) 
Cut-offs were determined by the concentration the assay exhibits <10% CV. Starred (*) values are ROC-derived cut-offs. 
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4.5 Diagnostic accuracy of 0h, 3h and max cTn values in important patient 
subgroups 
The results of the overall diagnostic accuracy of the different assays in important 
patient subgroups are shown in table 4.5 and ROC curves in figure 4.5. Patients with 
rheumatoid arthritis were also analysed for the diagnostic accuracy of that 
subgroup according to the three assays but only 2 events were recorded and 
therefore a reliable ROC curve could not be constructed. The Roche assay had the 
highest AUC per subgroup across the three assays. There was little difference in 
AUC between 0h, 3h and max values for each of the assays. The diagnostic accuracy 
for females was greater than for males across all assays and the max values in 
female subgroup according to Roche had the highest AUC (0.997). The AUC 
between the three TSSO groups did not change depending on time elapsed 
between symptom onset and assessment but max values AUC were higher than 0h 
and 3h AUC for each TSSO group within assays. The iSTAT assay reported a very low 
AUC for the 0h TSSO ≥ 6h curve with a wide 95% CI (0.564, 95% CI 0.389 – 0.738). 
Table 4.5 Diagnostic accuracy of absolute and relative cTn deltas in patient subgroups using ROC 
curve analysis 
  Roche Singulex iSTAT 
 
 n 0h 3h Max 0h 3h Max 0h 3h Max 
Male 437 0.930 0.984 0.985 0.864 0.848 0.892 0.864 0.924 0.836 
Female 285 0.972 0.973 0.997 0.893 0.900 0.895 0.955 0.927 0.908 
Elderly (≥70 
y) 
151 0.891 0.972 0.985 0.834 0.855 0.901 0.853 0.892 0.867 
Renal failure 30 0.848 0.899 0.899 0.788 0.737 0.854 0.848 0.848 0.571 
Stroke 40 0.764 0.944 0.944 0.741 0.750 0.741 0.741 0.843 0.787 
TSSO < 3h 308 0.927 0.987 0.988 0.906 0.895 0.933 0.932 0.955 0.877 
TSSO 3h ≤ x 
< 6h 
153 0.988 0.958 0.996 0.804 0.782 0.832 0.930 0.944 0.873 
TSSO ≥ 6h 164 0.978 0.984 0.991 0.869 0.875 0.867 0.564 0.834 0.906 
0h: cTn value at 0h; 3h: cTn value at 3h; Max: maximum cTn value from 0h and 3h samples; TSSO: time since symptom 
onset  
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Figure 4.5 ROC curves for the diagnostic accuracy of 0h, 3h and max values of the Roche, Singulex and 
iSTAT assays for AMI diagnosis in important patient subgroups. A) male subgroup; B) female subgroup; C) 
elderly subgroup; D) renal subgroup; E) stroke subgroup; F) < 3h TSSO subgroup; G) 3h ≤ x < 6h TSSO 
subgroup; H) > 6h TSSO subgroup. 0h: 0h cTn sample; 3h: 3h cTn sample; max: maximum value from the 0h 
and 3h samples. 
G H 
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4.6 Summary of the diagnosis of NSTEMI with non-kinetic cTn values 
The above analyses show an approach for safe cut-off for AMI rule out. hs-cTn 
assays can detect cTn in 50% of the healthy population and therefore finding a safe 
cut-off is necessary. The LoDs of the assays or ROC-derived cut-offs were used as 
thresholds. The diagnostic accuracy of cTn by the Roche, Singulex and iSTAT assays 
were observed to assess if patients at low- to no risk of developing AMI could be 
identified. These showed: 
 Singulex assay could rule out AMI from a baseline value with 100% 
sensitivity 
 iSTAT assay has a high specificity and therefore a good candidate for fast 
rule in, due to its high FS 
 Roche assay was an appropriate intermediate and for subgroups 
 Higher thresholds will rule out more patients safely and reduce the number 
of false positives 
The different FS of the assays dictated the performance of the assays and showed 
an important compromise in this cohort: 
 A low enough theshold can confidently rule out 100% of patients but will 
increase the number of false positives 
 A higher threshold can rule in patients more confidently but will increase 
the number of false negatives 
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Chapter 5: Diagnosis of NSTEMI with kinetic cTn deltas  
Chapter 5: Diagnosis of NSTEMI with kinetic 
cTn deltas 
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The baseline characteristics of the cohort are found at the beginning of chapter 2, 
diagnosis of NSTEMI using cTn values of the Roche, Singulex and iSTAT assays. 
5.1 Mean Δabsolute according to the Roche, Singulex and iSTAT assays 
The Δabsolute of cTn between 0h and 3h were significantly different between AMI 
patients and non-AMI patients across all assays (figure 5.1). The mean Δabsolute in the 
AMI and no AMI groups for the Roche assay were 111.06 pg/ml ± 22.0 (95% CI 71.5 
– 157.7) and 1.1 ± 0.1 (95% CI 1.0 – 1.3), respectively. The mean difference between 
these groups for the Roche assay was 109.93 ± 7.5 (95% CI 95.3 – 124.6; p > 0.001). 
For the Singulex assay, the Δabsolute means were 649.26 ± 250.1 (95% CI 285.2 – 
1243.9) and 51.4 ± 25.0 (95% CI 9.7 – 107.7) for the AMI and no AMI groups yielding 
a mean difference of 597.8 ± 243.3 (95% CI 112.3 – 639.3; p = 0.017). The Δabsolute 
means of the iSTAT results were 525.97 ± 172.5 (95% CI 223.7 – 880.2) for the AMI 
and no AMI groups, which gave a mean difference of 513.88 ± 181.1 (95% 152.5 – 
875.3; p = 0.006). 
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Figure 5.1 Mean Δabsolute cTn concentrations according to the Roche, Singulex and iSTAT assays. Bars 
are clustered by whether an outcome has occurred or not occurred (AMI and no AMI). Bars include 
results from one assay, as specified by the legends and are assorted by colours. The y-axis shows mean 
baseline cTn in pg/ml. Error bars indicate 95% CI. 
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5.2 Mean %Δbaseline according to the Roche, Singulex and iSTAT assays 
The mean %Δbaseline according to the different assays are seen in figure 5.2. The 
absolute relative delta to baseline (%Δbaseline) of cTn between AMI and non-AMI 
groups were significant for the Roche and iSTAT assays but not for the Singulex 
assay. The mean %Δbaseline according to the Roche assay for the AMI group is 
320.11% ± 194.2 (95% 99.6 – 783.5) and 19.12% ± 2.2 (95% CI 15.2 – 23.9) in the no 
AMI group giving a mean difference of 301.00% ± 36.8 (95% CI 171.7 – 430.3; p < 
0.001). The means for the AMI and no AMI groups according to the Singulex assay 
are 266.1% ± 57.6 (95% CI 164.2 – 391.1) and 259.7% ± 214.7 (95% CI 54.8 – 735.1), 
respectively, with a mean difference of 6.34% ± 182.2 (95% CI -351.6 – 364.3; p = 
0.972). The iSTAT reported means of 474.4 ± 214.7 (95% CI 175.5 – 943.5) and 46.8 
± 13.3 (95% CI 29.5 – 75.9) for the AMI and no AMI groups, respectively, with a 
mean difference of 427.6 ± 85.5 (95% 259.7 – 595.5; p = 0.056). 
  
Figure 5.2  Mean %Δbaseline cTn 
concentrations according to the Roche, 
Singulex and iSTAT assays. Bars are 
clustered by whether an outcome has 
occurred or not occurred (AMI and no 
AMI). Bars include results from one 
assay, as specified by the legends and are 
assorted by colours. The y-axis shows 
mean %Δbaseline. Error bars indicate 95% 
CI. 
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5.3 Mean %Δmean according to the Roche, Singulex and iSTAT assays 
The mean %Δmean according to the Roche, Singulex and iSTAT assays are shown in 
figure 5.3. The absolute relative delta to mean (%Δmean) of cTn between AMI and no 
AMI groups were significantly different according to the results of each assay. The 
Roche assay reported means of the AMI and no AMI groups as 64.5% ± 6.5 (95% CI 
52.7 – 77.8) and 16.9% ± 1.3 (95% CI 14.3 – 19.4), respectfully, with a mean 
difference of 47.6% ± 6.7 (95% CI 34.2 – 60.9; p < 0.001). For the Singulex assay, the 
means were 77.6% ± 8.3 (95% 62.9 – 96.8) and 36.5% ± 1.9 (95% CI 32.9 – 40.2) for 
the AMI and no AMI groups, which yielded a mean difference of 41.1% ± 8.6 (95% 
CI 24.0 – 58.2; p < 0.001). The iSTAT assay reported means of 83.3% ± 9.0 (95% CI 
67.1 – 101.8) and 56.9% ± 4.1 (95% CI 48.4 – 64.8) for the AMI and no AMI groups 
that produced a mean difference of 26.4% ± 9.9 (95% CI 6.8 – 46.1; p = 0.009).  
  
Figure 5.3  Mean %Δmean cTn concentrations 
according to the Roche, Singulex and iSTAT 
assays. Bars are clustered by whether an outcome 
has occurred or not occurred (AMI and no AMI). 
Bars include results from one assay, as specified by 
the legends and are assorted by colours. The y-axis 
shows mean %Δmean. Error bars indicate 95% CI. 
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5.4 Distribution of cTn Δabsolute, %Δbaseline and %Δmean in AMI and no AMI groups 
The distribution of the Roche deltas by AMI and no AMI groups are shown in figure 
5.4.1. The vast majority of samples in the no AMI groups for Δabsolute, %Δbaseline and 
%Δmean are in the lowest bin of each histogram (100%, 96.1% and 98.1%). The same 
is true of the AMI group with 73.5%, 55.6% and 75.0% of patients experiencing < 
100 pg/ml Δabsolute, < 100% %Δbaseline and < 20% %Δmean, respectively. 
The distribution of the Singulex deltas by AMI and no AMI groups are shown in 
figure 5.4.2. The vast majority of samples in the no AMI groups for Δabsolute, %Δbaseline 
and %Δmean are in the lowest bin of each histogram (98.0%, 82.9% and 90.3%). The 
same is true of the AMI group with 69.1%, 60.9% and 64.3% of patients 
experiencing < 100 pg/ml Δabsolute, < 100% %Δbaseline and < 20% %Δmean, respectively. 
The distribution of the iSTAT deltas by AMI and no AMI groups are shown in figure 
5.4.3. The vast majority of samples in the no AMI groups for Δabsolute, %Δbaseline and 
%Δmean are in the lowest bin of each histogram (100%, 72.3% and 73.2%). The same 
is true of the AMI group with 58.8%, 56.5% and 59.1% of patients experiencing < 
100 pg/ml Δabsolute, < 100% %Δbaseline and < 20% %Δmean, respectively. 
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Figure 5.4.1 Distribution of cTn 
deltas in AMI and no AMI 
groups according to the Roche 
assay. A) shows the histogram 
of Δabsolute, B) shows the 
histogram of %Δbaseline and C) 
shows the histogram of %Δmean. 
AMI groups (left) are in blue and 
no AMI groups (right) are shown 
in green. Distribution is shown 
as percentage cohort per 100 
pg/ml from 0 – 1000 pg/ml for 
Δabsolute, 0 – 1000% for %Δbaseline 
and 0 – 200% for %Δmean. 
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Figure 5.4.2 Distribution of cTn 
deltas in AMI and no AMI 
groups according to the Singulex 
assay. A) shows the histogram of 
Δabsolute, B) shows the histogram 
of %Δbaseline and C) shows the 
histogram of %Δmean. AMI groups 
(left) are in blue and no AMI 
groups (right) are shown in 
green. Distribution is shown as 
percentage cohort per 100 pg/ml 
from 0 – 1000 pg/ml for Δabsolute, 
0 – 1000% for %Δbaseline and 0 – 
200% for %Δmean. 
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Figure 5.4.3 Distribution of cTn 
deltas in AMI and no AMI groups 
according to the iSTAT assay. A) 
shows the histogram of Δabsolute, B) 
shows the histogram of %Δbaseline 
and C) shows the histogram of 
%Δmean. AMI groups (left) are in 
blue and no AMI groups (right) 
are shown in green. Distribution is 
shown as percentage cohort per 
100 pg/ml from 0 – 1000 pg/ml 
for Δabsolute, 0 – 1000% for 
%Δbaseline and 0 – 200% for %Δmean. 
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5.5 Diagnostic accuracy of cTn Δabsolute, %Δbaseline and %Δmean for AMI diagnosis 
The diagnostic accuracy of the three assays for AMI diagnosis is shown in figure 5.5. 
The Δabsolute was highest for all assays. For the Roche assay, the AUC for Δabsolute, 
%Δbaseline and %Δmean were 0.982 (95% CI, 0.960 – 1.000), 0.824 (95% CI, 0.773 – 
0.875) and 0.812 (95% CI, 0.762 – 0.863), respectively. The respective AUC for the 
Singulex assay were 0.855 (95% CI, 0.795 – 0.915), 0.669 (95% CI, 0.592 – 0.745) 
and 0.652 (95% CI, 0.577 – 0.727) and for the iSTAT were 0.868 (95% CI, 0.808 – 
0.928), 0.763 (95% CI, 0.701 – 0.825) and 0.671 (95% CI, 0.619 – 0.723). 
However, the highest sensitivity found for Δabsolute was with the Roche assay at 
89.7% (95% CI, 79.9 – 95.8) vs 85.3% (95% CI, 75.3 – 92.4) and 54.0% (95% CI 40.9 – 
66.6) for the Singulex and iSTAT assays (p < 0.001) (Table 5.5). The highest 
sensitivity for %Δbaseline was produced by the Roche assay (98.4%, 95% CI 91.5 – 
100.0 for Roche; 97.1%, 95% CI 90.1 – 100.0 for the Singulex; 84.1%, 95% CI 72.7 – 
92.1 for the iSTAT, p < 0.001 for all). The sensitivity of the %Δbaseline and %Δmean of 
the Singulex assay, 97.1% (95% CI 90.1 – 100.0) are significantly different to the 
Δabsolute sensitivity of 85.3% (95% CI 75.3  – 92.4) at p < 0.001. The proportion of 
patients under the cut-offs is lowest in the Singulex assay, 47%, 7% and 7%, 
respectively, for the Δabsolute, %Δbaseline and %Δmean, but also has the lowest effective 
cut-offs at 14%. This is in comparison to 78%, 36% and 41%, and 93%, 62% and 62% 
of patients under the respective cut-offs of the Roche and iSTAT assays, but the cut-
offs must be above 341 pg/ml and 1061 pg/ml, and 66 pg/ml and 67 pg/ml for the 
%Δbaseline and %Δmean variables, respectfully. The differences in the number of 
patients ruled out between Roche and the two assays were significant (p < 0.001) 
for all variables. 
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Figure 5.5 ROC curves of cTn 
Δabsolute, %Δbaseline and %Δmean 
according to the Roche, 
Singulex and iSTAT assays for 
AMI diagnosis. Each graph 
represents the results from one 
assay. Each line within the 
graphs represents the ROC 
curve associated with either 
Δabsolute, %Δbaseline and %Δmean, as 
specified in the legends. A) 
Roche assay curves; B) Singulex 
assay curves; C) iSTAT assay 
curves. Absolute: Δabsolute; 
relative baseline: %Δbaseline; 
relative mean %Δmean. 
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Table 5.5 AUROC curves for the diagnosis of AMI for cTn Δabsolute, %Δbaseline and %Δmean 
after 3 hours from presentation 
 AUC  Cut-off Patients 
below 
cut-off 
(%) 
cTnlow  Sensitivity Specificity PPV NPV 
Roche          
Δabsolute 0.823 
(0.770 
– 
(0.876) 
 5.03 78 - 89.7 
(79.9 – 
95.8) 
97.4 
(95.7 -
98.5 
80.3 
(71.0 
– 
87.1) 
98.8 
(97.5 
– 
99.4) 
%Δbaseline 0.823 
(0.770 
– 
0.876) 
 1.4774* 36 341 98.4 
(91.5 – 
100.0) 
46.2 
(41.8 – 
50.6) 
18.1 
(16.9 
– 
19.4) 
99.6 
(97.2 
– 
99.9) 
%Δmean 0.812 
(0.759 
– 
0.865) 
 0.4739* 41 1061 98.4 
(91.4 -
100.0) 
45.7 
(41.3 – 
50.1) 
18.0 
(16.8 
– 
19.3) 
99.6 
(97.1 
– 
99.9) 
Singulex          
Δabsolute 0.855 
(0.795 
– 
0.915) 
 0.53 47 - 85.3 
(75.3  – 
92.4) 
50.9 
(46.9 – 
54.8) 
16.8 
(15.2 
– 
18.6) 
96.8 
(94.5 
– 
98.1) 
%Δbaseline 0.669 
(0.592 
– 
0.745) 
 3.6901* 7 14 97.1 
(90.1 – 
100.0) 
7.4 (5.4 
– 10.0) 
11.2 
(10.7 
– 
11.6) 
95.6 
(84.2 
– 
98.9) 
%Δmean 0.652 
(0.577 
– 
0.727) 
 3.7050* 7 14 97.1 
(90.1 – 
100.0) 
7.4 (5.4 
– 10.0) 
11.2 
(10.7 
– 
11.6) 
95.6 
(84.2 
– 
98.9) 
iSTAT          
Δabsolute 0.873 
(0.813 
– 
0.933) 
 10 93 - 54.0 
(40.9 – 
66.6) 
99.0 
(97.8 – 
99.7) 
87.2 
(73.4 
– 
94.4) 
94.7 
(93.1 
– 
95.9) 
%Δbaseline 0.769 
(0.706 
– 
0.832) 
 1.5150* 62 6600 84.1 
(72.7 – 
92.1) 
67.2 
(63.0 – 
71.3) 
23.8 
(20.9 
– 
26.9) 
97.2 
(95.2 
– 
98.4) 
%Δmean 0.672 
(0.619 
– 
0.724) 
 1.4950* 62 6700 85.7 
(74.6 – 
93.3) 
67.4 
(63.2 – 
71.5) 
24.2 
(21.4 
– 
27.3) 
97.5 
(95.5 
– 
98.6)- 
Cut-offs were determined by the concentration the assay exhibits <10% CV. Starred (*) values are ROC-
derived cut-offs. All AUC were p < 0.001 
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5.6 AMI diagnosis with %Δbaseline and %Δmean with fixed cut-offs 
The 10% cut-off was chosen as it is the universally agreed maximum amount of 
variation in a clinically used assay. Therefore it can be said that when measuring 
above the concentration at which the CV <10% variation outside of this bracket can 
be attributed to cTn fluctuations in patients and not attributed to the assay’s 
variation. By using this method, as seen in table 5.6, the sensitivities are similar with 
the Singulex %Δbaseline sensitivity being significantly higher, 86.7% (95% CI 76.8 – 
93.4) in comparison to the  Roche, 76.0% (95% CI 64.8 – 85.1, p < 0.001), and iSTAT, 
68.0% (95% CI 56.2 – 78.3, p < 0.001) assays . The Singulex assay yielded the 
greatest %Δmean sensitivity at 82.7% (95% CI 72.2 – 90.4) while the Roche and iSTAT 
assays produce 77.3% (95% CI 66.2 – 86.2 p < 0.001) and 70.7% (95% CI 59.0 – 
80.6p < 0.001), respectfully. The number of missed diagnoses for Roche would be 
18 and 17, for Singulex would be 10 + 13 and for the iSTAT would be 24 and 22, all 
respectively. 
 
 
Table 5.6 Diagnostic accuracy of absolute relative deltas with cut-offs at 10% for AMI 
diagnosis 
Variable Assay Cut-off 
(%) 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV (95% 
CI) 
NPV(95% CI) 
%Δbaseline Roche 10 76.0 (64.8 – 
85.1) 
60.5 (56.6 – 
64.3) 
18.3 (16.0 – 
20.8) 
95.6 (93.5 – 
97.0) 
Singulex 10 86.7 (76.8 – 
93.4) 
22.8 (19.6 – 
26.2) 
11.6 (10.6 – 
12.6) 
93.6 (89.0 – 
96.4) 
iSTAT 10 68.0 (56.2 – 
78.3) 
73.0 (69.4 – 
76.4) 
22.7 (19.3 – 
26.4) 
95.2 (93.4 – 
96.5) 
%Δmean Roche 10 77.3 (66.2 – 
86.2) 
60.9 (57.0 – 
64.7) 
18.7 (16.5 – 
21.2) 
95.6 (93.8 – 
97.2) 
Singulex 10 82.7 (72.2 – 
90.4) 
12.2 (9.5 – 
15.3) 
12.2 (11.1 – 
13.4) 
82.7 (73.4 – 
89.2) 
iSTAT 10 70.7 (59.0 – 
80.6) 
73.2 (69.6 – 
76.6) 
23.5 (20.2 – 
27.1) 
95.6 (93.8 – 
96.8) 
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5.7 Diagnostic accuracy of Δabsolute, %Δbaseline and %Δmean cTn deltas based on 
baseline cTn 
Two groups were omitted, the rule out group for the Singulex assay (< 0.53 pg/ml; 
n=50, none with AMI) as there were no patients with cTnI below the cut-off of 0.53, 
and the rule in group for the iSTAT assay (≥ 5460 pg/ml; n=2, 1 with AMI) as there 
were too few patients included.  
 As displayed in table 5.7.1, the rule out group (< 5.03 pg/ml) for the Roche assay 
included 322 patients, 4 of whom had AMI. The AUCs for this group were 0.998 
(95% CI, 0.994 – 1.000), 0.998 (95% CI, 0.992 – 1.000) and 0.985 (95% CI, 0.971 – 
0.998) for Δabsolute, %Δbaseline and %Δmean and were the highest out of all the groups 
for Roche. The respective AUC for the intermediate group (n = 291, 41 with AMI) 
were 0.983 (95% CI, 0.968 – 0.997), 0.861 (95% CI, 0.790 – 0.932) and 0.850 (95% 
CI, 0.779 – 0.921) and for the rule in group (n = 27, 25 with AMI) were 0.960 (95% 
CI, 0.883 – 1.000) for all variables.  
The sensitivities in the Roche intermediate group were all 100.0% (95% CI, 91.4 – 
100.0) and NPVs all 100.0%, both higher than the rule out counterparts. The 
specificities for Δabsolute and both %Δ were 79.5% (95% CI, 73.9 – 84.3) and 26.1% 
(95% CI, 20.8 – 32.0) with PPVs at 44.1% (95% CI, 38.2 – 50.1) and 18.0% (95% CI, 
16.9 – 19.1), all respectively. The Roche rule in group presented a specificity and 
PPV of 100.0% for all variables, and a sensitivity of 96.0% (95% CI 79.6 – 99.9) and 
NPV of 50.0% (95% CI, 12.8 – 87.2).  
The sensitivities in the Roche rule out group were all 50.0% (95% CI, 6.8 – 93.2) and 
the specificities were 99.7% (95% CI, 98.3 – 100.0) and 62.3% (95% CI, 56.8 – 67.7) 
for Δabsolute and %Δ, respectively, and the PPVs were 66.7% (95% CI, 18.3 – 94.7) and 
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1.7% (95% CI, 0.6 – 4.3), respectively. The respective NPVs were 99.4% (95% CI, 98.3 
– 99.8) and 99.0% (95% CI, 97.4 – 99.6). 
Table 5.7.1 Diagnostic accuracy of cTn Δabsolute, %Δbaseline and %Δmean after 3h grouped by baseline levels for 
AMI diagnosis according to the Roche assay 
Cut-offs were determined by the concentration the assay exhibits <10% CV. Starred (*) values are ROC-derived cut-offs.  
 AUC (95% 
CI) 
P ROC 
cutoff 
Sensitivit
y 
Specificit
y 
PPV NPV χ2 p 
value 
Roche         
< 5.03 pg/ml         
n=322, 4 with 
AMI 
        
Δabsolute 0.998 
(0.994 – 
1.000) 
0.015 10.5 50.0 (6.8 
– 93.2) 
99.7 (98.3 
– 100.0) 
66.7 
(18.3 – 
94.7) 
99.4 
(98.3 – 
99.8) 
<0.001 
%Δbaseline 0.998 
(0.992 – 
1.000) 
0.015 10 50.0 (6.8 
– 93.2) 
62.3 (56.8 
– 67.7) 
1.7 (0.6 
– 4.3) 
99.0 
(97.4 – 
99.6) 
0.487 
%Δmean 0.985 
(0.971 – 
0.998) 
0.018 9 50.0 (6.8 
– 93.2) 
62.3 (56.8 
– 67.7) 
1.7 (0.6 
– 4.3) 
99.0 
(97.4 – 
99.6) 
0.487 
5.03 < x < 10 
pg/ml 
        
n=295, 41 with 
AMI 
        
Δabsolute 0.983 
(0.968 – 
0.997) 
< 
0.001 
2.5 100.0 
(91.4 – 
100.0) 
79.5 (73.9 
– 84.3) 
44.1 
(38.2 – 
50.1) 
100.0 <0.001 
%Δbaseline 0.861 
(0.790 – 
0.932) 
< 
0.001 
2.8 100.0 
(91.4 – 
100.0) 
26.1 (20.8 
– 32.0) 
18.0 
(16.9 – 
19.1) 
100.0 <0.001 
%Δmean 0.850 
(0.779 – 
0.921) 
< 
0.001 
2.8 100.0 
(91.4 – 
100.0) 
26.1 (20.8 
– 32.0) 
18.0 
(16.9 – 
19.1) 
100.0 <0.001 
≥ 105 pg/ml         
n= 27, 25 with 
AMI 
        
Δabsolute 0.960 
(0.883 – 
1.000) 
0.125 6.0 96.0 (79.6 
– 99.9) 
100.0 100.0 50.0 
(12.8 – 
87.2) 
0.077 
%Δbaseline 0.960 
(0.883 – 
1.000) 
0.125 1.5 96.0 (79.6 
– 99.9) 
100.0 100.0 50.0 
(12.8 – 
87.2) 
0.077 
%Δmean 0.960 
(0.883 – 
1.000) 
0.125 1.5 96.0 (79.6 
– 99.9) 
100.0 100.0 50.0 
(12.8 – 
87.2) 
0.077 
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The diagnostic accuracy of the Singulex assay Δabsolute, %Δbaseline and %Δmean with 
patients grouped by baseline cTn are shown in table 5.7.2. In the intermediate 
group, the %Δbaseline and %Δmean showed good rule out capability with sensitivities of 
100.0 (95% CI, 94.5 – 100.0) and NPVs of 100.0 but very low specificities (1.8%, 95% 
CI 0.2 – 1.9) and PPVs (10.9%, 95% CI 10.9 – 11.0). The NPV of Δabsolute was lower at 
96.4% (95% CI, 93.7 – 98.0) with a sensitivity of 85.5% (95% CI, 75.0 – 92.8) and the 
specificity and PPV were low (46.6%, 95% CI 42.5 – 50.8; 16.2%, 95% CI 14.6 – 17.9, 
respectively). The rule out group had low patient numbers (n = 8, 5 with AMI) to 
attain the highest rule in diagnostic utility. The Δabsolute, %Δbaseline and %Δmean all 
displayed the same sensitivity and PPV at 80.0% (95% CI, 28.4 – 99.5) and 57.1% 
(95% CI, 46.2 – 67.4), respectively, and 0% specificity and NPV.  
Table 5.7.2 Diagnostic accuracy of cTn Δabsolute, %Δbaseline and %Δmean after 3h grouped by baseline levels for 
AMI diagnosis according to the Singulex assay  
Cut-offs were determined by the concentration the assay exhibits <10% CV. Starred (*) values are ROC-derived cut-offs.  
 AUC (95% 
CI) 
P Cut-
off 
Sensitivity Specificity PPV NPV χ2 p 
value 
Singulex         
0.53 < x < 1620 
pg/ml 
        
n=646, 69 with 
AMI 
        
Δabsolute 0.827 (0.765 – 
0.892) 
< 0.001 0.53 85.5 (75.0 – 
92.8) 
46.6 (42.5 – 
50.8) 
16.2 
(14.6 – 
17.9) 
96.4 
(93.7 – 
98.0) 
< 0.001 
%Δbaseline 0.680 (0.600 – 
0.760) 
<0.001 0.66 100.0 (94.5 
– 100.0) 
1.8 (0.2 – 
1.9) 
10.9 
(10.9 – 
11.0) 
100.0 0.630 
%Δmean 0.665 (0.586 – 
0.744) 
<0.001 0.65 100.0 (94.5 
– 100.0) 
1.8 (0.2 – 
1.9) 
10.9 
(10.9 – 
11.0) 
100.0 0.630 
 ≥ 1620 pg/ml         
n=8, 5 with AMI         
Δabsolute 0.200 (0.000 – 
0.570) 
0.180 513 80.0 (28.4 – 
99.5) 
0.0 (0.0 – 
70.8) 
57.1 
(46.2 – 
67.4) 
0 0.625 
%Δbaseline 0.200 (0.000 – 
0.570) 
0.180 12 80.0 (28.4 – 
99.5) 
0.0 (0.0 – 
70.8) 
57.1 
(46.2 – 
67.4) 
0 0.625 
%Δmean 0.200 (0.000 – 
0.570) 
0.180 12 80.0 (28.4 – 
99.5) 
0.0 (0.0 – 
70.8) 
57.1 
(46.2 – 
67.4) 
0 0.625 
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The diagnostic accuracy of the iSTAT assay Δabsolute, %Δbaseline and %Δmean with 
patients grouped by baseline cTn are shown in table 5.7.3. In the rule out group, the 
sensitivity and NPV was found to be 60.0% (95% CI, 14.7 – 94.7) and 99.2% (95% CI, 
97.6 – 99.7), respectively, for all deltas. The specificity and PPVs for Δabsolute and 
%Δmean were 76.4% (95% CI, 71.4 – 81.0) and 3.9% (95% CI, 1.9 – 7.8), respectively, 
and for %Δbaseline were 76.1% (95% CI, 71.0 – 80.7) and 3.8% (95% CI, 1.8 – 7.7), 
respectively. 
The intermediate iSTAT group also displayed similarities between the performance 
of Δabsolute and %Δmean. Sensitivity, PPV and NPV were the same for Δabsolute and 
%Δmean at 82.5% (95% CI, 70.9 – 91.0), 34.9% (95% CI, 30.6 – 39.5) and 94.4% (95% 
CI, 90.7 – 96.7), respectively. Whereas the respective results for %Δbaseline were 
81.0% (95% CI, 69.1 – 89.8), 34.5% (95% CI, 30.1 – 39.1) and 93.9% (95% CI, 90.2 – 
96.3). All deltas reported the same specificity at 65.6% (95% CI, 59.7 – 71.1). 
Table 5.7.3 AUROC for AMI diagnosis by absolute and relative cTn deltas between baseline and 3h grouped by 
baseline levels according to the iSTAT assay 
Cut-offs were determined by the concentration the assay exhibits <10% CV. Starred (*) values are ROC-derived cut-offs. 
 AUC (95% 
CI) 
P Cut-off Sensitivity Specificity PPV NPV χ2 p 
value 
iSTAT         
< 5 pg/ml         
n=324, 11 with AMI         
Δabsolute 0.717 (0.435 
– 0.998) 
0.097 5 60.0 (14.7 – 
94.7) 
76.4 (71.4 – 
81.0) 
3.9 (1.9 
– 7.8) 
99.2 (97.6 – 
99.7) 
0.093 
%Δbaseline 0.668 (0.416 
– 0.921) 
0.198 50 60.0 (14.7 – 
94.7) 
76.1 (71.0 – 
80.7) 
3.8 (1.8 
– 7.7) 
99.2 (97.6 – 
99.7) 
0.096 
%Δmean 0.670 (0.417 
– 0.922) 
0.193 100 60.0 (14.7 – 
94.7) 
76.4 (71.4 – 
81.0) 
3.9 (1.9 
– 7.8) 
99.2 (97.6 – 
99.7) 
0.093 
5 <x< 5460 pg/ml         
n=348, 56 with AMI         
Δabsolute 0.865 (0.802 
– 0.928) 
< 
0.001 
4.5 82.5 (70.9 – 
91.0) 
65.6 (59.7 – 
71.1) 
34.9 
(30.6 – 
39..5) 
94.4 (90.7 – 
96.7) 
< 0.001 
%Δbaseline 0.747 (0.676 
– 0.817) 
< 
0.001 
1.5150 81.0 (69.1 – 
89.8) 
65.6 (59.7 – 
71.1) 
34.5 
(30.1 – 
39.1) 
93.9 (90.2 – 
96.3) 
< 0.001 
%Δmean 0.645 (0.581 
– 0.708 
0.001 1.4950 82.5 (70.9 – 
91.0) 
65.6 (59.7 – 
71.1) 
34.9 
(30.6 – 
39..5) 
94.4 (90.7 – 
96.7) 
< 0.001 
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5.8 Diagnostic accuracy of baseline cTn in predictor composites with cTn 
deltas, acute ischaemia, and H-FABP diagnosis for AMI diagnosis for cardiac-
associated conditions 
The diagnostic accuracy of composite predictors of 0h cTn plus cardiac ischaemia, 
cTn deltas and H-FABP test results are shown below. The results of the Roche assay 
are shown in table 5.8.1. The cTn + ECG composite produced sensitivity and NPV of 
94.7% (95% CI, 86.9 – 98.5) and 98.9% (95% CI, 97.1 – 100.0), respectively. The 
specificity and PPV of cTn + ECG were 54.8% (95% CI, 50.6 – 58.5) and 19.5% (95% 
CI, 18.0 – 21.1). By making the composite of cTn + Δabsolute, %Δbaseline or %Δmean 
instead of ECG ischaemia, the sensitivity is 100.0% (95% CI, 95.0 – 100.0) and NPVs 
are 100%. However, specificities are low at 56.3% (95% CI, 52.4 – 60.2), 0.3% (95% 
CI, 0.0 – 1.1) and 38.2% (95% CI, 34.0 – 42.1), respectively, as well as PPVs (20.5%, 
95% CI 19.1 – 22.0; 10.2%, 95% CI 10.1 – 1.2; 15.4%, 95% CI 14.6 – 16.2, 
respectively). Diagnostic accuracy of the tests were significantly different to each 
other, Δabsolute, %Δbaseline and %Δmean at p = 0.041, < 0.001 and < 0.001, respectively. 
The addition of both ECG ischaemia and Δabsolute, %Δbaseline or %Δmean to cTn 
produced the same sensitivities at 97.3% (95% CI, 90.7 – 100.0), which were lower 
than the deltas alone, and NPVs at 100%. The respective specificities were 56.3% 
(95% CI, 52.4 – 60.2), 0.9% (95% CI, 0.3 – 2.0) and 37.2% (95% CI, 33.5 – 41.1) and 
the PPVs were similar than cTn + deltas or + ECG alone at 19.8% (95% CI, 18.4 – 
21.3), 10.3% (95% CI, 9.9 – 10.6) and 15.3% (95% CI, 14.4 – 16.2). This composite 
was significantly different to cTn + Δabsolute and %Δmean alone (p < 0.001 and = 0.008), 
respectively, but not for %Δbaseline (p = 1.000). The addition of H-FABP improves 
sensitivity across all deltas once more to 100.0% (95% CI, 95.2 – 100.0) and NPV to 
100.0%. Specificities are similar to the composite without the addition of H-FABP 
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analysis at 52.3% (95% CI, 48.3 – 56.2), 0.9% (95% CI, 0.3 – 2.0) and 35.8% (95% CI, 
32.1 – 39.7), respectively. The same occurs with the PPVs at 19.8% (95% CI, 18.4 – 
21.3), 10.3% (95% CI, 9.9 – 10.6) and 15.3% (95% CI, 14.6 – 16.1), respectively. 
Diagnostic accuracy of the predictors + Δabsolute and + %Δmean were significantly 
different to each other, at p < 0.001 and < 0.001, respectively, but + %Δbaseline was 
not (p = 0.500). 
 
  
Table 5.8.1 Diagnostic accuracy of baseline cTn in predictor composites with cTn deltas, acute 
ischaemia, and H-FABP for AMI diagnosis according to the Roche assay 
 
  Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV (95% 
CI) 
NPV (95% CI) χ2 p value 
Roche,  n = 719       
cTn + ECG 
 
 94.7 (86.9 
– 98.5) 
54.8 (50.6 – 
58.5) 
19.5 (18.0 
– 21.1) 
98.9 (97.1 – 
100.0) 
<0.001 
cTn + delta Δabsolute 
pg/ml 
100.0 
(95.0 – 
100.0) 
56.3 (52.4 – 
60.2) 
20.5 (19.1 
– 22.0) 
100.0 <0.001 
%Δbaseline 100.0 
(95.0 – 
100.0) 
0.3 (0.0 – 
1.1) 
10.2 (10.1 
– 1.2) 
100.0 1.000 
%Δmean 100.0 
(95.0 – 
100.0) 
38.2 (34.0 – 
42.1) 
15.4 (14.6 
– 16.2) 
100.0 <0.001 
cTn + ECG + 
delta 
Δabsolute 
pg/ml 
97.3 (90.7 
– 100.0) 
54.1 (50.2 – 
58.0) 
19.8 (18.4 
– 21.3) 
99.4 (97.8 – 
99.9) 
<0.001 
%Δbaseline 97.3 (90.7 
– 100.0) 
0.9 (0.3 – 
2.0) 
10.3 (9.9 – 
10.6) 
75.0 (38.1 – 
93.6) 
0.199 
%Δmean 97.3 (90.7 
– 100.0) 
37.2 (33.5 – 
41.1) 
15.3 (14.4 
– 16.2) 
99.2 (96.8 – 
99.8) 
<0.001 
cTn + ECG + 
delta + H-FABP 
Δabsolute 
pg/ml 
100.0 
(95.2 – 
100.0) 
52.3 (48.3 – 
56.2) 
19.6 (18.3 
– 20.9) 
100.0 <0.001 
%Δbaseline 100.0 
(95.2 – 
100.0) 
0.9 (0.3 – 
2.0) 
10.5 (10.4 
– 10.6) 
100.0 0.516 
%Δmean 100.0 
(95.2 – 
100.0) 
35.8 (32.1 – 
39.7) 
15.3 (14.6 
– 16.1) 
100.0 <0.001 
cTn = baseline cTn; ECG = evidence of ischaemia by ECG; H-FABP = positive or negative test for H-FABP; n = number of 
patients positive for variable in question, in the case of cut-offs a positive result is above the cut-off. 
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The results of the diagnostic accuracy of the predictor composites for the Singulex 
assay are shown in table 5.8.2. The cTn + ECG composite produced high sensitivity 
and NPV of 98.7 (95% CI, 2.8 – 100.0) and 98.5% (95% CI, 90.0 – 99.8), respectively 
and a specificity and PPV of 9.9% (95% CI, 7.7 – 12.5) and 11.3% (95% CI, 10.9 – 
11.7), respectively. The cTn + Δabsolute and + %Δmean did not increase the sensitivity 
from cTn + ECG (98.6%, 95% CI, 92.5 – 100.0 vs 98.7%, 95% CI 92.8 – 100.0) but 
%Δbaseline did (100.0%, 95% CI 95.0 – 100.0) and its NPV also increased to 100%. The 
NPVs of cTn + Δabsolute and + %Δmean did not increase (98.3%, 95% CI 88.9 – 100.0 
and 95.0%, 95% CI 72.1 – 99.3, respectively) nor did the specificities (8.9%, 95% CI 
6.8 – 11.4 and 3.0%, 95% CI 92.5 – 100.0, respectively). The specificity of cTn + 
Δabsolute did decrease to 1.9% (95% CI, 1.0 – 3.3) and the PPVs across cTn + Δabsolute, + 
%Δbaseline and + %Δmean were 10.9% (95% CI, 10.5 – 11.2), 10.3% (95% CI, 10.2 – 10.4) 
and 10.3% (95% CI, 10.0 – 10.6), respectively. The difference seen was not 
significant for + Δabsolute (p = 0.180) but were found to be significant for + %Δbaseline 
or + %Δmean (both p < 0.001). 
The combination of cTn + ECG + Δabsolute, + %Δbaseline or + %Δmean did not improve 
diagnostic accuracy from cTn + Δabsolute, + %Δbaseline or + %Δmean (p = 0.500, = 1.000 
and = 1.000). The cTn + ECG + Δabsolute was similar to cTn + Δabsolute with only 
sensitivity and PPV changing to 98.7% (95% CI, 92.8 – 100.0) and 11.2% (95% CI, 
10.8 – 11.5), respectively. The cTn + ECG + %Δmean had small changes to sensitivity, 
specificity, PPV and NPV at 98.7% (95% CI, 92.8 – 100.0), 3.1 (95% CI, 1.9 – 4.8), 
10.6% (95% CI, 10.3 – 10.9) and 95.2% (95% CI, 73.1 – 99.3). The results for cTn + 
ECG + %Δbaseline were also similar to cTn + %Δbaseline with only specificity and PPV 
increasing slightly (2.0%, 95% CI 1.1 – 3.4; 10.6% (95% CI, 10.5 – 10.7, respectively, 
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p = … vs cTn + %Δbaseline). The addition of H-FABP to cTn + ECG + %Δbaseline or + 
%Δmean did not improve diagnostic accuracy for any parameter but did produce 
smaller specificity and PPV for cTn + ECG + Δabsolute + H-FABP (8.5%, 95% CI 6.5 – 
11.0 and 11.1%, 95% CI 10.8 – 11.5, respectively). The differences seen were not 
significant for + Δabsolute, + %Δbaseline or + %Δmean (p = 0.500, = 1.000 and 1.000, 
respectively). The similarities between the diagnostic accuracy of the cTn + ECG + 
Δabsolute/%Δbaseline/%Δmean + H-FABP and without the addition of H-FABP  
resulted in non-significant differences (p = 0.500, = 1.000 and = 1.000, respectively). 
  
Table 5.8.2 Diagnostic accuracy of baseline cTn in predictor composites with cTn deltas, acute 
ischaemia, and H-FABP for AMI diagnosis according to the Singulex assay 
 
  Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV (95% 
CI) 
NPV (95% CI) χ2 p value 
Singulex, n = 
715 
      
cTn + ECG 
 
 98.7 (92.8 
– 100.0) 
9.9 (7.7 – 
12.5) 
11.3 (10.9 
– 11.7) 
98.5 (90.0 – 
99.8) 
0.009 
cTn + delta Δabsolute 
pg/ml 
98.6 (92.5 
– 100.0) 
8.9 (6.8 – 
11.4) 
10.9 (10.5 
– 11.2) 
98.3 (88.9 – 
100.0) 
0.022 
%Δbaseline 100.0 
(95.0 – 
100.0) 
1.9 (1.0 – 
3.3) 
10.3 (10.2 
– 10.4) 
100.0 0.622 
%Δmean 98.6 (92.5 
– 100.0) 
3.0 (92.5 – 
100.0) 
10.3 (10.0 
– 10.6) 
95.0 (72.1 – 
99.3) 
0.711 
cTn + ECG + 
delta 
Δabsolute 
pg/ml 
98.7 (92.8 
– 100.0) 
8.9 (6.8 – 
11.3) 
11.2 (10.8 
– 11.5) 
98.3 (88.9 – 
99.8) 
0.022 
%Δbaseline 100.0 
(95.2 – 
100.0) 
2.0 (1.1 – 
3.4) 
10.6 (10.5 
– 10.7) 
100.0 0.381 
%Δmean 98.7 (92.8 
– 100.0) 
3.1 (1.9 – 
4.8) 
10.6 (10.3 
– 10.9) 
95.2 (73.1 – 
99.3) 
0.338 
cTn + ECG + 
delta + H-FABP 
Δabsolute 
pg/ml 
98.7 (92.8 
– 100.0) 
8.5 (6.5 – 
11.0) 
11.1 (10.8 
– 11.5) 
98.2 (88.5 – 
99.8) 
0.022 
%Δbaseline 100.0 
(95.2 – 
100.0) 
2.0 (1.1 – 
3.4) 
10.6 (10.5 
– 10.7) 
100.0 0.236 
%Δmean 98.7 (92.8 
– 100.0) 
3.1 (1.9 – 
4.8) 
10.6 (10.3 
– 10.9) 
95.2 (73.1 – 
99.3) 
0.338 
cTn = baseline cTn; ECG = evidence of ischaemia by ECG; H-FABP = positive or negative test for H-FABP; n = number of 
patients positive for variable in question, in the case of cut-offs a positive result is above the cut-off. 
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The results of the diagnostic accuracy of the predictor composites for the iSTAT 
assay are shown in table 5.8.3. The specificity and PPV for cTn + ECG were 92.4% 
(95% CI, 89.9 – 94.3) and 95.0% (95% CI, 93.6 – 96.2), respectively, and sensitivity 
and PPV were 58.0% (95% CI, 45.5 – 69.8) and 46.5% (95% CI, 38.2 – 55.1), 
respectively. The cTn + Δabsolute was greater than cTn + ECG across sensitivity, 
specificity, PPV and NPV at 62.3% (95% CI, 49.8 – 73.7), 98.3% (95% CI, 97.0 – 99.2), 
81.1% (95% CI, 69.4 – 89.1) and 95.8% (95% CI, 94.4 – 96.9), respectively, p < 0.001 
vs equivalents of cTn + ECG. For cTn + %Δbaseline and + %Δmean the sensitivities 
(81.2%, 95% CI 69.9 – 89.6 and 82.6%, 95% CI 71.6 – 90.7, respectively) and NPVs 
(97.0%, 95% CI 95.2 – 98.2 and 97.4%, 95% CI 95.8 – 98.5, respectively) were higher 
but specificities (70.9%, 95% CI 67.1 – 74.5 and 72.4%, 95% CI 68.8 – 75.9, 
respectively) and NPVs (24.2%, 95% CI 21.3 – 27.5 and 24.7%, 95% CI 21.7 – 27.9, 
respectively) were lower (p < 0.001 for all). 
For the cTn + ECG + Δabsolute only sensitivity increased (71.0%, 95% CI 58.8 – 81.3) 
compared to cTn + Δabsolute, specificity, PPV and NPV decreased to 92.2% (95% CI, 
89.7 – 94.2), 51.0% (95% CI, 43.3 – 58.8) and 96.5% (95% CI, 95.0 – 97.6), 
respectively. For cTn + ECG + %Δbaseline and + %Δmean, sensitivities increased to 85.5% 
(95% CI, 75.0 – 92.8 and 87.0% (95% CI, 76.7 – 93.9), respectively, and NPVs 
increased to 97.6% (95% CI, 95.8 – 98.6) and 97.9% (95% CI, 96.1 – 98.8), 
respectively. The specificities of the respective predictors decreased to 68.1% (95% 
CI, 64.2 – 71.8) and 68.2% (95% CI, 64.3 – 71.9) and PPVs to 23.5% (95% CI, 20.9 – 
26.3) and 23.9% (95% CI, 21.3 – 26.7) The differences seen resulted in p < 0.001 for 
the three deltas. The cTn + ECG + %Δbaseline/%Δmean + H-FABP had increased 
sensitivity to 92.8% (95% CI, 83.9 – 97.6) for both deltas but specificities (60.1%, 
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95% CI 56.0 – 64.0 and 60.2%, 95% CI, 56.2 – 64.2, respectively), PPVs (both at 
21.1%, 95% CI 19.2 – 23.1) and NPVs (both at 98.6%, 95% CI 96.9 – 99.4) decreased 
when H-FABP was added to the composite. For The cTn + ECG + Δabsolute + H-FABP 
composite, sensitivity, specificity and PPV decreased (76.8%, 95% CI 65.1 – 86.1; 
81.5%, 95% CI 78.2 – 84.6; 32.3%, 95% CI 27.8 – 37.1, respectively) and only  
NPV increased (96.8%, 95% CI 95.2 – 97.9, all p < 0.001). 
  
Table 5.8.3 Diagnostic accuracy of baseline cTn in predictor composites with cTn deltas, acute 
ischaemia, and H-FABP for AMI diagnosis according to the iSTAT assay 
 
  Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV (95% 
CI) 
NPV(95% CI) χ2 p value 
iSTAT, n = 670       
cTn + ECG 
 
 58.0 (45.5 
– 69.8) 
92.4 (89.9 – 
94.3) 
46.5 (38.2 
– 55.1) 
95.0 (93.6 – 
96.2) 
< 0.001 
cTn + delta Δabsolute 62.3 (49.8 
– 73.7) 
98.3 (97.0 – 
99.2) 
81.1 (69.4 
– 89.1) 
95.8 (94.4 – 
96.9) 
< 0.001 
%Δbaseline 81.2 (69.9 
– 89.6) 
70.9 (67.1 – 
74.5) 
24.2 (21.3 
– 27.5) 
97.0 (95.2 – 
98.2) 
< 0.001 
%Δmean 82.6 (71.6 
– 90.7) 
72.4 (68.8 – 
75.9) 
24.7 (21.7 
– 27.9) 
97.4 (95.8 – 
98.5) 
< 0.001 
cTn + ECG + 
delta 
Δabsolute 71.0 (58.8 
– 81.3) 
92.2 (89.7 – 
94.2) 
51.0 (43.3 
– 58.8) 
96.5 (95.0 – 
97.6) 
< 0.001 
%Δbaseline 85.5 (75.0 
– 92.8) 
68.1 (64.2 – 
71.8) 
23.5 (20.9 
– 26.3) 
97.6 (95.8 – 
98.6) 
< 0.001 
%Δmean 87.0 (76.7 
– 93.9) 
68.2 (64.3 – 
71.9) 
23.9 (21.3 
– 26.7) 
97.9 (96.1 – 
98.8) 
< 0.001 
cTn + ECG + 
delta + H-FABP 
Δabsolute 76.8 (65.1 
– 86.1) 
81.5 (78.2 – 
84.6) 
32.3 (27.8 
– 37.1) 
96.8 (95.2 – 
97.9) 
< 0.001 
%Δbaseline 92.8 (83.9 
– 97.6) 
60.1 (56.0 – 
64.0) 
21.1 (19.2 
– 23.1) 
98.6 (96.9 – 
99.4) 
< 0.001 
%Δmean 92.8 (83.9 
– 97.6) 
60.2 (56.2 – 
64.2) 
21.1 (19.2 
– 23.2) 
98.6 (96.9 – 
99.4) 
< 0.001 
cTn = baseline cTn; ECG = evidence of ischaemia by ECG; H-FABP = positive or negative test for H-FABP; n = number of 
patients positive for variable in question, in the case of cut-offs a positive result is above the cut-off. 
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5.9 Diagnostic accuracy of absolute and relative cTn deltas in important 
patient subgroups 
The results of overall diagnostic accuracy of the different assays in important 
patient subgroups are shown in table 5.9 and ROC curves in figure 5.9. The 
diagnostic accuracy of Δabsolute was higher than %Δbaseline and %Δmean in all assays 
across the subgroups but most prominent in the elderly and patients with renal 
failure. In the elderly subgroup, the Roche assay reported 0.979, 0.773 and 0.771, 
the Singulex assay reported 0.901, 0.764 and 0.760 and the iSTAT assay reported 
0.826, 0.724 and 0.619, all respectively. For the renal failure subgroup, the Roche 
assay reported 0.911, 0.778 and 0.778, the Singulex assay reported 0.878, 0.789 
and 0.789 and the iSTAT assay reported 0.833, 0.644 and 0.606, all respectively. The 
diagnostic accuracy in females was greater than in males and by using the Roche 
assay for Δabsolute a nearly perfect AUC was found (0.993) but was lower for the 
Singulex and iSTAT assays (0.9110 and 0.938, respectively). The rheumatoid arthritis 
subgroup had perfect diagnostically accurate AUC for Δabsolute of all assays and 
%Δbaseline of the iSTAT assay but due to the low patient number with rheumatoid 
arthritis (n = 22), these results are not reliable and a study focused on rheumatoid 
arthritis with a larger cohort would be needed to validate these results. 
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Table 5.9 Diagnostic accuracy of absolute and relative cTn deltas in patient subgroups using ROC 
curve analysis 
 
  Roche Singulex iSTAT 
 
 n Δ %Δb %Δm Δ %Δb %Δm Δ %Δb %Δm 
Male 437 0.972 0.823 0.809 0.860 0.692 0.677 0.836 0.736 0.645 
Female 285 0.993 0.849 0.847 0.910 0.705 0.691 0.938 0.837 0.708 
Elderly (≥70 
y) 
151 0.979 0.773 0.771 0.901 0.764 0.760 0.826 0.724 0.619 
Renal failure 30 0.911 0.778 0.778 0.878 0.789 0.789 0.833 0.644 0.606 
Stroke 40 1.000 0.937 0.958 0.734 0.656 0.656 0.646 0.646 0.458 
Rheumatoid 
arthritis 
22 1.000 0.969 0.969 1.000 0.938 0.938 1.000 1.000 0.875 
TSSO < 3h 308 0.965 0.870 0.854 0.893 0.768 0.757 0.860 0.788 0.663 
TSSO 3h ≤ x 
< 6h 
153 0.992 0.852 0.851 0.811 0.703 0.675 0.926 0.848 0.703 
TSSO ≥ 6h 164 0.991 0.810 0.800 0.884 0.641 0.626 0.850 0.701 0.633 
Δ: Δabsolute; %Δb: %Δbaseline; %Δm: %Δmean; TSSO: time since symptom onset 
 
Figure 5.9 ROC curves for the 
diagnostic accuracy of Δabsolute, 
%Δbaseline and %Δmean according to 
the Roche, Singulex and iSTAT 
assays for AMI diagnosis in 
important patient subgroups. A) 
male subgroup; B) female subgroup; 
C) elderly subgroup; D) renal 
subgroup; E) stroke subgroup; F) 
rheumatoid arthritis subgroup; G) < 
3h TSSO subgroup; H) 3h ≤ x < 6h 
TSSO subgroup; I) > 6h TSSO 
subgroup. Absolute: Δabsolute; relative 
baseline: %Δbaseline; relative mean: 
%Δmean. 
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5.10 Summary of the diagnosis of NSTEMI with kinetic cTn deltas 
The three assays were assessed for the capability of rapid rule out for NSTEMI 
based on cTn deltas. Absolute and relative deltas were based on the FS of the 
assays for maximum sensitivity and therefore only cTn above a calculated level 
were deemed reliable for the relative deltas. The analyses showed: 
 Relative deltas outcome performed absolute deltas 
 Lower thresholds for Singuex cTnlow allowed more of the cohort to be ruled 
out with 100% sensitivity and NPV 
 Tailoring rule in/rule out deltas based on baseline cTn can aid diagnostic 
accuracy 
 Δabsolute is more accurate at lower concentrations and %Δ is more accurate at 
higher concentrations 
 For Singulex, the early rise in H-FABP in AMI pathology does not improve 
accuracy as its very low FS detects cTn rise, and therefore AMI, earlier 
regardless 
 For iSTAT, its poor FS does not detect cTn rises early and therefore the 
addition of an early biomarker such as H-FABP increases its NPV 
 Combining biomarkers that cover more AMI physiology will improve 
diagnostic accuracy  
119 
 
 
Chapter 6: Does non-kinetic cTn predict 30-day outcome?  
Chapter 6: Does non-kinetic cTn predict 30-
day outcome? 
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6.1 Baseline characteristics of the 30-day MACE and 30-day no MACE patients  
The baseline characteristics of the patients are presented in Table 6.1. In total, 10 
conditions were highlighted to assess the prognostic strength of the deltas. The 10 
conditions were all-cause mortality, AMI, revascularisation, PCI, CABG, stenosis, 
tests for heart disease, cardiac arrest, arrhythmia and acute heart failure. 40 
patients (5.5%) of the 724 cohort experienced MACE within 30 days from 
presentation. There were three (0.2%) deaths in the MACE group, one of AMI and 
two of non-cardiac related diseases (1 of carcinomatosis from the lung and 1 of 
colon cancer). The cause of death for the only death of the no MACE group (0.5%) 
was not recorded. 
There were 40 composite MACE events (5.5%) within 30 days including 11 instances 
of PCI, 8 of stenosis, 6 of acute heart failure, 2 patients who experienced cardiac 
arrest and 4 of CABG. There were no patients who had diabetes mellitus and 
experienced 30-day composite MACE and therefore the variable was removed from 
the analyses. 
The average age of the MACE patients was 57.2 years and the majority were male 
(56.3%) but the frequency was less than in the total cohort (60.6%). Patients with 
ischaemia present on ECG had higher than expected incidences of MACE (16.2%, p 
< 0.001). Hyperlipidaemia was found in 43.0% of MACE patients and hypertension 
found in 47.9% of the MACE group. 
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Table 6.1 Baseline characteristics of 30-day MACE positive and 30-day MACE negative 
patients 
 
Variable Total (n = 724) MACE (n = 
142) 
No MACE (n = 
582) 
p value 
Age (mean, 95% 
CI) 
 
55.5 (54.4 – 
56.7) 
57.2 (54.8 – 
59.6) 
55.1 (53.8 – 
56.3) 
0.144 
Sex, male (%) 
 
439 (60.6) 80 (56.3) 359 (61.7) 0.242 
Prior myocardial 
infarction (%) 
 
175 (24.2) 36 (25.4) 139 (23.9) 0.714 
Previous angina 
(%) 
 
193 (26.7) 37 (26.1) 156 (26.8) 0.857 
Prior coronary 
intervention (%)  
 
141(19.5) 28 (19.7) 113 (19.4) 0.935 
Previous 
hypertension (%) 
325 (44.8) 68 (47.9) 257 (44.2) 0.433 
Previous 
hyperlipidaemia 
(%) 
 
264 (36.5) 61 (43.0) 203 (35.0) 0.075 
Current smoker 
(%) 
 
157 (21.7) 33 (23.6) 124 (21.6) 0.614 
ECG ischaemia (%) 
 
58 (8.1) 23 (16.2) 35 (6.0) < 0.001 
Prior CABG (%) 
 
46 (6.4) 8 (5.6) 38 (6.5) 0.695 
Diabetes mellitus 
(%) 
 
9 (1.2) 2 (1.4) 7 (1.2) 0.838 
Chronic kidney 
disease (%) 
 
26 (3.6) 9 (6.4) 21 (3.6) 0.142 
H-FABP positive 
(%) 
88 (12.2) 22 (15.5) 66 (11.3) 0.175 
MACE: major adverse cardiac events as described in the text within 30 days 
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6.2 Baseline cTn concentrations of different 30-day composite outcomes 
The composite MACE group included all outcomes; AV1 included all-cause 
mortality, AMI, revascularisation, PCI, CABG and stenosis; adverse events 2 included 
cardiac arrest, arrhythmia and acute heart failure. All outcomes included events 
that occurred 30 days post-presentation. 
The differences between cTn levels at baseline are shown in figure 6.2. According to 
independent-samples median tests, the differences in median baseline cTn in the 
composite MACE and adverse events 1 were all p < 0.001 for all assays. For adverse 
events 2, only the Singulex showed a significant difference between positive and 
negative groups (p = 0.019) whereas the Roche and iSTAT assays did not (p = 0.621 
and p = 0.870, respectively). 
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  A 
 
B 
 
C 
 
Figure 6.2 Median cTn values at baseline 
by different 30-day prognoses according 
to the Roche, Singulex and iSTAT assays. 
Bars are clustered by whether an 
outcome has occurred or not occurred. 
Bars include results from one assay, as 
specified by the legends and are colour 
coded. Error bars indicate 95% CI. 
Composite: composite MACE; AV1 – 
adverse events 1; AV2 – adverse events 
2. 
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6.3 30-day composite MACE prediction by cTn 0h, 3h and max values 
according to the Roche, Singulex and iSTAT assays 
The ROC curves corresponding to the cTn values of the different assays are 
displayed in figure 6.3 and the AUCs are available in table 6.3. The Roche assay 
produced AUROC of 0.656 (95% CI, 0.594 – 0.717), 0.664 (95% CI, 0.601 – 0.726) 
and 0.661 (95% CI, 0.598 – 0.724) for the 0h, 3h and max values variables, 
respectively all p < 0.001. The Singulex assay had AUROCs for 0h, 3h and max values 
of 0.726 (95% CI, 0.664 – 0.788), 0.741 (95% CI, 0.682 – 0.800) and 0.736 (95% CI, 
0.677 – 0.796), respectively. The iSTAT produced AUROCs for 0h, 3h and max values 
of 0.606 (95% CI, 0.539 – 0.673), 0.652 (95% CI, 0.587 – 0.716) and 0.601 (95% CI, 
0.533 – 0.669), respectively. 
The prognostic accuracy of the Roche, Singulex and iSTAT assays are displayed in 
table 6.3. For Roche, the sensitivity for the 0h, 3h and max values were 65.0% (95% 
CI, 55.9 – 73.4), 65.9% (95% CI, 56.8 – 74.2) and 68.3% (95% CI, 59.3 – 76.4), 
respectively. All of which were greater than the respective specificities at 55.8% 
(95% CI, 51.4 – 60.2), 53.1% (95% CI, 48.7 – 57.5) and 49.8% (95% CI, 45.4 – 54.2). 
NPVs were 87.0% (95% CI 83.8 – 89.6) for 0h, 86.7% (95% CI 83.4 – 89.4) for 3h and 
86.8% (95% CI 83.3 -89.6). The PPVs were much lower at 26.1% (95% CI, 23.1 – 
29.3), 86.7% (95% CI, 83.4 – 89.4) and 86.8% (95% CI, 83.3 -89.6), for the 0h, 3h and 
max value variables, respectively. 
For the 0h, 3h and max values of the Singulex assay, the sensitivities (96.3%, 95% CI 
91.6 – 98.8; 97.8%, 95% CI 93.6 – 100.0; 98.5%, 95% CI 94.7 – 99.8, respectively) 
and NPVs (8.6%, 95% CI 7.8 – 9.4; 94.6%, 95% CI 84.6 – 98.2; 93.6%, 95% CI 77.8 – 
98.4, respectively) were both high with the exception of the 0h NPV. Specificities 
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were low for 0h (21.4%, 95% CI 91.8 – 98.4), 3h (21.9%, 95% CI 21.2 – 22.5) and 
max values 21.2% (95% CI, 20.7 – 21.7). The lowest performance was found with 
the respective specificities at 8.6% (95% CI, 6.3 – 11.3), 9.9% (95% CI, 7.5 – 12.8) 
and 5.5% (95% CI 3.7 – 7.9). 
Conversely, the iSTAT specificities were the highest at 97.1% (95% Ci, 95.2 – 98.4), 
95.8% (95% CI, 93.7 – 97.4) and 95.4% (95% CI, 93.2 – 97.1) for 0h, 3h, max values, 
respectively. The NPVs were high but not as high as the specificities (82.5%, 95% CI 
81.2 – 83.8; 82.9%, 95% CI 81.5 – 84.3; 82.6%, 95% CI 81.1 – 83.9). PPVs for the 0h, 
3h and max values were 64.1% (95% CI, 48.9 – 76.9), 59.2% (95% CI, 45.9 – 71.2) 
and 55.1% (95% CI, 42.0 – 67.5), respectively, and the lowest values were found in 
the sensitivities (20.2%, 95% CI 13.5 – 28.3; 23.4% (95% CI, 16.3 – 31.8; 21.8%, 95% 
CI 14.9 – 30.1, respectively). 
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Figure 6.3 ROC curve of cTn 0h, 3h and maximum values according 
to the Roche, Singulex and iSTAT assays for 30-day composite 
MACE Each graph represents the results from one assay. Each line 
within the graphs represents the ROC curve associated with either 
0h, 3h or maximum values, as specified in the legends. A) Roche 
assay curves; B) Singulex assay curves; C) iSTAT assay curves. 0h: 0h 
cTn sample; 3h: 3h cTn sample; max: maximum cTn value of the 0h 
or 3h samples. The composite MACE group included all outcomes: 
all-cause mortality, AMI, revascularisation, PCI, CABG, stenosis, 
tests for heart disease, cardiac arrest, arrhythmia and acute heart 
failure. 
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Table 6.3 30-day composite MACE prediction by cTn 0h, 3h and max values according to the 
Roche, Singulex and iSTAT assays 
 
 AUC (95% 
CI) 
P Cut-off 
(pg/ml) 
Sensitivity Specificity PPV NPV 
Roche        
0h 0.656 
(0.594 – 
0.717) 
< 0.001 5.03 65.0 (55.9 – 
73.4) 
55.8 (51.4 – 
60.2) 
26.1 
(23.1 – 
29.3) 
87.0 
(83.8 – 
89.6) 
3h 0.664 
(0.601 – 
0.726) 
< 0.001 5.03 65.9 (56.8 – 
74.2) 
53.1 (48.7 – 
57.5) 
25.2 
(22.3 – 
28.2) 
86.7 
(83.4 – 
89.4) 
Max 0.661 
(0.598 – 
0.724) 
< 0.001 5.03 68.3 (59.3 – 
76.4) 
49.8 (45.4 – 
54.2) 
24.6 
(21.9 – 
89.6) 
86.8 
(83.3 -
89.6) 
Singulex        
0h 0.726 
(0.664 – 
0.788) 
< 0.001 0.53 96.3 (91.6 – 
98.8) 
8.6 (6.3 – 
11.3) 
21.4 
(91.8 – 
98.4) 
8.6 (7.8 
– 9.4) 
3h 0.741 
(0.682 – 
0.800) 
< 0.001 0.53 97.8 (93.6 – 
100.0) 
9.9 (7.5 – 
12.8) 
21.9 
(21.2 – 
22.5) 
94.6 
(84.6 – 
98.2) 
Max 0.736 
(0.677 – 
0.796) 
< 0.001 0.53 98.5 (94.7 – 
99.8) 
5.5 (3.7 – 
7.9) 
21.2 
(20.7 – 
21.7) 
93.6 
(77.8 – 
98.4) 
iSTAT        
0h 0.606 
(0.539 – 
0.673) 
< 0.001 100 20.2 (13.5 – 
28.3) 
97.1 (95.2 – 
98.4) 
64.1 
(48.9 – 
76.9) 
82.5 
(81.2 – 
83.8) 
3h 0.652 
(0.587 – 
0.716) 
< 0.001 100 23.4 (16.3 – 
31.8) 
95.8 (93.7 – 
97.4) 
59.2 
(45.9 – 
71.2) 
82.9 
(81.5 – 
84.3) 
Max 0.601 
(0.533 – 
0.669) 
< 0.001 100 21.8 (14.9 – 
30.1) 
95.4 (93.2 – 
97.1) 
55.1 
(42.0 – 
67.5) 
82.6 
(81.1 – 
83.9) 
Cut-offs were determined by the concentration the assay exhibits <10% CV. Starred (*) values are ROC-
derived cut-offs. 
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6.4 30-day AV1 prediction by cTn 0h, 3h and max values according to the 
Roche, Singulex and iSTAT assays 
The prognostic accuracy of the Roche, Singulex and iSTAT assays for 30-day AV1 
prediction are shown as ROC curves in figure 6.4. The AUC for the 0h, 3h and max 
values for the Roche assay are 0.814 (95% CI, 0.756 – 0.872), 0.837 (95% CI, 0.780 – 
0.893) and 0.837 (95% CI, 0.783 – 0.891), respectively. The respective AUC for the 
Singulex assay are 0.867 (95% CI, 0.804 – 0.931), 0.861 (95% CI, 0.795 – 0.927) and 
0.872 (95% CI, 0.812 – 0.931), respectively and for the iSTAT assay are 0.867 (95% 
CI, 0.804 – 0.931), 0.784 (95% CI, 0.712 – 0.855) and 0.707 (95% CI, 0.619 – 0.795), 
respectively. 
The prediction accuracy of the three assays for 0h, 3h and max values for 30-day 
AV1 prognosis are shown in table 6.4. The sensitivities of the Roche assay for 0h, 3h 
and max values are 89.3% (95% CI, 78.1 – 96.0), 83.3% (95% CI, 71.5 – 91.7) and 
86.9% (95% CI, 75.8 – 94.2), respectively and NPVs of 98.2% (95% CI, 96.2 – 99.1), 
97.2% (95% CI, 95.2 – 98.4) and 97.7% (95% CI, 95.6 – 98.8), respectively. The 
respective specificities were 56.0% (95% CI, 51.8 – 60.1), 54.3% (95% CI, 50.3 – 
58.2) and 51.7% (95% CI, 47.8 – 55.6) and the PPVs were low for 0h, 3h and max 
values at 16.5% (95% CI, 14.8 – 18.4), 14.6% (95% CI, 12.9 – 16.4) and 14.5% (95% 
CI, 13.0 – 16.1). 
The Singulex assay produced the highest sensitivity for the AV1 composite out of 
the three assays and were 98.1% (95% CI, 89.9 – 100.0), 96.2% (95% CI, 86.8 – 99.5) 
and 100.0% (95% CI, 94.0 – 100.0) for 0h, 3h and max values. The respective NPV 
are also high at 98.2% (95% CI, 96.2 – 99.1), 97.2% (95% CI, 95.2 – 98.4) and 
100.0%. The specificities for 0h, 3h and max values are low at 7.7% (95% CI, 5.6 – 
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10.3), 8.7% (95% CI, 6.4 – 11.5) and 5.1% (95% CI, 3.5 – 7.2), respectively and were 
also low for the PPVs at 16.5% (95% CI, 14.8 – 18.4), 10.0% (95% CI, 9.4 – 10.5) and 
9.8% (95% CI, 9.6 – 9.9), respectively. 
As with previous analyses, the iSTAT assay had much higher cut-offs that lead to the 
differences between the iSTAT and the other assays, especially when considering 
sensitivity and specificity. For the iSTAT sensitivities for 0h, 3h and max values were 
20.2% (95% CI, 13.5 – 28.3), 23.4% (95% CI, 16.3 – 31.8) and 21.8% (95% CI, 14.9 – 
30.1), respectively (all p < 0.001 vs equivalents of Roche and Singulex assays). The 
respective specificities were higher at 97.1% (95% CI, 95.2 – 98.4), 95.8% (95% CI, 
93.7 – 97.4) and 95.4% (95% CI, 93.2 – 97.1) and the PPVs were the highest of all 
assays (64.1%, 95% CI 48.9 – 76.9; 59.2%, 95% CI 45.9 – 71.2; 55.1%, 95% CI 42.0 – 
67.5, all p < 0.001 vs equivalents of Roche and Singulex). The NPVs for 0h, 3h and 
max values were 82.5% (95% CI, 81.2 – 83.8), 82.9% (95% CI, 81.5 – 84.3) and 82.6% 
(95% CI, 81.1 – 83.9), respectively. 
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Figure 6.4 ROC curve of cTn  0h, 3h and maximum values 
according to the Roche, Singulex and iSTAT assays for 30-day 
adverse events 1 prognosis. Each graph represents the results 
from one assay. Each line within the graphs represents the ROC 
curve associated with either 0h, 3h or maximum values, as 
specified in the legends. A) Roche assay curves; B) Singulex assay 
curves; C) iSTAT assay curves. 0h: 0h cTn sample; 3h: 3h cTn 
sample; max: maximum cTn value of the 0h or 3h samples. 
Adverse events 1 included all-cause mortality, AMI, 
revascularisation, PCI, CABG and stenosis. 
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Table 6.4 30-day adverse events 1 prediction by cTn 0h, 3h and max values according to the 
Roche, Singulex and iSTAT assays 
 AUC (95% 
CI) 
P Cut-off 
(pg/ml) 
Sensitivity Specificity PPV NPV 
Roche        
0h 0.814 
(0.756 – 
0.872) 
< 0.001 5.03 89.3 (78.1 – 
96.0) 
56.0 (51.8 – 
60.1) 
16.5 
(14.8 – 
18.4) 
98.2 
(96.2 – 
99.1) 
3h 0.837 
(0.780 – 
0.893) 
< 0.001 5.03 83.3 (71.5 – 
91.7) 
54.3 (50.3 – 
58.2) 
14.6 
(12.9 – 
16.4) 
97.2 
(95.2 – 
98.4) 
Max 0.837 
(0.783 – 
0.891) 
< 0.001 5.03 86.9 (75.8 – 
94.2) 
51.7 (47.8 – 
55.6) 
14.5 
(13.0 – 
16.1) 
97.7 
(95.6 – 
98.8) 
Singulex        
0h 0.867 
(0.804 – 
0.931) 
< 0.001 0.53 98.1 (89.9 – 
100.0) 
7.7 (5.6 – 
10.3) 
9.6 (9.2 
– 10.0) 
97.6 
(85.2 – 
100.0) 
3h 0.861 
(0.795 – 
0.927) 
< 0.001 0.53 96.2 (86.8 – 
99.5) 
8.7 (6.4 – 
11.5) 
10.0 (9.4 
– 10.5) 
95.6 
(84.3 – 
98.6) 
Max 0.872 
(0.812 – 
0.931) 
< 0.001 0.53 100.0 (94.0 
– 100) 
5.1 (3.5 – 
7.2) 
9.8 (9.6 
– 9.9) 
100.0 
iSTAT        
0h 0.728 
(0.642 – 
0.814) 
< 0.001 100 20.2 (13.5 – 
28.3) 
97.1 (95.2 – 
98.4) 
64.1 
(48.9 – 
76.9) 
82.5 
(81.2 – 
83.8) 
3h 0.784 
(0.712 – 
0.855) 
< 0.001 100 23.4 (16.3 – 
31.8) 
95.8 (93.7 – 
97.4) 
59.2 
(45.9 – 
71.2) 
82.9 
(81.5 – 
84.3) 
Max 0.707 
(0.619 – 
0.795) 
< 0.001 100 21.8 (14.9 – 
30.1) 
95.4 (93.2 – 
97.1) 
55.1 
(42.0 – 
67.5) 
82.6 
(81.1 – 
83.9) 
Cut-offs were determined by the concentration the assay exhibits <10% CV. Starred (*) values are ROC-derived cut-
offs. 
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6.5 30-day AV2 prediction by cTn 0h, 3h and max values according to the 
Roche, Singulex and iSTAT assays 
The predictive accuracy for AV2 by the cTn values is shown as ROC curves in figure 
6.5.  The Roche AUC are 0.582 (95% CI 0.479 – 0.686), 0.568 (95% CI 0.458 – 0.677) 
and 0.570 (95% CI 0.463 – 0.676) for 0h, 3h and max values, respectively. The 
respective AUC for the Singulex assay is 0.611 (95% CI, 0.510 – 0.712), 0.642 (95% 
CI, 0.546 – 0.737) and 0.621 (95% CI, 0.524 – 0.719) and for the iSTAT assay are 
0.526 (95% CI, 0.410 – 0.641), 0.559 (95% CI, 0.438 – 0.680) and 0.597 (95% CI, 
0.478 – 0.716). 
The predictive accuracy of cTn values for composite endpoint AV2 prognosis 
according to the three assays is shown in table 6.5. The Roche assay had 
intermediate but consistent results for 0h, 3h and max values when concerning 
sensitivity (59.3%, 95% CI 38.8 – 77.6; 52.2%, 95% CI 48.0 – 56.5; 59.3%, 95% CI 38.8 
– 77.6, respectively) and specificity (50.3%, 95% CI 46.0 – 54.5; 52.2%, 95% CI 48.0 – 
56.5; 46.9%, 95% CI 42.7 – 51.1, respectively). The PPVs for 0h, 3h and max values 
were low but also consistent at 5.4% (95% CI 4.00 – 7.4), 5.3% (95% CI, 3.8 – 7.4) 
and 5.1% (95% CI, 3.8 – 6.9), respectively, and the NPVs were high at 96.2% (95% CI, 
94.2 – 97.6), 96.1% (95% CI, 94.1 – 97.4) and 96.0% (95% CI, 93.7 – 97.4), 
respectively. 
The Singulex assay showed promising rule out capabilities with sensitivities of 96.3 
(95% CI, 81.0 – 99.9) for 0h, 3h and max values and NPVs of 97.9% (95% CI, 86.8 – 
99.7), 98.0% (95% CI, 87.8 – 99.7) and 96.6% (95% CI, 79.8 – 99.5), respectively. This 
had a significant effect on the respective specificities at 8.2% (95% CI, 6.1 – 10.8), 
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8.9% (95% CI, 6.7 – 11.6) and 5.0% (95% CI, 3.4 – 7.2) and the PPVs at 4.8% (95% CI, 
4.5 – 5.2), 4.8% (95% CI, 4.5 – 5.2) and 4.7% (95% CI, 4.3 – 5.0). 
The iSTAT assay had high specificities for 0h, 3h and max values at 93.6% (95% CI, 
91.2 – 95.5), 92.1% (95% CI, 89.6 – 94.2) and 92.1% (95% CI, 89.6 – 94.2), 
respectively, and high NPVs at 95.6% (95% CI, 95.3 – 96.0), 95.7% (95% CI, 95.2 – 
96.2) and 92.1% (95% CI, 89.6 – 94.2), respectively. The respective sensitivities are 
low at 4.0% (95% CI 0.1 – 20.4), 8.0% (95% CI, 1.0 – 26.0) and 8.0% (95% CI, 1.0 – 
26.0), as are the PPVs at 2.7% (95% CI, 0.4 – 16.3), 4.4% (95% CI 1.2 – 15.0) and 
4.4% (95% CI 1.2 – 15.0) for 0h, 3h and max values, respectively. 
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Figure 6.5 ROC curve of cTn 0h, 3h and maximum values 
according to the Roche, Singulex and iSTAT assays for 30-day 
adverse events 2 prognosis. Each graph represents the results 
from one assay. Each line within the graphs represents the ROC 
curve associated with either 0h, 3h or maximum values, as 
specified in the legends. A) Roche assay curves; B) Singulex assay 
curves; C) iSTAT assay curves. 0h: 0h cTn sample; 3h: 3h cTn 
sample; max: maximum cTn value of the 0h or 3h samples. 
Adverse events 2 included cardiac arrest, arrhythmia and acute 
heart failure. 
B 
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Table 6.5 30-day AV2 prediction by cTn 0h, 3h and max values according to the Roche, Singulex 
and iSTAT assays 
 
 AUC (95% 
CI) 
P Cut-off 
(pg/ml) 
Sensitivity Specificity PPV NPV 
Roche        
0h 0.582 
(0.479 – 
0.686) 
0.140 5.03 59.3 (38.8 – 
77.6) 
50.3 (46.0 – 
54.5) 
5.4 (4.00 
– 7.4) 
96.2 
(94.2 – 
97.6) 
3h 0.568 
(0.458 – 
0.677) 
0.226 5.03 55.6 (35.3 – 
74.5) 
52.2 (48.0 – 
56.5) 
5.3 (3.8 
– 7.4) 
96.1 
(94.1 – 
97.4) 
Max 0.570 
(0.463 – 
0.676) 
0.212 5.03 59.3 (38.8 – 
77.6) 
46.9 (42.7 – 
51.1) 
5.1 (3.8 
– 6.9) 
96.0 
(93.7 – 
97.4) 
Singulex        
0h 0.611 
(0.510 – 
0.712) 
0.037 0.53 96.3 (81.0 – 
99.9) 
8.2 (6.1 – 
10.8) 
4.8 (4.5 
– 5.2) 
97.9 
(86.8 – 
99.7) 
3h 0.642 
(0.546 – 
0.737) 
0.008 0.53 96.3 (81.0 – 
99.9) 
8.9 (6.7 – 
11.6) 
4.8 (4.5 
– 5.24) 
98.0 
(87.8 – 
99.7) 
Max 0.621 
(0.524 – 
0.719) 
0.022 0.53 96.3 (81.0 – 
99.9) 
5.0 (3.4 – 
7.2) 
4.7 (4.3 
– 5.0) 
96.6 
(79.8 – 
99.5) 
iSTAT        
0h 0.526 
(0.410 – 
0.641) 
0.661 100 4.0 (0.1 – 
20.4) 
93.6 (91.2 – 
95.5) 
2.7 (0.4 
– 16.3) 
95.6 
(95.3 – 
96.0) 
3h 0.559 
(0.438 – 
0.680) 
0.317 100 8.0 (1.0 – 
26.0) 
92.1 (89.6 – 
94.2) 
4.4 (1.2 
– 15.0) 
95.7 
(95.2 – 
96.2) 
Max 0.597 
(0.478 – 
0.716) 
0.100 100 8.0 (1.0 – 
26.0) 
92.1 (89.6 – 
94.2) 
4.4 (1.2 
– 15.0) 
95.7 
(95.2 – 
96.2) 
Cut-offs were determined by the concentration the assay exhibits <10% CV. Starred (*) values are ROC-derived cut-
offs. 
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6.6 Comparison of the 0h cut-offs of the Roche, Singulex and iSTAT assays as 
event predictors 
Survival analysis was done using the cut-offs used previously in the analyses (Roche: 
5.03 pg/ml; Singulex 0.53 pg/ml; iSTAT 100 pg/ml) and presented as Kaplan-Meier 
curves (figure 6.6). Events are defined as a composite MACE event within 30-days. 
Differences in survival were assessed for significance using the log rank test. For the 
Roche assay, the mean time to event for the low cTn group was 29.86 days (95% CI, 
29.79 – 29.93) and for the high cTn group was 29.80 days (95% CI, 29.58 – 30.01). 
The difference was not significant (p = 0.449). The mean time to events for the low 
cTn and high cTn group according to the Singulex assay were 30.00 days (95% CI, 
30.00 – 30.00) and 29.81 days (95% CI, 29.69 – 29.92; p = 0.170). According to the 
iSTAT assay, the mean time to event in the low and high cTn groups were 29.88 
days (95% CI, 29.82 – 29.93) and 28.88 days (95% CI, 26.35 – 31.40; p = 0.300), 
respectively. 
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Figure 6.6 Kaplan-Meier curves for the prognostic value of the 0h cTn 
sample values for composite MACE prediction between high and low 
cTn groups according to the Roche, Singulex and iSTAT assays. A) Roche 
assay high and low cTn groups; B) Singulex high and low cTn groups; C) 
iSTAT high and low cTn groups. High cTn groups are in green and low cTn 
groups in blue. Events occurred within 30-days of presentation to the ED 
and time to event is counted in days. All curves use the cut-offs of 5.03 
pg/ml for the Roche assay, 0.53 pg/ml for the Singulex assay and 100 
pg/ml for the iSTAT assay. 
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6.7 Summary of predicting 30 day MACE outcome with cTn values 
These analyses assessed if cTn at 0h or 3h could be used to predict 30 day outcome 
for ACS-related and HF-related conditions. They showed: 
 Only small differences between 0h, 3h and max values occurred and only small 
differences between assays for same outcome were also similar 
 Roche had better accuracy for prediciting ACS-related outcomes (AV1) than HF-
related outcomes (AV2) 
 iSTAT had high specificity for predicting a MACE event within 30 days  
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Chapter 7: Does kinetic cTn predict 30-day outcome?  
Chapter 7: Does kinetic cTn predict 30-
day outcome? 
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The baseline characteristics of the cohort are found in at the beginning of chapter 
4, prediction of 30-day MACE using cTn values of the Roche, Singulex and iSTAT 
assays. As previously, 10 cardiac-related conditions were grouped into three 
composites to assess the prognostic strength of the deltas. The 10 conditions were 
all-cause mortality, AMI, revascularisation, PCI, CABG, stenosis, tests for heart 
disease, cardiac arrest, arrhythmia and acute heart failure. The composite MACE 
group included all outcomes; AV1 included all-cause mortality, AMI, 
revascularisation, PCI, CABG and stenosis; adverse events 2 included cardiac arrest, 
arrhythmia and acute heart failure. All outcomes included events that occurred 30 
days post-presentation. 
7.1 Δabsolute of different 30-day composite outcomes 
The Δabsolute of the different assays according to 30-day diagnosis of the 
aforementioned conditions are shown in figure 7.1. Independent samples Mann-
Whitney U tests showed that there were significant differences in the distributions 
between positive and negative composite MACE groups and AV1 across all assays, p 
< 0.001. In the case of AV2, Roche, Singulex and iSTAT reported no difference in the 
distribution between the positive and negative patients (p = 0.742, 0.630 and 0.183, 
respectively).  
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Figure 7.1 Median cTn Δabsolute by different 30-
day prognoses according to the Roche, 
Singulex and iSTAT assays Bars are clustered by 
whether an outcome has occurred or not 
occurred. Bars include results from one assay, 
as specified by the legends and are colour 
coded. Error bars indicate 95% CI. Composite: 
composite MACE; AV1 – adverse events 1; AV2 
– adverse events 2. 
A 
B 
C 
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7.2 %Δbaseline of different 30-day composite outcomes  
The %Δbaseline of the different composite outcomes according to the three different 
assays are shown in figure 7.2. The difference in distribution was measured via 
Mann Whitney U test for independent samples for all %Δbaseline. For composite 
MACE outcomes, distributions between positive and negative groups were 
considered different according to the Roche and iSTAT assays (p = 0.026 and p < 
0.001, respectively) but not for the Singulex assay (p = 0.849). The same occurred 
for the AV1 composite with p < 0.001 for Roche and iSTAT and p = 0.174 for the 
Singulex assay. For the AV2, no significant difference for the Roche, Singulex and 
iSTAT assays were found (p = 0.712, 0.055 and 0.086). 
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Figure 7.2 Median cTn %Δbaseline by 
different 30-day prognoses according 
to the Roche, Singulex and iSTAT 
assays. Bars are clustered by whether 
an outcome has occurred or not 
occurred. Bars include results from one 
assay, as specified by the legends and 
are colour coded. Error bars indicate 
95% CI. Composite: composite MACE; 
AV1 – adverse events 1; AV2 – adverse 
events 2. 
C 
B 
A 
 
 
 
145 
 
7.3 %Δmean of different 30-day composite outcomes 
 
The different medians of %Δmean of the positive and negative patients of different 
30-day composite outcomes are shown in figure 7.3. The Singulex assay did not 
show any significant difference between the positive and negative groups for the 
composite MACE, AV1 and AV2 (p = 0.702, 0.181, 0.053). The Roche assay reported 
significant differences between the positive and negative groups of the composite 
MACE and AV1 outcomes (p = 0.047, and < 0.001, respectively) but not in the AV2 
outcomes group (p = 0.727). The iSTAT assay showed a significant difference 
between positive and negative groups in the composite MACE and AV1 outcomes 
(both p < 0.001) but not in the AV2 group (p = 0.164). 
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Figure 7.3 Median cTn %Δmean by 
different 30-day prognoses according 
to the Roche, Singulex and iSTAT 
assays. Bars are clustered by whether 
an outcome has occurred or not 
occurred. Bars include results from one 
assay, as specified by the legends and 
are colour coded. Error bars indicate 
95% CI. Composite: composite MACE; 
AV1 – adverse events 1; AV2 – adverse 
events 2. 
 
C 
B
 C 
A
 C 
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7.4 30-day composite MACE prediction by cTn Δabsolute, %Δbaseline and %Δmean 
according to the Roche, Singulex and iSTAT assays 
The ROC curve analysis is available in figure 7.4 and the AUROC available in table 
7.4. The Roche assay produced AUROCs for the Δabsolute, %Δbaseline and %Δmean of 
0.638 (95% CI, 0.572 – 0.703), 0.581 (95% CI, 0.519 – 0.643) and 0.575 (95% CI, 
0.513 – 0.636), respectively. The respective AUROCs for the Singulex assay show 
higher overall diagnostic accuracy at for Δabsolute 0.690 (95% CI, 0.628 – 0.752) but 
not for, %Δbaseline and %Δmean (0.533, 95% CI 0.468 – 0.599; 0.524, 95% CI 0.460 – 
0.589, respectively). The iSTAT assay had the highest overall prognostic accuracy for 
the respective variables at 0.657 (95% CI, 0.593 – 0.720), 0.614 (95% CI, 0.553 – 
0.675) and 0.587 (95% CI, 0.529 – 0.645). 
The prognostic accuracy of cTn deltas for adverse events 1 within 30 days according 
to the Roche, Singulex and iSTAT assays are shown in table 7.4. For the Roche assay, 
the Δabsolute sensitivity is lower than the %Δbaseline and %Δmean (30.7%, 95% 22.7 – 
39.6; 41.3%, 95% CI 31.9 – 51.1; 65.1%, 95% CI 55.4 – 74.0, respectively) but the 
opposite is true with the PPV (48.7%, 95% CI 38.9 – 58.6; 31.7%, 95% CI 25.9 – 38.1; 
23.4%, 95% CI 20.7 – 26.5). The specificity for Δabsolute was higher at 92.3% (95% CI, 
89.7 – 94.4) than the %Δbaseline and %Δmean (76.7%, 95% CI 72.3 – 80.7 and 44.2% 
95% CI 39.4 – 49.2, respectively). 
The Singulex assay showed a 100% NPV for all deltas and a sensitivity of 100% (95% 
CI, 96.7 – 100.0) for all deltas meaning all patients below the cut-off could be 
successfully ruled out of 30-day composite MACE prognosis. The low cut-off means 
there is very low specificity across all deltas (0.7%, 95% CI 0.2 – 2.1) and low PPV (all 
20.9%, 95% CI 20.8 – 21.0). 
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The higher Δabsolute cut-off for the iSTAT produced a lower sensitivity (19.4%, 95% CI 
12.8 – 27.4) than the other two assays and sensitivities of 56.0% (95% CI, 46.1 – 
65.5) and 56.8% (95% CI, 47.1 – 66.3) for %Δbaseline and %Δmean, respectively. 
Specificities for Δabsolute, %Δbaseline and %Δmean were higher at 96.5% (95% CI, 94.4 – 
97.9), 66.6% (95% CI, 61.8 – 71.1) and 66.8% (95% CI, 62.1 – 71.3), respectively. The 
NPVs are consistent across the Δabsolute, %Δbaseline and %Δmean at 82.3% (95% CI, 81.0 
– 83.5), 85.2% (95% CI, 82.2 – 87.8) and 85.5% (95% CI, 82.5 – 88.1) but there were 
discrepancies between the PPVs (58.5%, 95% CI 43.9 – 71.8; 30.5%, 95% CI 26.2 – 
35.2; 31.0%, 95% CI 26.6 – 35.7, respectively). 
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Figure 7.4 ROC curve of cTn Δabsolute, %Δbaseline and %Δmean according to 
the Roche, Singulex and iSTAT assays for 30-day composite MACE. Each 
graph represents the results from one assay. Each line within the graphs 
represents the ROC curve associated with either Δabsolute, %Δbaseline and 
%Δmean, as specified in the legends. A) Roche assay curves; B) Singulex 
assay curves; C) iSTAT assay curves. Absolute: Δabsolute; relative baseline: 
%Δbaseline; relative mean %Δmean. The composite MACE group included all 
outcomes: all-cause mortality, AMI, revascularisation, PCI, CABG, 
stenosis, tests for heart disease, cardiac arrest, arrhythmia and acute 
heart failure. 
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Table 7.4 30-day composite MACE prediction by cTn Δabsolute, %Δbaseline and %Δmean according to 
the Roche, Singulex and iSTAT assays 
 
 AUC (95% 
CI) 
P Cut-off Sensitivity Specificity PPV NPV 
Roche        
Δabsolute 0.638 
(0.572 – 
0.703) 
< 0.001 5.03 30.7 (22.7 – 
39.6) 
92.3 (89.7 – 
94.4) 
48.7 
(38.9 – 
58.6) 
84.7 
(83.2 – 
86.3) 
%Δbaseline 0.581 
(0.519 – 
0.643) 
 0.009 0.4762* 41.3 (31.9 – 
51.1) 
76.7 (72.3 – 
80.7) 
31.7 
(25.9 – 
38.1) 
83.3 
(80.9 – 
85.5) 
%Δmean 0.575 
(0.513 – 
0.636) 
 0.017 3.8476* 65.1 (55.4 – 
74.0) 
44.2 (39.4 – 
49.2) 
23.4 
(20.7 – 
26.5) 
82.9 
(78.6 – 
86.5) 
Singulex        
Δabsolute 0.690 
(0.628 – 
0.752) 
< 0.001 0.53 100.0 (96.7 
– 100.0) 
0.7 (0.2 – 
2.1) 
20.9 
(20.8 – 
21.0) 
100.0 
%Δbaseline 0.533 
(0.468 – 
0.599) 
0.282 0.2901* 100.0 (96.7 
– 100.0) 
0.7 (0.2 – 
2.1) 
20.9 
(20.8 – 
21.0) 
100.0 
%Δmean 0.524 
(0.460 – 
0.589) 
0.432 0.2915* 100.0 (96.7 
– 100.0) 
0.7 (0.2 – 
2.1) 
20.9 
(20.8 – 
21.0) 
100.0 
iSTAT        
Δabsolute 0.657 
(0.593 – 
0.720) 
< 0.001 100 19.4 (12.8 – 
27.4) 
96.5 (94.4 – 
97.9) 
58.5 
(43.9 – 
71.8) 
82.3 
(81.0 – 
83.5) 
%Δbaseline 0.614 
(0.553 – 
0.675) 
< 0.001 1.5150* 56.0 (46.1 – 
65.5) 
66.6 (61.8 – 
71.1) 
30.5 
(26.2 – 
35.2) 
85.2 
(82.2 – 
87.8) 
%Δmean 0.587 
(0.529 – 
0.645) 
0.005 1.4950* 56.8 (47.1 – 
66.3) 
66.8 (62.1 – 
71.3) 
31.0 
(26.6 – 
35.7) 
85.5 
(82.5 – 
88.1) 
Cut-offs were determined by the concentration the assay exhibits <10% CV. Starred (*) values are ROC-derived cut-
offs. 
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7.5 30-day AV1 prediction cTn Δabsolute, %Δbaseline and %Δmean according to the 
Roche, Singulex and iSTAT assays 
The prognostic accuracy of the three assays for prognosis of AV1 within 30 days is 
shown in figure 7.5. For the Roche assay, the AUC for Δabsolute, %Δbaseline and %Δmean 
were 0.776 (95% CI, 0.700 – 0.853), 0.692 (95% CI, 0.615 – 0.768) and 0.682 (95% 
CI, 0.607 – 0.757), respectively. The respective AUC for the Singulex assay were 
0.827 (95% CI, 0.757 – 0.897), 0.595 (95% CI, 0.492 – 0.677) and 0.585 (95% CI, 
0.492 – 0.677) and for the iSTAT were 0.747 (95% CI, 0.666 – 0.828), 0.686 (95% CI, 
0.609 – 0.763) and 0.628 (95% CI, 0.560 – 0.696). 
The prediction accuracy of the three assays for AV1 prognosis are shown in table 
7.5. The Roche assay showed differences in sensitivity between the Δabsolute (19.0%, 
95% CI 9.9 - 31.4) and %Δbaseline and %Δmean (59.8%, 95% CI, 50.4 – 68.8; 60.5%, 95% 
CI 51.1 – 69.3, respectively, both p < 0.001 vs Δabsolute). The specificity showed an 
opposite pattern between the higher Δabsolute result (88.5%, 95% CI 85.6 – 91.0) and 
%Δbaseline and %Δmean at 43.1% (95% CI, 38.5 – 47.7) and 43.1% (95% CI, 38.5 – 47.7), 
respectively (both p < 0.001 vs Δabsolute). The PPVs for Δabsolute, %Δbaseline and %Δmean 
are low at 14.3% (95% CI, 8.6 – 22.9), 20.8% (95% CI, 18.1 – 23.7) and 21.2% (95% 
CI, 18.6 – 24.1), respectively, but NPVs are higher at 91.5% (95% CI, 90.5 – 92.4), 
81.1% (95% CI, 77.1 – 84.6) and 81.1% (95% CI, 77.1 – 84.6), respectively. 
The Singulex assay had sensitivities of 100.0% (95% CI, 94.3 – 100.0) for both %Δ 
and 100% NPV for the same parameter but the Δabsolute sensitivity was 60.0% (95% 
CI, 46.5 – 72.4) and its NPV was 92.7% (95% CI, 90.2 – 94.6). However, the 
specificities for %Δbaseline and %Δmean are 0.8% (95% CI, 0.3 – 2.0) and 0.5% (95% CI, 
0.1 – 1.5) and 50.6% (95% CI, 46.5 – 54.7) for Δabsolute. The PPVs for Δabsolute, %Δbaseline 
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and %Δmean are 10.8% (95% CI, 8.9 – 13.2), 9.6% (95% CI, 9.6 – 9.7) and 9.6% (95% 
CI, 9.6 – 9.7), respectively. 
The sensitivities of the iSTAT assay for Δabsolute, %Δbaseline and %Δmean were 37.5% 
(95% CI, 23.4 – 49.6), 55.4% (95% CI 41.5 – 68.7) and 71.4% (95% CI, 57.8 – 82.7). 
The specificity of Δabsolute is higher than the %Δbaseline and %Δmean (78.2%, 95% CI, 
74.5 – 81.6; 66.4%, 95% CI 62.3 – 70.4) and the PPVs follow the same pattern 
(48.8%, 95% CI 35.5 – 62.2; 20.5%, 95% CI 16.3 – 25.5; 17.9%, 95% CI 15.1 – 21.1, 
respectively). The NPVs of the iSTAT for Δabsolute, %Δbaseline and %Δmean are similar 
(93.6%, 95% CI 92.4 – 94.7; 94.5%, 95% CI 92.8 – 95.9; 95.7%, 95% CI 93.7 – 97.2, 
respectively). 
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Figure 7.5 ROC curves of cTn Δabsolute, %Δbaseline and %Δmean according to 
the Roche, Singulex and iSTAT assays for 30-day AV1. Each graph 
represents the results from one assay. Each line within the graphs 
represents the ROC curve associated with either Δabsolute, %Δbaseline and 
%Δmean, as specified in the legends. A) Roche assay curves; B) Singulex 
assay curves; C) iSTAT assay curves. Absolute: Δabsolute; relative baseline: 
%Δbaseline; relative mean %Δmean. AV1 included all-cause mortality, AMI, 
revascularisation, PCI, CABG and stenosis. 
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Table 7.5 30-day AV1 prediction cTn Δabsolute, %Δbaseline and %Δmean according to the 
Roche, Singulex and iSTAT assays 
 
 AUC P Cut-off Sensitivity Specificity PPV NPV 
Roche        
Δabsolute 0.776 
(0.700 – 
0.853) 
< 0.001 5.03 19.0 (9.9 - 
31.4) 
88.5 (85.6 
– 91.0) 
14.3 
(8.6 – 
22.9) 
91.5 
(90.5 – 
92.4) 
%Δbaseline 0.692 
(0.615 – 
0.768) 
< 0.001 0.4762 59.8 (50.4 
– 68.8) 
43.1 (38.5 
– 47.7) 
20.8 
(18.1 – 
23.7) 
81.1 
(77.1 – 
84.6) 
%Δmean 0.682 
(0.607 – 
0.757) 
< 0.001 0.4739 60.5 (51.1 
– 69.3) 
43.1 (38.5 
– 47.7) 
21.2 
(18.6 – 
24.1) 
81.1 
(77.1 – 
84.6) 
Singulex        
Δabsolute 0.827 
(0.757 – 
0.897) 
< 0.001 0.53 60.0 (46.5 
– 72.4) 
50.6 (46.5 
– 54.7) 
10.8 
(8.9 – 
13.2) 
92.7 
(90.2 – 
94.6) 
%Δbaseline 0.595 
(0.492 – 
0.677) 
0.110 0.6074 100.0 (94.3 
– 100.0) 
0.8 (0.3 – 
2.0) 
9.6 
(9.6 – 
9.7) 
100.0 
%Δmean 0.585 
(0.492 – 
0.677) 
0.181 0.2915 100.0 (94.3 
– 100.0) 
0.5 (0.1 – 
1.5) 
9.6 
(9.6 – 
9.7) 
100.0 
iSTAT        
Δabsolute 0.747 
(0.666 – 
0.828) 
< 0.001 100 37.5 (23.4 
– 49.6) 
96.2 (94.2 
– 97.6) 
48.8 
(35.5 – 
62.2) 
93.6 
(92.4 – 
94.7) 
%Δbaseline 0.686 
(0.609 – 
0.763) 
< 0.001 1.5150 55.4 (41.5 
– 68.7) 
78.2 (74.5 
– 81.6) 
20.5 
(16.3 – 
25.5) 
94.5 
(92.8 – 
95.9) 
%Δmean 0.628 
(0.560 – 
0.696) 
0.001 1.4950 71.4 (57.8 
– 82.7) 
66.4 (62.3 
– 70.4) 
17.9 
(15.1 – 
21.1) 
95.7 
(93.7 – 
97.2) 
Cut-offs were determined by the concentration the assay exhibits <10% CV. Starred (*) values are ROC-
derived cut-offs. 
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7.6 30-day AV2 prediction cTn Δabsolute, %Δbaseline and %Δmean according to the 
Roche, Singulex and iSTAT assays 
30-day MACE prediction of AV2 by the cTn deltas is shown as ROC curves in figure 
7.6. The Roche AUC are 0.536 (95% CI, 0.415 – 0.658), 0.511 (95% CI, 0.394 – 0.628) 
and 0.514 (95% CI, 0.377 – 0.618) for 0h, 3h and max values, respectively. The 
respective AUC for the Singulex assay is 0.497 (95% CI, 0.377 – 0.618), 0.342 (95% 
CI, 0.225 – 0.460) and 0.344 (95% CI, 0.228 – 0.459) and for the iSTAT assay are 
0.580 (95% CI, 0.450 – 0.709), 0.574 (95% CI, 0.445 – 0.703) and 0.558 (95% CI, 
0.436 – 0.681). 
The predictive accuracy of cTn deltas for composite endpoint AV2 prognosis by the 
different assays is shown in table 7.6. For the Roche assay, there were differences 
between the Δabsolute and %Δ sensitivities and specificities. The sensitivity of the 
Δabsolute was 14.8% (95% CI, 4.2 – 33.7) whereas the %Δbaseline and %Δmean were 
higher at 63.0% (95% CI, 42.4 – 80.6) and 63.0% (95% CI, 42.4 – 80.6). The opposite 
was true for the respective the specificities at 88.4% (95% CI, 85.4 – 90.9), 41.1% 
(95% CI, 37.0 – 45.4) and 41.1% (95% CI, 37.0 – 45.4). The NPVs were consistently 
high at 95.6% (95% CI, 94.8 – 96.2), 95.8% (95% CI, 93.3 – 97.4) and 95.8% (95% CI, 
93.3 – 97.4) and NPVs consistently low for PPVs at 5.8% (95% CI, 2.4 – 13.5), 4.9% 
(95% CI, 3.7 – 6.5) and 4.9% (95% CI, 3.7 – 6.5) for Δabsolute, %Δbaseline and %Δmean, 
respectively. 
The differences between Δabsolute and %Δ sensitivities and specificities was also seen 
in the Singulex assay. The sensitivities were lower for Δabsolute than %Δbaseline and 
%Δmean 48.2% (95% CI, 28.7 – 68.1), 100.0% (95% CI, 87.2 – 100.0) and 100.0% (95% 
CI, 87.2 – 100.0), respectively. The respective specificities showed the opposite 
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pattern displaying 49.7% (95% CI, 45.5 – 54.0), 5.7% (95% CI, 4.0 – 8.0) and 5.2% 
(95% CI, 3.5 – 7.4). PPVs were low cut consistent at 4.4 (3.0 – 6.5) and 4.9 (4.8 – 5.0) 
for the Δabsolute and the two %Δ, and the NPVs were consistently high at 95.2% (95% 
CI, 93.2 – 96.7) and 100.0%, respectively. 
The iSTAT assay displayed a similar pattern to the Roche assay with respect to 
sensitivities and specificities. However, the sensitivities were lower at 4.0% (95% CI, 
0.1 – 20.4) and 52.0% (95% CI, 31.3 – 72.2) for the Δabsolute and the two %Δ but the 
respective specificities were higher than that of the Roche assay at 93.2% (95% CI, 
90.8 – 95.2) and 62.5% (95% CI, 58.3 – 66.5). As with the Roche and Singulex assays, 
the PPVs were low at 2.6 (0.4 – 15.5) and 5.8 (4.0 – 8.4) for the Δabsolute and the two 
%Δ, respectively, and the NPVs were high at 95.6% (95% CI, 95.2 – 95.9) and 96.7% 
(95% CI, 95.1 – 97.8), respectively. 
 
  
157 
 
 
 
  
Figure 7.6 ROC curves of cTn Δabsolute, %Δbaseline and %Δmean according to 
the Roche, Singulex and iSTAT assays for 30-day AV2. Each graph 
represents the results from one assay. Each line within the graphs 
represents the ROC curve associated with either Δabsolute, %Δbaseline and 
%Δmean, as specified in the legends. A) Roche assay curves; B) Singulex 
assay curves; C) iSTAT assay curves. Absolute: Δabsolute; relative baseline: 
%Δbaseline; relative mean %Δmean. AV2 included cardiac arrest, arrhythmia 
and acute heart failure. 
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Table 7.6 30-day AV2 prediction cTn Δabsolute, %Δbaseline and %Δmean according to the Roche, 
Singulex and iSTAT assays 
 
 AUC 
(95% 
CI) 
P Cut-off 
(pg/ml) 
Sensitivity Specificity PPV NPV 
Roche        
Δabsolute 0.520 
(0.411 
– 
0.629) 
0.721 5.03 14.8 (4.2 – 
33.7) 
88.4 (85.4 – 
90.9) 
5.8 (2.4 
– 13.5) 
95.6 
(94.8 – 
96.2) 
%Δbaseline 0.480 
(0.379 
– 
0.581) 
0.722 0.4762 63.0 (42.4 – 
80.6) 
41.1 (37.0 – 
45.4) 
4.9 (3.7 
– 6.5) 
95.8 
(93.3 – 
97.4) 
%Δmean 0.481 
(0.379 
– 
0.583) 
0.736 0.4739 63.0 (42.4 – 
80.6) 
41.1 (37.0 – 
45.4) 
4.9 (3.7 
– 6.5) 
95.8 
(93.3 – 
97.4) 
Singulex        
Δabsolute 0.525 
(0.421 
– 
0.628) 
0.644 0.53 48.2 (28.7 – 
68.1) 
49.7 (45.5 – 
54.0) 
4.4 (3.0 
– 6.5) 
95.2 
(93.2 – 
96.7) 
%Δbaseline 0.342 
(0.225 
– 
0.460) 
0.052 3.0077 100.0 (87.2 
– 100.0) 
5.7 (4.0 – 
8.0) 
4.9 (4.8 
– 5.0) 
100.0 
%Δmean 0.344 
(0.228 
– 
0.459) 
0.053 2.8870 100.0 (87.2 
– 100.0) 
5.2 (3.5 – 
7.4) 
4.9 (4.8 
– 5.0) 
100.0 
iSTAT        
Δabsolute 0.580 
(0.450 
– 
0.709) 
0.134 100 4.0 (0.1 – 
20.4) 
93.2 (90.8 – 
95.2) 
2.6 (0.4 
– 15.5) 
95.6 
(95.2 – 
95.9) 
%Δbaseline 0.574 
(0.445 
– 
0.703) 
0.152 1.5150 52.0 (31.3 – 
72.2) 
62.5 (58.3 – 
66.5) 
5.8 (4.0 
– 8.4) 
96.7 
(95.1 – 
97.8) 
%Δmean 0.558 
(0.436 
– 
0.681) 
0.248 1.4950 52.0 (31.3 – 
72.2) 
62.5 (58.3 – 
66.5) 
5.8 (4.0 
– 8.4) 
96.7 
(95.1 – 
97.8) 
Cut-offs were determined by the concentration the assay exhibits <10% CV. Starred (*) values are ROC-derived cut-
offs. 
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7.7 Prediction of 30-day composite MACE with baseline cTn in predictor 
composites with cTn Δabsolute, %Δmean or %Δbaseline, acute ischaemia, and H-FABP 
The results for the Roche assay are reported in table 7.7.1. Sensitivity and specificity 
of 64.1% (95% CI 55.6 – 72.0) and 52.8% (95% CI, 48.6 – 56.9), respectively, for the 
cTn + ECG composite. Both parameters improved with cTn + %Δbaseline (100.0%, 95% 
CI 97.4 – 100.0, p < 0.001) and cTn + %Δmean (72.1%, 95% CI 63.9 – 79.4) but only 
cTn + %Δbaseline was accompanied by 100% NPV. Improvement did not occur for cTn 
+ Δabsolute (63.6, CI 95% 55.0 – 71.6 and 54.0%, 95% CI 49.8 – 58.1, respectively).  The 
addition of ECG improved prognosis for Δabsolute and %Δmean (both 100.0%, 95% CI 
93.8 – 100.0, p < 0.001) but the cTn + ECG + %Δbaseline was not different and had a 
much lower specificity (1.5%, 95% CI 0.7 – 2.7) than Δabsolute (54.0%, 95% CI 49.8 – 
58.1) and %Δmean (35.9% (95% CI 32.0 – 40.0). However, all cTn + ECG + deltas had 
100%. Adding H-FABP reduced sensitivity for Δabsolute, %Δmean or %Δbaseline (68.3%, 
95% CI 60.0 – 75.9; 99.3%, 95% CI 96.1 – 100.0; 75.4%, 95% CI 67.4 – 82.2, 
respectively). The specificities were consistent with other composites at 50.5% 
(95% CI, 46.4 – 54.7), 1.0% (95% CI, 0.4 – 2.2) and 34.0% (95% CI, 30.2 – 38.0), 
respectively but the NPVs reduced to 86.7% (95% CI, 83.5 – 89.4), 85.7% (95% CI 
42.1 – 98.0) and 85.0% (95% CI, 80.9 – 88.5), respectively. 
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Table 7.7.1  Prediction of 30-day composite MACE with baseline cTn in predictor composites with 
cTn Δabsolute, %Δmean or %Δbaseline, acute ischaemia, and H-FABP with cTn according to the Roche 
assay 
  Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV (95% 
CI) 
NPV (95% CI) χ2 p value 
Roche,  n = 719       
cTn + ECG 
 
 64.1 (55.6 
– 72.0) 
52.8 (48.6 – 
56.9) 
24.9 (22.2 
– 27.8) 
85.8 (82.7 – 
88.3) 
<0.001 
cTn + delta Δabsolute 
pg/ml 
63.6 (55.0 
– 71.6) 
54.0 (49.8 – 
58.1) 
25.2 (22.4 
– 28.2) 
85.9 (82.8  
88.5) 
<0.001 
%Δbaseline 100.0 
(97.4 – 
100.0) 
0.4 (0.0 – 
1.3) 
19.7 (19.6 
– 19.7) 
100.0 0.646 
%Δmean 72.1 (63.9 
– 79.4) 
35.9 (32.0 – 
40.0) 
21.5 (19.6 
– 23.6) 
84.1 (79.8 – 
87.6) 
0.044 
cTn + ECG + 
delta 
Δabsolute 
pg/ml 
100.0 
(93.8 – 
100.0) 
53.1 (49.2 – 
56.9) 
15.6 (14.6 
– 16.7) 
100.0 <0.001 
%Δbaseline 100.0 
(93.8 – 
100.0) 
1.5 (0.7 – 
2.7) 
8.1 (8.0 – 
8.2) 
100.0 0.432 
%Δmean 100.0 
(93.8 – 
100.0) 
36.7 (33.1 – 
40.5) 
12.1 (11.5 
– 12.7) 
100.0 <0.001 
cTn + ECG + 
delta + H-FABP 
Δabsolute 
pg/ml 
68.3 (60.0 
– 75.9) 
50.5 (46.4 – 
54.7) 
25.2 (22.7 
– 27.9) 
86.7 (83.5 – 
89.4) 
<0.001 
%Δbaseline 99.3 (96.1 
– 100.0) 
1.0 (0.4 – 
2.2) 
19.7 (19.4 
– 19.9) 
85.7 (42.1 – 
98.0) 
0.587 
%Δmean 75.4 (67.4 
– 82.2) 
34.0 (30.2 – 
38.0) 
21.8 (20.0 
– 23.7) 
85.0 (80.9 – 
88.5) 
0.019 
cTn = baseline cTn; ECG = evidence of ischaemia by ECG; H-FABP = positive or negative test for H-FABP; n = number of 
patients positive for variable in question, in the case of cut-offs a positive result is above the cut-off. 
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The results for the Singulex assay are reported in table 7.7.2. The sensitivities of the 
Singulex assay are consistent across all composites and deltas with consistently low 
specificities. In the cTn + ECG composite, the sensitivity was 95.8% (95% CI, 91.0 – 
98.4) with a specificity of 10.3% (95% CI 8.0 – 13.1) and PPV and NPV of 20.7% (95% 
CI, 20.0 – 21.4) and 90.9% (95% CI, 81.5 – 95.8), respectively. The addition of 
Δabsolute, %Δbaseline and %Δmean to cTn instead of ECG did not have an effect on the 
sensitivities (96.4%, 95% CI 91.9 – 98.8; 97.9%, 95% CI 93.9 – 99.6; 97.9%, 95% CI, 
93.9 – 99.6, respectively), the PPVs (20.6%, 95% CI, 19.9 – 21.3; 19.5%, 95% CI 19.1 
– 19.9; 19.7%, 95% CI 19.3 – 20.2, respectively) or the Δabsolute NPV at 91.5 (95% CI, 
81.5 – 96.4) and Δabsolute specificity at 9.4% (95% CI, 7.2 – 12.1). The NPVs of 
%Δbaseline and %Δmean were lower at 75.0% (95% CI, 45.1 – 91.6) and 85.0% (95% CI, 
62.7 – 95.0) and respective specificities were lower at 1.6% (95% CI, 0.7 – 3.0) and 
3.0% (95% CI, 1.7 – 4.7). 
The cTn + ECG + delta composite had sensitivities of 100.0% (95% CI, 93.8 – 100.0) 
and 100.0% NPVs for all deltas. The specificities for Δabsolute, %Δbaseline and %Δmean 
were low at 9.0 (6.9 – 11.4), 2.1 (1.2 – 3.5) and 3.3% (95% CI, 2.1 – 5.0) and low 
PPVs at 8.7% (95% CI, 8.5 – 8.9), 8.2% (95% CI, 8.1 – 8.2) and 8.3% (95% CI, 8.1 – 
8.4), all respectively. 
 
The addition of H-FABP into the composite reduced sensitivity to 97.2% (95% CI 
92.9 – 99.2) and 98.6% (95% CI 95.0 – 99.8) for Δabsolute and both %Δ, respectively. 
The NPVs remained high but are still lower than without the addition of H-FABP at 
93.0% (95% CI, 83.0 – 97.3), 84.6% (95% CI, 55.2 – 96.1) and 90.5% (95% CI, 69.1 – 
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97.6) for Δabsolute, %Δbaseline and %Δmean, respectively. Specificities remained low at 
9.1% (95% CI, 6.9 – 11.7), 1.9% (95% CI, 1.0 – 3.4) and 3.3% (95% CI, 2.0 – 5.1) and 
PPVs were 20.7% (95% CI, 20.1 – 21.3), 19.7% (95% CI, 19.3 – 20.1) and 19.9% (95% 
CI, 19.5 – 20.3), all respectively. 
 
  
Table 7.7.2  Prediction of 30-day composite MACE with baseline cTn in predictor composites with 
cTn Δabsolute, %Δmean or %Δbaseline, acute ischaemia, and H-FABP with cTn according to the Singulex 
assay 
  Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV (95% 
CI) 
NPV(95% CI) χ2 p value 
Singulex, n = 
715 
      
cTn + ECG 
 
 95.8 (91.0 
– 98.4) 
10.3 (8.0 – 
13.1) 
20.7 (20.0 
– 21.4) 
90.9 (81.5 – 
95.8) 
0.013 
cTn + delta Δabsolute 
pg/ml 
96.4 (91.9 
– 98.8) 
9.4 (7.2 – 
12.1) 
20.6 (19.9 
– 21.3) 
91.5 (81.5 – 
96.4) 
0.013 
%Δbaseline 97.9 (93.9 
– 99.6) 
1.6 (0.7 – 
3.0) 
19.5 (19.1 
– 19.9) 
75.0 (45.1 – 
91.6) 
0.428 
%Δmean 97.9 (93.9 
– 99.6) 
3.0 (1.7 – 
4.7) 
19.7 (19.3 
– 20.2) 
85.0 (62.7 – 
95.0) 
0.426 
cTn + ECG + 
delta 
Δabsolute 
pg/ml 
100.0 
(93.8 – 
100.0) 
9.0 (6.9 – 
11.4) 
8.7 (8.5 – 
8.9) 
100.0 0.005 
%Δbaseline 100.0 
(93.8 – 
100.0) 
2.1 (1.2 – 
3.5) 
8.2 (8.1 – 
8.2) 
100.0 0.308 
%Δmean 100.0 
(93.8 – 
100.0) 
3.3 (2.1 – 
5.0) 
8.3 (8.1 – 
8.4) 
100.0 0.155 
cTn + ECG + 
delta + H-FABP 
Δabsolute 
pg/ml 
97.2 (92.9 
– 99.2) 
9.1 (6.9 – 
11.7) 
20.7 (20.1 
– 21.3) 
93.0 (83.0 – 
97.3) 
0.006 
%Δbaseline 98.6 (95.0 
– 99.8) 
1.9 (1.0 – 
3.4) 
19.7 (19.3 
– 20.1) 
84.6 (55.2 – 
96.1) 
0.515 
%Δmean 98.6 (95.0 
– 99.8) 
3.3 (2.0 – 
5.1) 
19.9 (19.5 
– 20.3) 
90.5 (69.1 – 
97.6) 
0.186 
cTn = baseline cTn; ECG = evidence of ischaemia by ECG; H-FABP = positive or negative test for H-FABP; n = number of 
patients positive for variable in question, in the case of cut-offs a positive result is above the cut-off. 
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The prognostic accuracy of baseline cTn in predictor composites with cTn deltas, 
acute ischaemia, and H-FABP for MACE prognosis at 30 days according to the iSTAT 
assay is shown in table 7.7.3. For the cTn + ECG composite, the specificity was 
90.9% (95% CI, 88.2 – 93.2) and the NPV was 83.5% (95% CI, 81.9 – 84.9). The 
sensitivity and PPV for this composite were 28.2% (95% CI, 20.8 – 36.5) and 43.7% 
(95% CI, 34.7 – 53.1), respectively. In regards to cTn + delta, there were differences 
between Δabsolute, and %Δbaseline/mean in sensitivity (23.0%, 95% CI, 16.2 – 31.0; 52.6%, 
95% CI 43.8 – 61.3; 53.3%, 95% CI 44.6, – 62.0, respectively), specificity (95.7%, 95% 
CI 93.7 – 97.3; 70.1%, 95% CI 66.1 – 74.0; 70.3%, 95% CI 66.3 – 74.1, respectively) 
and PPVs (57.4%, 95% CI 44.9 – 69.1; 30.6%, 95% CI 26.4 – 35.1; 31.0%, 95% CI 26.8 
– 35.6, respectively). The cTn + Δabsolute, + %Δbaseline and + %Δmean were similar at 
83.2% (95% CI, 81.9 – 84.5), 85.5% (95% CI, 83.1 – 87.7) and 85.8% (95% CI, 83.3 – 
87.9), respectively. The cTn + ECG + Δabsolute, + %Δbaseline and + %Δmean show 
differences between the Δabsolute and %Δ once more, but the values are greater than 
cTn + delta for the sensitivities (32.6%, 95% CI 24.8 – 41.2; 55.6%, 95% CI 46.8 – 
64.1; 56.3%, 95% CI 47.5 – 64.8, respectively) and specificities (90.2%, 95% CI 87.3 – 
92.6; 67.2%, 95% CI 63.0 – 71.1; 67.4%, 95% CI 63.2 – 71.3, respectively). The PPVs 
are lower than the cTn + delta  (45.4%, 95% CI 36.9 – 54.2; 29.8%, 95% CI 25.9 – 
34.0; 30.2%, 95% CI 26.3 – 34.4, respectively) and the NPVs are similar (84.2%, 95% 
CI 82.6 – 85.8; 85.8%, 95% CI 83.2 – 88.0; 86.0%, 95% CI 83.4 – 88.3, respectively). 
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Table 7.7.3  Prediction of 30-day composite MACE with baseline cTn in predictor 
composites with cTn Δabsolute, %Δmean or %Δbaseline, acute ischaemia, and H-FABP with cTn 
according to the iSTAT assay 
  Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV(95% 
CI) 
χ2 p 
value 
iSTAT, n = 
670 
      
cTn + ECG 
 
 28.2 (20.8 
– 36.5) 
90.9 (88.2 – 
93.2) 
43.7 
(34.7 – 
53.1) 
83.5 (81.9 
– 84.9) 
< 0.001 
cTn + delta Δabsolute 
pg/ml 
23.0 (16.2 
– 31.0) 
95.7 (93.7 – 
97.3) 
57.4 
(44.9 – 
69.1) 
83.2 (81.9 
– 84.5) 
< 0.001 
%Δbaseline 52.6 (43.8 
– 61.3) 
70.1 (66.1 – 
74.0) 
30.6 
(26.4 – 
35.1) 
85.5 (83.1 
– 87.7) 
< 0.001 
%Δmean 53.3 (44.6 
– 62.0) 
70.3 (66.3 – 
74.1) 
31.0 
(26.8 – 
35.6) 
85.8 (83.3 
– 87.9) 
< 0.001 
cTn + ECG + 
delta 
Δabsolute 
pg/ml 
32.6 (24.8 
– 41.2) 
90.2 (87.3 – 
92.6) 
45.4 
(36.9 – 
54.2) 
84.2 (82.6 
– 85.8) 
< 0.001 
%Δbaseline 55.6 (46.8 
– 64.1) 
67.2 (63.0 – 
71.1) 
29.8 
(25.9 – 
34.0) 
85.8 (83.2 
– 88.0) 
< 0.001 
%Δmean 56.3 (47.5 
– 64.8) 
67.4 (63.2 – 
71.3) 
30.2 
(26.3 – 
34.4) 
86.0 (83.4 
– 88.3) 
< 0.001 
cTn + ECG + 
delta + H-
FABP 
Δabsolute 
pg/ml 
41.5 (33.1 
– 50.3) 
79.8 (76.1 – 
83.1) 
33.9 
(28.4 – 
40.0) 
84.5 (82.4 
– 86.3) 
< 0.001 
%Δbaseline 63.7 (55.0 
– 71.8) 
59.4 (55.1 – 
63.6) 
28.2 
(25.0 – 
31.6) 
86.7 (83.8 
– 89.2) 
< 0.001 
%Δmean 63.7 (55.0 
– 71.8) 
59.6 (55.3 – 
63.7) 
28.3 
(25.1 – 
31.7) 
86.8 (83.8 
– 89.2) 
< 0.001 
cTn = baseline cTn; ECG = evidence of ischaemia by ECG; H-FABP = positive or negative test for H-FABP; n = 
number of patients positive for variable in question, in the case of cut-offs a positive result is above the cut-
off. 
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7.8 Univariate and multivariate analysis for cTn as measured by the Roche, 
Singulex and iSTAT assays and of cardiovascular risk factors for composite 
MACE at 30 days 
There were 40 composite MACE events (5.5%) within 30 days including 11 instances 
of PCI, 8 of stenosis, 6 of acute heart failure, 2 patients who experienced cardiac 
arrest and 4 of CABG. There were no patients who had diabetes mellitus and 
experienced 30-day composite MACE and therefore the variable was removed from 
the analyses. 
The results of the univariate Cox regression proportional hazards analyses for 30-
day composite MACE are shown in tables 7.8.1, 7.8.2, 7.8.3 and 7.8.4. Only patients 
with prior angina showed a significant association with 30-day MACE risk with a 
hazard ratio of 0.462 (95% CI, 0.238 – 0.896, p = 0.022) and Singulex Δabsolute with a 
hazard ratio of 2.466 (95% CI, 1.288 – 4.723, p = 0.006). The two variables were 
entered into a multivariate Cox regression proportional hazards model where both 
were shown to be independent predictors for 30-day MACE, as displayed in table 
7.8.5. Patients with prior angina had a hazard ratio of 0.463 (95% CI, 0.238 – 0.901, 
p = 0.023) suggesting a statistically and possibly clinically significant decrease in risk 
of MACE at 30 days for this group. On the other hand, patients with Δabsolute ≥ 0.53 
pg/ml according to the Singulex were associated with an increased risk of 30 day 
MACE yielding a hazard ratio of 2.425 (95% CI, 1.266 – 4.646, p = 0.008). 
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Table 7.8.1 Univariate Cox proportional hazard analyses of predicting 30-day composite 
MACE 
Variables Hazard ratio 95% CI p value 
Age (per year increase) 0.990 0.974 – 1.013 0.498 
Sex (male vs female) 0.634 0.340 – 1.183 0.152 
Prior MI 0.616 0.313 – 1.211 0.160 
Prior angina 0.462 0.238 – 0.896 0.022 
Prior PCI 0.696 0.340 – 1.423 0.321 
Prior CABG 0.455 0.178 – 1.161 0.099 
Hypertension 1.085 0.578 – 2.035 0.800 
Hyperlipidaemia 0.817 0.436 – 1.532 0.529 
Chronic kidney disease 0.473 0.145 – 1.536 0.213 
Smoker 0.781 0.371 – 1.647 0.517 
 
Table 7.8.2 Roche univariate Cox proportional hazard analyses of predicting 30-day 
composite MACE 
Variables Hazard ratio 95% CI p value 
≥ 5.03 pg/ml 0.798 0.427 – 1.495 0.482 
Δabsolute 1.636 0.679 – 3.943 0.272 
%Δbaseline 0.841 0.451 – 1.568 0.585 
%Δmean 0.841 0.451 – 1.568 0.586 
 
Table 7.8.3 Singulex univariate Cox proportional hazard analyses of predicting 30-day 
composite MACE 
Variables Hazard ratio 95% CI p value 
≥ 0.53 pg/ml 2.458 0.592 – 10.198 0.215 
Δabsolute 2.466 1.288 – 4.723 0.006 
%Δbaseline 1.116 0.396 – 3.148 0.835 
%Δmean 1.250 0.553 – 2.828 0.592 
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Table 7.8.4 iSTAT univariate Cox proportional hazard analyses of predicting 30-day 
composite MACE 
Variables Hazard ratio 95% CI p value 
≥ 100 pg/ml 1.777 0.543 – 5.816 0.342 
Δabsolute 0.476 0.065 – 3.501 0.466 
%Δbaseline 1.478 0.720 – 3.031 0.287 
%Δmean 1.478 0.720 – 3.031 0.287 
 
Table 7.8.5 Multivariate Cox proportional hazard analyses of predicting 30-day composite 
MACE 
Variables Hazard ratio 95% CI p value 
Prior angina 0.463 0.238 – 0.901 0.023 
Singulex Δabsolute 2.425 1.266 – 4.646 0.008 
 
7.9 Comparison of the Δabsolute cut-offs of the Roche, Singulex and iSTAT assays 
as event predictors 
Survival analysis was done using the cut-offs used previously in the analyses (Roche: 
5.03 pg/ml; Singulex 0.53 pg/ml; iSTAT 100 pg/ml) and presented as Kaplan-Meier 
curves (figure 7.9). Events are defined as a composite MACE event within 30-days. 
Differences in survival were assessed for significance using the log rank test. For the 
Roche assay, the mean time to event for the low cTn group was 29.85 days (95% CI, 
29.72 – 29.98) and for the high cTn group was 29.74 days (95% CI, 29.52 – 29.95). 
The difference was not significant (p = 0.234). The mean time to events for the low 
cTn and high cTn group according to the Singulex assay were 29.95 days (95% CI, 
29.91 – 30.00) and 29.68 days (95% CI, 29.46 – 29.90; p = 0.003) producing a 
statistically significant result, although possibly limited in clinical utility. According 
to the iSTAT assay, the mean time to event in the low and high cTn groups were 
29.83 days (95% CI, 29.70 – 29.96) and 30.00 days (95% CI, 30.00 – 30.00; p = 
0.421), respectively. 
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Figure 7.9 Kaplan-Meier curves for the prognostic value of the Δabsolute 
for 30-day composite MACE prediction between high and low cTn 
groups according to the Roche, Singulex and iSTAT assays. A) Roche 
assay high and low cTn groups; B) Singulex high and low cTn groups; C) 
iSTAT high and low cTn groups. High cTn groups are in green and low cTn 
groups in blue. Events occurred within 30-days of presentation to the ED 
and time to event is counted in days. All curves use the cut-offs of 5.03 
pg/ml for the Roche assay, 0.53 pg/ml for the Singulex assay and 100 
pg/ml for the iSTAT assay. 
 
170 
 
7.10 Summary of predicting 30 day MACE outcome with cTn deltas 
For these results, cTn deltas were assessed for MACE rule in and rule out prediction 
and survival at 30 days. Risk factors for AMI and CVD were chosen to assess which 
factors are associated with poor short-term outcome. 
 Δabsolute values are not as specific for AV1/2 as %Δ 
 iSTAT had high specificity but low PPV reducing the possibility that it will be a 
good short-term AMI predictor due to the large number of false positives this 
would yield 
 Singulex had many patients with 0h cTn values below that of cTnlow, which could 
allow more patients at risk to be identified useful for 30 day AMI prediction 
 Prior angina was a negative predictor of all composite MACE at 30 days and 
Singulex Δabsolute was a positive predictor for the same outcome  
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8.1 mCRP immunoassay development 
The original proposal was to create a competitive immunoassay for use on clinical 
samples to measure mCRP concentration of chest pain patients. The competitive 
immunoassay was very variable in intra-assay and inter-assay precision. It was then 
decided that an ELISA would be developed with a commercial detection antibody 
that would compensate the low analytical sensitivity of the non-commercial 8C10 
antibody. The high variability was hypothesised to originate from three main 
sources: 1) a non-commercial antibody that had to be used at very high 
concentrations; 2) the association between mCRP and mammalian blocking buffers; 
3) the hydrophobicity of mCRP. 
8.1.1 8c10 mCRP antibody clone 
Although the mCRP antibody clone 8C10 has been used elsewhere (47-49, 67), its 
use is limited to immunohistochemistry or as a blocking antibody to abolish mCRP 
signalling. For these methods, the high working concentration needed is less of a 
problem than when using the clone for molecular purposes, such as in an 
immunoassay. The precision of the antibody to identify mCRP molecules selectively 
and specifically is paramount to accurately report the concentration of mCRP and to 
form a reliable standard curve from which to calculate the mCRP concentrations. 
By changing protocols to develop a sandwich ELISA, the lack of sensitivity of the 
mCRP 8C10 antibody was to be overcome by the high sensitivity of the ab24462 
and ab19175 antibodies. The ab24462 antibody did not produce a signal and it was 
assumed that the monoclonal ab24462 and 8C10 were both binding to epitopes 
that were in close proximity on mCRP. Therefore a polyclonal anti-CRP antibody 
was used to prevent this occurring again. However, by using this antibody another 
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problem arose, the inaccuracy of the 8C10 antibody was enhanced by the sensitivity 
and scaling-up effect of the polyclonal ab19175 antibody. As a polyclonal antibody, 
ab19175 binds to many different CRP epitopes allowing one mCRP molecule to bind 
multiple detection antibodies enhancing the signal. In addition, the added 
sensitivity of ab19175 enhanced any inaccuracies arising from the 8C10 mCRP 
antibody and was seen as unworkable. There was only one standard curve that was 
usable for mCRP concentration determination that could not be repeated. 
Furthermore, the hypothesised functional sensitivity of the ELISA was at 2 µg/ml, 
which is far above what has been found in human serum (38) and therefore would 
not be clinically useful. 
8.1.2 mCRP and mammalian blocking buffers association 
The initial poor resolution was due to interaction between mCRP and BSA leading to 
non-specific binding. BSA was assessed as a potential blocking agent to reduce non-
specific binding. The results show a difference between different BSA 
concentrations and absorbance at fixed avidin concentrations. The higher the BSA 
concentration, the higher the absorbance. Further to these results, it was necessary 
to clarify whether the mCRP or the avidin-HRP complex was binding to the plate 
and/or BSA. In addition, how much the plate-avidin-HRP was contributing to the 
non-specific binding. The differences between each mCRP concentration within one 
BSA concentration and avidin concentration is negligible. This increase is not of the 
same magnitude as in figure 3.1.7 and therefore avidin-HRP-antibody and avidin-
HRP-plate association, seen in figure 3.1.8, does not account for the signal change 
between BSA concentrations. This means that the mCRP is interacting with the BSA 
and not the avidin or the plate. 
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As this also occurred with milk protein, it was deduced that interactions between 
mCRP and mammalian proteins are potentially ubiquitous. There is far too much 
interaction between BSA and milk protein with mCRP for them to be part of a 
coherent, reproducible and reliable assay. This meant a change to a non-
mammalian blocking agent (Monster Block™). This shown to be an effective block 
to non-specific binding and did show the same pattern to binding mCRP as BSA and 
milk protein. Higher concentration of Monster Block™ lowered signal suggesting it 
is effective blocking non-specific mCRP binding. Also, by using antibody coating 
buffer, signal strength was increased that suggests increased stability of the 
antibody and more effective coating of antibody to the plate. 
As the non-specific binding was abundant when using BSA and milk protein, the 
signal became saturated very quickly and therefore TMB incubation periods were 
reduced to try to resolve separate concentrations. However, when using the new 
blocking agent, it appears that the TMB incubation time must now be increased to 
resolve the different concentrations to increase sensitivity and accuracy of the 
assay. Dilutional recovery improved by using the antibody coating buffer and the 
Monster Block™ but decreased again upon adding the mCRP standards. 
8.1.3 Hydrophobicity of mCRP 
Through the dissociation from pCRP to mCRP, the solubility of mCRP is greatly 
reduced (192-194). The poor solubility of mCRP could affect its variability and 
recovery as the identification of stock mCRP concentration proves difficult when 
the protein does not fully solubilise leading to inaccurate stock concentrations. This 
could be overcome by changes to the pH of the buffers but this would impact on 
other reagents and the binding affinity between mCRP and its antibodies. 
175 
 
Furthermore, the lack of solubility may force mCRP from the solution and this may 
increase or be the cause of the high non-specific binding seen for mCRP. This may 
also explain the association between mCRP and the blocking buffers of BSA and 
milk proteins. The affinity between mCRP and the blocking buffers was greater than 
between mCRP and the CRP buffer indicating it is more energetically favourable for 
mCRP to associate with BSA and milk protein than to remain in the CRP buffer. 
The lack of solubility of mCRP has been overcome when using recombinant mCRP 
(rmCRP) expressed in E. coli (193). The group used anhydride reagents to solubilise 
rmCRP and purification to remove interfering endotoxins. This was considered for 
the current study but the source of CRP for the immunoassay was purification from 
human plasma and not from a recombinant source, which is necessary when 
creating a standard curve for human mCRP determination. Secondly, the 
solubilisation of mCRP in an anhydrous manner creates an effective solution but its 
use in wet laboratory protocols would return the mCRP to an effective precipitate. 
8.1.4 Future work for mCRP immunoassays 
The dilutional recovery may be improved by first incubating the mCRP standards 
overnight at 4°C and then adding the labelled mCRP after a defined period of time.. 
By allowing the standards to equilibrate with the antibody before adding the 
labelled mCRP, this should provide greater linearity in the assay. 
When adding competition, there appeared to be conflicting results between the 
different mCRP concentrations. Lower concentrations appear to compete correctly 
with labelled mCRP but higher concentrations appear to aid labelled mCRP binding. 
The readiness of CRP monomers forming dimers would mean that any competing 
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mCRP bound to the antibody would not adversely affect labelled mCRP binding 
enough for a valid assay. If unlabelled and labelled bind to produce a higher signal, 
this could suggest that CRP dimers have more affinity for the antibody than mCRP. 
The competing unlabelled mCRP would not be in competition with the labelled 
mCRP and therefore the competitive format may be abandoned. Further test must 
be done to assess this hypothesis. One such test would be to isolate dimeric CRP 
and mCRP and use a dot blot format to observe to which isoform the antibody 
shows the greatest affinity. 
One group have developed an ELISA for mCRP that was then used for measuring the 
amount of mCRP in human serum (38). This ELISA produced a measuring range of 1 
– 160 ng/ml and day-to-day CV was 10.6%. Although, the group claimed that the 
capture antibody that was used was developed by the group themselves but 
characterisation of the antibody was not included in the analyses. Furthermore, the 
protocol explains that BSA was used and the results above show that this is not an 
appropriate blocking agent for BSA and would have an effect on appropriate 
binding of mCRP. 
A possible route would be to use a pCRP kit and amend the protocol to include an 
mCRP antibody as the detection antibody. However, how the biotinylated antibody 
and mCRP interact after biotinylation is unknown. As mCRP is a molecule that has 
many unknown qualities, it would be difficult to create an assay for the 
determination of its concentration in serum. The shelf-life of the protein, 
interactions with other proteins and lipids and its hydrophobicity are all relatively 
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unknown to researchers, all of which cause barriers to create a clinically useful 
immunoassay. 
Another route would be to use flow cytometry to measure mCRP on MPs. This 
method is very sensitive and could provide the required analytical sensitivity for use 
in clinical diagnosis. It has been shown that measuring mCRP by flow cytometry is 
possible (46, 195) and by using this method the source of the MPs can also be 
measured, which may glean more information about the type of ACS the patient is 
experiencing. This was considered as an alternative to the immunoassay for this 
current study but the antibody was not sensitive enough to produce any useful data 
for measuring even high concentrations of mCRP (50 µg/ml) via flow cytometry. 
However, as flow cytometers are becoming more common in hospital laboratories 
and mCRP concentration is higher in AMI patients (46), this could be an avenue to 
pursue to include mCRP in ACS diagnosis. 
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8.2 cTn in the diagnosis of NSTEMI and prediction of 30-day MACE 
These analyses assessed the diagnostic and prognostic efficacy of three 
immunoassays that measure cTn that were the fifth-generation Elecsys, Roche 
Diagnostics hs-cTnT assay, the Singulex Clarity™ cTnI assay and the Abbott Point of 
Care iSTAT cTnI assay. To evaluate the diagnostic effectiveness of the assays, the 
two samples at 0h and 3h and the resulting Δabsolute, %Δbaseline and %Δmean were 
assessed with ROC-derived cut-offs and within certain patient subgroups. Δabsolute, 
%Δbaseline and %Δmean were also assessed by setting %Δ cut-offs set at 10%, utility of 
Δabsolute, %Δbaseline and %Δmean after patients were grouped by 0h cTn concentration 
and within predictor composites with cardiac ischaemia and H-FABP. The prognostic 
accuracy of the assays for 3 composite endpoint groups were assessed by 0h and 3h 
cTn concentration, Δabsolute, %Δbaseline and %Δmean and with composite predictor 
groups. This was done as the assays have different analytical characteristics and 
through treating the data by various methods, the different strengths of the assays 
were shown. In most of the analyses, the purpose was to achieve maximum 
sensitivity with the aim of producing quick, successful rule out. 
8.2.1 AMI diagnosis by cTn values at 0h and 3h 
As more and more sensitive cTn assays were produced allowing lower cut-offs, 
novel ways of determining cut-offs were proposed (196) and with the advent of 
ultra-sensitive assays detecting cTn at much lower levels (LoD 0.2 pg/mL) (197), the 
need for a categorisation of a safe cTn level was necessary. This also meant that at 
risk patients could be identified quicker and the need to wait for 6h for a detectable 
cTn in NSTEMI was no longer necessary (156-158, 198-200). Moreover, at the low 
end of the measuring range of the less sensitive assays, the concentration of cTn at 
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the 10% CV level would be above the 99th percentile, which is evaluated as not 
clinically usable (146, 191). Although some argue that 20% CV is acceptable as it 
does not result in false positives (201) and would include other assays that would 
otherwise not be acceptable (202). As a result, the European Society of Cardiology 
has recommended reducing the minimal time between sampling from 6h to 3h 
(163). 
Comparing assays that measure hs-cTnT and hs-cTnI may cause concern but as has 
been shown previously (203) that it can be done as the comparison lies not 
between the analytical parameters of the individual assays but the diagnostic 
accuracy of the resulting cut-offs. Indeed, the different analytical parameters of the 
assays impacts on the diagnostic accuracy, differences also lie between assays that 
measure the same cTn isoform, such as the Singulex and iSTAT assays. 
The Roche assay is the standard assay used in the MRI hospital laboratories and has 
mostly effective sensitivity and specificity, least interpatient variation and high rule 
out cut-offs. As with all the assays, the cut-offs were set according to their 
respective FS or higher, where appropriate. The relatively high FS of the Roche 
assay at 5.03 pg/ml means by using the 0h and 3h values, 51% and 52% of patients 
are below the cut-off resulting in sensitivities of 48.5% and 47.1% and cannot be 
stratified accurately within 3h. Using the patients’ maximum cTn value only 
increased the sensitivity marginally to 52%. 
Whereas the Singulex assay analysis showed its lower FS cut-off could produce 
100% sensitivity and NPV at 0h, meaning 21% of the cohort could be ruled out from 
AMI diagnosis. In fact, the 0h cut-off that produced this sensitivity was at 0.8550 
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pg/ml, which is higher than the reported FS of 0.53 pg/ml allowing more patients to 
be ruled out confidently. When taking the max value of the two samples, a cut-off 
of 1.3450 pg/ml also yielded 100% sensitivity and NPV with 30% of patients below 
the cut-off. The higher concentration would mean smaller %CV and more 
confidence in the result according to the Singulex precision profiles, as seen in the 
methodology. Although, for patients, a longer wait for the 3h sample is needed for 
the max values variable to be utilised, its superiority to the 3h alone means that 
both 0h and 3h could be considered as one but further studies must be done to 
assess its validity in other settings. 
By using these cut-offs, the effect on the specificity of the Singulex assay was 
marked. The specificity was compromised and was found to be 23.4%, 9.0% and 
5.3% for 0h, 3h and max values and PPVs of 10.8%, 10.0% and 10.3%, respectively, 
90% of patients will be initially incorrectly ruled in. However, the aim of the 
analyses was to use the higher analytical sensitivity of the Singulex assay to achieve 
the highest sensitivity and NPV for rule out. As NSTEMI patients present with lower 
cTn concentrations, the lower FS of the Singulex assay would be even more useful 
in this cohort, which it has shown by excluding 30% of the cohort. However, the 
precision profiles of the Singulex assay produced from the data provided cast doubt 
on whether the assay is reliable enough to be clinically useful. 
The low specificity can be attributed to a low cut-off but also can be down to high 
variability of the assay in the lower concentrations especially surrounding the 
chosen cut-off, which was chosen as it was reported the assay showed 10% CV at 
this level. A significantly greater CV at the reported FS would cause more random 
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assignment of patients, whose true cTn concentrations lie close to the cut-off, into 
rule in and rule out groups. 
In contrast, the higher FS of the iSTAT assay produced much higher specificities for 
rule in diagnoses. At 0h, 6% of patients could be ruled in for AMI diagnosis with a 
specificity of 98.7% and 8% of patients ruled in at 3h with 99.2% specificity. The 
PPVs were not as high (80.6% at 0h) indicating that even though 98.7% of patients 
who have AMI are correctly identified at baseline, there remains 20% who are 
incorrectly ruled in for AMI. However, as the iSTAT is a point of care device, the 
higher specificities are an important tool to provide clinicians with immediate data 
of patients who are at high risk and therefore treatments are provided as quickly as 
possible. The risk of this approach is a high false negative rate, a phenomenon 
which is shown in figure 8.2.1C. The high cut-off produces high specificity with few 
false positives and more confidence that patients above the cut-off will be correctly 
identified as having AMI and for treatments to be given. A lower cut-off, as seen 
with the Singulex assay and in figure 8.2.1A, will produce high sensitivities, which 
will reduce the probability of a missed diagnosis and is possibly a safer option when 
concerning uncertainty of diagnosis in ACS and in the confidence in a rule out 
diagnosis. 
These findings of early rule out within 3h are supported by previous studies (131, 
156-161). Macrae et al questioned the American Heart Association’s (AHA) 
definition of AMI calling for a 6h interval between sampling and explored if 3h 
would be sufficient to rule out. The recorded prevalence of AMI did not significantly 
decrease when sampling occurred at a 3h interval instead of a 6h interval (33.7% vs 
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35.7%, respectively, p > 0.05; n = 258). As was seen by Eggers et al (131), using a 
Figure 8.2.1 The 
effect of adjusting 
diagnostic cut-offs 
on diagnostic 
sensitivity and 
specificity. The 
blue curve includes 
all patients who 
truly do not have 
the disease; the 
red curve includes 
all patients who 
truly have the 
disease. The black 
lines indicate the 
cut-offs. TN – true 
negative; FN – 
false negative; FP – 
false positive; TP – 
true positive; TBC 
– to be confirmed. 
The patients to the 
left of the cut-off 
line will be 
considered as 
without AMI and 
the patients to the 
right of the cut-off 
will be considered 
as with AMI. A) 
shows a cut-off 
with a compromise 
for sensitivity and 
specificity, B) 
shows a low cut-
off with high 
sensitivity and low 
specificity, and C) 
shows a high cut-
off with high 
specificity and low 
sensitivity. 
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lower cut-off corresponding to 10% CV increased sensitivity and retained high 
specificity at 93% and 81% at 2h, respectively. Keller et al (157) found no significant 
difference in the diagnostic accuracy of sampling at baseline and the serial samples 
and that with patients presenting 3h after symptom onset, a NPV of 84.1% and a 
PPV of 86.7% was reported with baseline samples. 
With further advances in assay sensitivity, the smaller cTn concentration 
differences between baseline and 3h samples are proving to provide significantly 
greater sensitivities and NPVs at 3h. By using a hs-cTnI assay on a cohort of 1818 
across multiple centres, Keller et al (161) found that at baseline, the assay yielded a 
sensitivity of 82.3% and a NPV of 94.7%, which rose to 98.2% and 99.4% at 3h, 
respectively. Interestingly, the sensitivity and NPV for the hs-TnI and the cTnI were 
exactly the same at 3h but the 99th percentile cut-off for the respective assays were 
30 pg/ml and 32 pg/ml. The differences in LoD may not mean a better diagnostic 
test, necessarily, as if the 99th percentile is used as a universal cut-off, higher 
analytical sensitivity will not result in a higher diagnostic sensitivity. 
In a change to the recognised procedure of using the 99th percentile as a diagnostic 
cut-off, Body et al (99) investigated using the LoB as a cut-off for a novel rule out 
strategy. The assay used was the Roche Diagnostics Elecsys hs-cTnT 5th Gen assay 
and a cohort of 703, of whom 13 had AMI. No patient who experienced AMI had 
detectable hs-cTnT leading to a sensitivity and NPV of 100%. By using this strategy, 
27.7% of patients would be ruled out of AMI, 2 of whom had negative outcomes in 
the following 6 months. In a validation study leading on from this research (same 
paper), one patient (from a cohort of 915) had a cTnT rise and AMI producing a NPV 
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of 99.4%. In a slight amendment, the LoD of was used as a cut-off to assess if more 
patients could be safely ruled out this way. Of the 463 patients, 96 had hs-cTnT 
concentrations below the LoD and only one had an AMI. This produced a sensitivity 
of 98.7% and a NPV of 99.0% and increased to 100% for both in patients who were 
under the LoD and did not indicate ECG ischaemia. As expected, by using the 99th 
percentile as a cut-off, the sensitivity was reported as 94.9% and the NPV at 93.9%, 
which is similar to the results found in the literature for hs-cTn assays using 99th 
percentile cut-offs (7, 161, 162). 
A multicentre, international cohort from Australia, New Zealand and the UK (100) 
also used the LoD (1.2 ng/L) as a cut-off at presentation with sensitivity of 99.0% 
and NPV of 99.5%, which is very similar to Body et al. (99). However, due to its 
lower cut-off, fewer of the cohort would be ruled out, 18.8% in comparison to 
27.7%. This paper also address the importance of using decimals with hs-cTnI assays 
by using rounded cut-off values from 1.2 ng/L up to and including 5 ng/L. Rounded 
cut-offs did not have sensitivities of more than 98%, which is below the acceptable 
limit of missed diagnoses (204). Although the rounded cut-offs displayed results of 
more than 99%, NPVs are dependent on disease prevalence within a population 
and it was recommended that each site should produce its own NPV for its 
population (100). 
8.2.2 Diagnostic accuracy of cTn Δabsolute, %Δbaseline and %Δmean for AMI diagnosis 
The problem with using a single measurement of cTn is that is does not allow for 
the rise and fall pattern to be traced, as is called for in the universally accepted 
definition of AMI (164). The introduction of hs-cTn assays allowed more sensitive 
but less specific diagnoses and more unnecessary hospitalisations. This 
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phenomenon may not matter in early rule out, only that small changes or low 
concentrations are detected to distinguish between different sources of cTn rises. 
Chronic rises in cTn such as in chronic heart failure, left ventricular hypertrophy and 
coronary artery disease do not have a rise and fall pattern and can be distinguished 
from ACS (205). However, very small increases could be wrongly attributed to AMI 
when they are caused by non-ischaemic conditions such as myocarditis, pericarditis, 
cardiac contusion, or the damage caused by shocks from pacemakers, or non-
cardiac-related cTn release, such as in renal failure (206, 207). Higher specificity 
with more analytically sensitive assays have been shown using deltas. The aim of 
these analyses was to produce maximum sensitivity to find the optimum magnitude 
of cTn change that would confidently rule out 100% of patients below the cut-off. 
The clinical sensitivity of Δabsolute was lower than the sensitivities of the %Δbaseline and 
%Δmean for each assay. By using Δabsolute, %Δbaseline and %Δmean, the clinical sensitivity 
of the Roche assay was higher than using the 0h and 3h values alone. The Roche 
assay reported sensitivities of 89.7%, 98.4% and 98.4%, respectively. The increase in 
sensitivity did not have the effect of decreasing the specificities and in the case of 
Δabsolute the specificity was higher at 97.4%. This may be due to the Δabsolute cut-off 
was set by the analytical limits of the assays but the %Δbaseline and %Δmean were ROC-
derived cut-offs.  
The Singulex assay had similar sensitivity results for Δabsolute, %Δbaseline and %Δmean 
but its cut-offs were higher allowing more patients to be included in a possible rule 
out diagnosis. Also, as it is more sensitive than the Roche assay, the lowest possible 
baseline cTn concentration for an effective %Δ is much lower, both at 14 pg/ml. In 
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the cohort, 93 patients were below 14 pg/ml according to the Singulex assay, of 
whom 7 had %Δbaseline of less than 3.6901%. 
For the iSTAT assay, the %Δbaseline and %Δmean sensitivities also outperformed the 
Δabsolute sensitivity but the opposite occurred with specificity. By using the 100 pg/ml 
cut-off, specificity was 99.0% with 7% of the cohort above the threshold. The 
%Δbaseline and %Δmean specificities (67.2% and 67.4%, respectively) were lower than 
their sensitivities at 84.1% and 85.7%, respectively but only one patient fulfilled 
both criteria of lowest possible baseline cTn level for an effective %Δ and the %Δ 
cut-off. This may limit its clinical utility. 
Distinction between ACS-related rises in cTn and other causes is important as only a 
third of cTn rises are attributed to ACS (208). Mueller et al (209) investigated the 
basis of the rationale to use serial cTn testing to observe what magnitude of change 
can define an AMI and a non-ACS-related condition. The NSTEMI ACS was also 
analysed separately (STEMI exclusion of the same cohort) to distinguish between 
MI ACS and non-MI ACS. Absolute changes performed better than relative changes 
according to AUC of ROC curve analysis (AUC = 0.898 and 0.752, respectfully, p > 
0.0001). 
62.4% of patients with non-ACS conditions still had a rise of hs-cTnT of 20% 
compared with 75.2% of NSTEMI. 24.8% of NSTEMI did not experience this change 
during the first 6h but did during a 24h period. There is a large trade off in using 
absolute changes in this model, the high sensitivities seen is met with lower 
specificities, unlike Apple et al (210) who used a delta of >30% produced a 
sensitivity of 75% and a specificity of 91%. The retention of specificity in the Apple 
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analyses does make the diagnostic accuracy more robust overall but when looking 
at rule out, the strength of specificity could be seen as not as much of a concern. 
Moreover, the more sensitive an assay and higher its clinical sensitivity, the more it 
negatively affects the specificity (211, 212) as was seen with the Singulex assay. 
However, by optimising the cut-off via ROC curve analysis for rule in, specificity can 
also be high for hs-cTnI assays (213). 
In a study with shorter times between sampling than the current analysis, a cTnI 
ultra assay was compared with a hs-cTnT assay for deltas of 1h, 2h and 6h (160). 
The %Δ was outperformed at every time point with each assay by Δabsolute. The hs-
cTnT assay showed the strongest AUC with Δabsolute at 2h and the cTnI ultra assay 
demonstrated the strongest AUC with Δabsolute at 2h. This is more evidence that 
early sampling is as effective as 6h sampling and that early rule out with the newer 
more analytically sensitive assays could aid the busy, contemporary EDs. 
However, the benefit of Δabsolute and %Δ may be redundant when observing patients 
with abnormally high baseline cTn. From a cohort of 1282, a group with hs-cTnT > 
60 ng/L had PPV of 87.2%, which was unchanged when the cut-off was increased to 
> 80 ng/L and > 100 ng/L (214). Furthermore, the addition of %Δ at 20% did not 
improve PPV for quick rule in (1h %Δ 84% and 2h %Δ 88.9%) and was only increased 
slightly when the interval was extended to 4-14h (91.2% for > 80 ng/L and 90.4% for 
100 ng/L). Although the PPVs are not 100% and therefore there will be false 
positives, crucially the PPV does not increase with the addition of %Δ. The %Δ cut-
off could be increased but this would lead to fewer positive diagnoses and an 
increased risk of false negatives. It is also important to assess any conditions the 
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patients that would cause chronic rises in cTn as this could lead to unnecessary and 
potential damaging treatment to the patient. 
8.2.3 Diagnostic accuracy of Δabsolute, %Δbaseline and %Δmean cTn deltas based on 
baseline cTn 
If the cTn deltas were only used independently, the lack of specificity would be a 
problem. However, diagnoses are rarely based on one piece of evidence and clinical 
judgement will always remain an important part of diagnostics (215). In addition, by 
stratifying patients into different risk groups and assessing the optimal cut-offs for 
each group, diagnostic accuracy would be assumed to increase. The aim of these 
analyses was to stratify patients into rule out, intermediate and rule in groups 
based on ROC curve analysis and treat each group as its own cohort with further 
ROC curve analysis providing group-specific cut-offs for Δabsolute, %Δbaseline and 
%Δmean for highest possible clinical sensitivity. 
For the Roche rule out group, sensitivity was low at 50.0% (95% CI, 6.8 – 93.2) for all 
deltas but specificity was higher for Δabsolute (99.7%, 95% CI 98.3 – 100.0) than 
%Δbaseline and %Δmean 62.3% (95% CI, 56.8 – 67.7), which agrees with the 
phenomenon of Δabsolute having better diagnostic accuracy at lower baseline cTn 
values than %Δ. The lower PPVs for %Δ (1.7%, 95% CI, 0.6 – 4.3) than Δabsolute 
(66.7%, 95% CI 18.3 – 94.7) suggesting %Δ has less rule in power in the low-risk 
group. The intermediate group produced 100% sensitivity and NPV for all deltas 
suggesting all patients within this group will be identified as successfully ruled out if 
under the cut-off. The high-risk group showed 100% specificity and PPV implying 
that all patients below the cut-off could be successfully ruled out and all patients 
adjudicated with AMI by the Roche assay are correctly diagnosed. The reported 
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diagnostic accuracy of the high-risk group may be affected by the low number of 
patients (n = 27) and the high proportion patients who experienced AMI (with AMI 
= 25). 
The Singulex assay did not have any patients in the rule out group due to the 0h cTn 
having 100% sensitivity and NPV. According to the Singulex assay, the %Δ had 100% 
sensitivity and NPV, whereas the Δabsolute reported 85.5% (95% CI, 75.0 – 92.8) and 
96.4% (95% CI, 93.7 – 98.0), respectively. This is in opposition to the idea that 
Δabsolute is more clinically useful at lower cTn concentrations. This could be down to 
the wide range of cTn concentrations in this group leading to slightly poorer 
diagnoses and the possible variation seen in the Singulex assay could be mitigated 
by conversion to percentages. The rule in group presented very poor ROC curve 
analysis when combined with any of the deltas (0.200, 95% CI, 0.000 – 0.570) but 
this is due to low patient numbers in the group (n = 8, with AMI = 5) and the test 
unable to identify any patients without AMI correctly. 
For the iSTAT assay, the NPVs were all 99.2% (95% CI, 97.6 – 99.7) and 94.4% (95% 
CI, 90.7 – 96.7) for the rule out group, and in the intermediate group 93.9% (95% CI, 
90.2 – 96.3) and 94.4% (95% CI, 90.7 – 96.7) for Δabsolute, %Δbaseline and %Δmean, 
respectively, suggesting a good diagnostic accuracy of the iSTAT for rule out. 
However, the poorer specificity and sensitivity (60.0%, 95% CI 14.7 – 94.7 and 
76.4%, 95% CI 71.4 – 81.0 for Δabsolute in rule out group) would suggest a large 
portion of the cohort would be yet to be either ruled in or out. As a point of care 
device, the iSTAT assay is best at providing almost immediate results for the benefit 
of identifying those most at risk. By waiting 3h for a second sample and creating 
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either Δabsolute, %Δbaseline or %Δmean, the point of care device no longer delivers its 
purpose of quick stratification. For this reason, the lower diagnostic accuracy is not 
as much of a concern. 
In a similar idea, combining cTn levels at presentation and deltas, an attempt to 
triage patients more quickly was made by a study aimed to use hs-cTnT at 0h and 
1h to rule in and rule out AMI (216). It is a prospective validation study of 1282 
patients that uses absolute changes in hs-cTnT concentration between 0h and 1h to 
triage patients to rule out status, observational zone or rule in. CoV was 10% at 
13ng/L, 99th percentile at 14ng/L for hs-cTnT (Roche) and s-c-TnI-ultra has LoD of 
6ng/L, 99th percentile cut-off of 40ng/L and CoV of <10% at 30ng/L. By using the 1h 
algorithm, 63.5% were ruled out with a miss rate of 0.9%, 14.4% were ruled in and 
22.2% were triaged. Of those triaged, 22.5% experienced AMI and this 
observational group allows the diagnostic performance in the rule in and out 
groups to be much higher. However, the algorithm allows rule in stratification of 
patients to be done at presentation (criteria: 0h ≥ 52 ng/L or delta 1h ≥ 5 ng/L), 
which permits urgent care to patients most at risk at presentation with a PPV and 
specificity of 77.2% and 96.1%, respectively. The rule out criteria (0h < 12 ng/L and 
delta 1h < 3) reported a sensitivity and NPV of 96.7% and 99.1%, respectively. 
This algorithm produces better NPV and sensitivity than the Roche and Singulex 
Δabsolute alone but the Singulex did provide a 100% NPV by using 0h values at a cut-
off above its 10% CV. In the stratification of this current research, the Roche assay 
achieved a sensitivity and NPV of 100% for all deltas for the intermediate group 
(5.03 < x < 10 pg/ml; n=295, 41 with AMI) by using low delta cut-offs. The Roche 
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assay produced the same results when using a composite predictor of 0h cTnT and 
delta values (cut-offs of 5.03 pg/ml for 0h and Δabsolute, 1.4774% for %Δbaseline, 
0.4739% for %Δmean) but as the deltas are over 3h instead of 1h more patients may 
be at risk by waiting longer for a correct diagnosis. 
The approach of assessing rule in and rule out patients differently, with respect to 
diagnosis, was used by Sandoval et al. (217). Patients were ruled out by the 99th 
percentile of the hs-cTnI and a normal ECG with 100% sensitivity and NPV at 0h and 
3h. Whereas patients were ruled in by delta values alone and produced a specificity 
of 89.3% with an absolute delta of > 5 ng/L. With regard to rule out, this is 
comparable to the sensitivity and NPVs of the Roche assay, 94.7% and 98.9%, and 
the Singulex assay, 98.7% and 98.5%. This paper also observed the possible need 
for differing deltas for different baseline hs-cTnI as patients presenting with 
negative hs-cTnI who had an absolute delta of > 5 ng/L provided a specificity of 
94.2% but with those presenting with a positive hs-cTnI and a delta of > 5 ng/L, the 
specificity dropped to 54.2%. The absolute delta would have to be raised to > 100 
ng/L to obtain a specificity of 94.1% highlighting that certain tools may be better 
suited to different risk groups of NSTEMI. 
Not only could the application of rule in and rule out differ in the magnitude of cTn 
change but different deltas could be used. Δabsolute cut-offs are more diagnostically 
useful at lower concentrations but will not be as useful as higher concentrations. 
The reasons for this are two-fold – the same Δabsolute at a higher concentration 
means less pathophysiologically and at very high concentrations other ischaemic 
cardiac conditions are more likely to be the cause of a cTn rise and mask Δabsolute. 
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For these reasons, it may be more clinically useful to reserve Δabsolute analysis to the 
low-risk ACS group. 
On the other hand, concerning %Δbaseline and %Δmean are more clinically useful at 
higher cTn concentrations. Not only does the effect of biological and analytical 
variation lessen at higher concentrations but to surpass the FS in absolute terms, 
the baseline or mean concentrations have to be at a minimum concentration for 
the %Δ to be effective. For the Roche assay, the lowest concentration for %Δmean 
would have to be 1061 pg/ml for the cut-off of 0.4739% to exceed 5.03 pg/ml in 
absolute terms. 
With regards to the high Roche %Δbaseline and %Δmean clinical sensitivities, there were 
no patients who had a %Δ lower than the quoted cut-offs (1.4774 and 0.4739, 
respectively) and whose baseline level was greater than what was needed for the 
%Δ to be greater than the analytical sensitivity of the assay (341 pg/ml and 1061 
pg/ml, respectively). The high clinical sensitivities are not clinically useful and 
therefore the use of Roche %Δ for rule out may not be appropriate. However, the 
Singulex assay has much lower analytical sensitivity allowing for lower baseline cTn 
required (14 pg/ml) for the %Δbaseline and %Δmean cut-offs of 3.6901% and 3.7050% to 
be effective. The baseline values required for the iSTAT assay are very high at 6,660 
pg/ml and 6,700 pg/ml, which only two patients in the cohort exceeded but also 
exceeded the %Δ cut-offs.  
Considering the universal definition of AMI requires a rise and fall pattern of cTn for 
a positive diagnosis, the quantification of this threshold for the greatest PPV and 
specificity should be elucidated. The use of the deltas have shown to be not as 
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clinically useful in rule out as using 0h and 3h sample concentrations. However, the 
use of concentrations from single samples is dependent on the assay that is used 
and each assay must be assessed for its clinical utility based on its analytical 
parameters. 
8.2.4 Absolute relative deltas with fixed cut-offs based on %CV 
The 10% CV level was explored further by using it as a cut-off for %Δbaseline and 
%Δmean for the reasons described above. As the cut-offs are higher than the ROC-
derived cut-offs for %Δbaseline and %Δmean, the sensitivity and NPVs are not as high. 
By using this cut-off alone, the Roche assay would miss 2% of AMI diagnoses in 
comparison to the %Δbaseline and %Δmean ROC-derived cut-offs (1.4774% and 
0.4739%, respectively) that would miss 1% of diagnoses. The ROC-derived cut-off 
for %Δbaseline Singulex allow only 0.3% of patients to be missed instead of 3% if the 
cut-off is raised to 10% and for the iSTAT assay 2% of patients would be diagnosed 
by using the %Δmean cut-off of 1.4950% instead of 9% when using the 10% cut-off. 
The precision profiles of the individual assays would have to be consulted to assess 
at which concentrations the %CV is lower than the ROC-derived cut-offs and may be 
very high and not clinically useful. However, as stated above, there are problems 
with using the lower ROC-derived cut-offs in that they are only effective above 
certain baseline cTn concentrations, which may supersede the concentration 
needed to overcome the %CV. 
By using ROC curve analysis, the maximum sensitivity can be set but with Δabsolute 
the assay is the limiting factor. However, the Δabsolute must be set by the assay’s own 
analytics otherwise - by using a lower ROC-derived cut-off for an absolute value - a 
true change cannot be confidently observed. However, this is an important factor 
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that cannot be ignored to keep consistent analytical accuracy and to the universally 
accepted 10% CV level. 
8.2.5 Diagnostic value of baseline cTn in predictor composites with cTn deltas, acute 
ischaemia, and H-FABP diagnosis for AMI diagnosis according to the 3 assays 
The addition of other associated factors into possible AMI diagnosis allows a 
broader range of causes for the AMI instead of focusing on cTn and cTn deltas 
arising from cTn sampling. As seen above, and across the literature, cTn has high 
diagnostic value in ACS and can be used more quickly with assays that are more 
sensitive. However, the diagnoses remain problematic in certain patients. The use 
of novel cardiac biomarker H-FABP could allow for even faster diagnosis as it has 
been shown to be a sensitive marker for AMI. Ischaemia as evidenced on ECG was 
also used as ischaemia is a prerequisite of AMI and could provide a more 
informative diagnosis. The cut-offs used for the quantifiable variables, cTn and 
deltas, are as quoted in tables 4.4 and 5.5 in chapters 4 and 5, respectively. H-FABP 
and ECG ischaemia were categorical and as adjudicated by hospital staff as positive 
or negative. 
The sensitivities and NPVs of the Roche assay were high for all composites. The 
sensitivity of cTn + ECG was 94.7% (95% CI, 86.9 – 98.5) but the cTn + deltas were 
all 100.0% (95% CI, 95.0 – 100.0). By combining both to produce cTn + ECG + delta, 
the sensitivity decreased to 97.3% (95% CI, 90.7 – 100.0) for all deltas. The addition 
of H-FABP again increased the sensitivity to 100.0 (95% CI, 95.2 – 100.0). Overall, 
the significant differences between the composites do have a significant effect on 
potential future diagnostic practises as the accepted level of sensitivity required for 
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rule out is 99% and especially for cTn + delta and cTn + ECG + delta + H-FABP as 
they had 100% NPV suggesting all rule out diagnoses would be correct. 
The Singulex assay did not see significant differences by adding factors to the 
composites but the %Δbaseline did produce 100% sensitivity and NPV for all 
composites. The composites with Δabsolute and %Δmean did not reach 99% and 
therefore would not be clinically useful for rule out. However, a bigger validation 
cohort may provide a higher sensitivity and better clinical utility for rule out. 
The higher PPVs of the iSTAT assay (98.6%, 95% CI 96.9 – 99.4 for both cTn + ECG + 
%Δ + H-FABP) can be put down to its higher cTn baseline cut-off and therefore the 
lower number of false positives that occurs with the lower cut-offs observed with 
the Singulex and Roche assays. However, the iSTAT assay reported lower PPVs with 
cTn + %Δ (cTn+ %Δbaseline at 97.0%, 95% CI 95.2 – 98.2) as the % cut-offs were very 
low and would also result in a high number of false positives. Conversely, this has 
resulted in sensitivities of Δabsolute to be lower than the specificity (62.3%, 95% CI 
49.8 – 73.7 and 98.3%, 95% CI, 97.0 – 99.2 for cTn + Δabsolute, respectively) and lower 
than its %Δ counterparts (81.2%, 95% CI 69.9 – 89.6 and 82.6%, 95% CI 71.6 – 90.7 
for %Δbaseline and %Δmean sensitivities, respectively. 
The significant rise of sensitivity and NPV was seen with each addition of a variable 
to the composite but as the cut-offs were already set at the limit of the assay’s 
reportable range, the iSTAT may be more suitable to be used as a rule in device in 
combination with ECG, deltas and H-FABP. As a point of care device, this use is 
preferable as it will alert clinicians to high-risk patients quicker. However, by 
combining the iSTAT results with other variables, the decision would have to wait 
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until H-FABP assay results return from the lab. Instead, the device could alert 
clinicians to medium risk patients to which the H-FABP results could produce a rule 
in diagnosis. In addition, the %Δ would be better suited to higher baseline cTn, as 
previously discussed, which would present in patients of medium risk. The high 
sensitivity would allow more accurate positive diagnosis of patients who are above 
the cut-off. The low PPV of these relative delta results mean that this may not be 
possible. 
This is the first time H-FABP has been used in this specific combination with cTn 
deltas. Previously, H-FABP has been shown to be a better exclusion marker than 
cTnI for early NSTEMI diagnosis (180-183) and the early rise of h-FABP allows high 
diagnostic accuracy < 3h with AUC of 0.841 (181). However, multivariate analysis 
showed complete exclusion was only possible with cTnI and H-FABP combination 
with a sensitivity of 96.9% and NPV of 98.8% (180). This allowed AMI to be excluded 
immediately in 44.7% of the cohort (n = 705) with a miss-rate of 0.6%. This study 
shows the added benefit of H-FABP but also that H-FABP alone will not be 
diagnostically accurate enough to confidently exclude patients from AMI. This may 
be because H-FABP does not have specific cardiac expression (218, 219) and the 
cause of the rise may be non-ACS, such as in chronic heart failure (220), or non-
cardiac, such as in pulmonary embolism (221) or even possibly in 
neurodegenerative diseases (222). 
Due to the rapid increase of systemic h-FABP concentration, its rise may precede 
that of cTn, especially if patients present < 1h from symptom onset and could be 
cTn negative at presentation. In fact, 55% of AMI patients were h-FABP positive at 
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presentation in comparison to 34.6% of AMI who were hs-TnI positive (p = 0.015) 
(184). The diagnostic accuracy of h-FABP in early presenters negative for cTn has 
been found to be AUC = 0.946 with a relative risk of 9.042 of later developing AMI 
(185). These studies are small scale (n = 56 and n = 55, respectively) but they do 
show that h-FABP could have an added benefit at very early presentation and 
should be included in clinical diagnosis algorithms. 
However, not all studies show the added benefit of h-FABP to cTn negative 
patients. A cohort of 317 patients from France showed that there was no significant 
increase in NPV from 95% or cTnI alone to 96% when h-FABP was included in the 
diagnosis (223). The analysis was split into high and low-risk groups depending on 
pretest probability of AMI and there was no difference between cTnI alone or when 
combined with h-FABP (99% vs 100%) in the low-risk group. This study was 
conducted on STEMI and NSTEMI patients, however, and could influence the 
results. The study ROC curve analysis was conducted with 2 different assays, which 
could lead to imprecisions and a semi-qualitative assay was used, from which 
quantitative data was used. 
The POCT iSTAT assay was commented on being limited when used in conjunction 
with other biomarkers that require lab-based results as other results would take 
longer to return. This may be overcome by using h-FABP POCT also, such as the 
Cardio Detect med that was shown to have higher sensitivity than cTnT < 3h at 79% 
vs 32% (183) and a qualitative approach that had a sensitivity of 93.0% for patients 
presenting within 12h (186). This study was carried out on a STEMI cohort (n = 52) 
but it still demonstrates the usefulness of the POCT devices and that by combining 
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the results from two devices the exclusion could be quicker and more accurate 
(180, 183). However, the use of these devices may require training to use properly, 
may take up time of frontline healthcare staff and therefore might not be the 
solution to quick rule out. 
With regards to using ECG ischaemia, creating a composite predictor algorithm 
including ECG ischaemia and cTn Δabsolute may be better suited to rule in diagnosis. It 
has been shown that the PPV of 1h Δabsolute 20 ng/L was 86.5% and that this 
increased to 90.5% when ECG ischaemia was included (224). This information may 
be useful to attempt a quick rule in diagnosis using POCT devices for cTn, H-FABP 
and ECG, which could include 1h Δabsolute if the cTn at presentation is not yet high 
enough to rule in AMI diagnosis. A study could assess the utility of first attempting 
to rule in patients with cTn, H-FABP and ECG ischaemia and if a diagnosis cannot be 
made using 1h Δabsolute, H-FABP and ECG ischaemia to rule in. The first rule in 
composite does contravene observing the necessary rise and fall pattern of cTn and 
true rule in of AMI according to international guidelines may require more 
observation. However, there is evidence that the addition of deltas does not improve 
diagnostic rule in accuracy (214). 
8.2.6 Prediction of 30-day MACE with cTn 0h & 3h samples 
The prognostic accuracy of the 3 assays was assessed for their accuracy for 3 
composite endpoints, composite MACE group included all outcomes; AV 1 included 
all-cause mortality, AMI, revascularisation, PCI, CABG and stenosis; AV2 included 
cardiac arrest, arrhythmia and acute heart failure. The accurate prognosis of MACE 
is important as even small rises in cTn can indicate poor long-term outcomes and 
intervention is beneficial for high-risk patients and detrimental to low-risk patients 
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(225). The differences between the 0h, 3h and max values sampling were minimal, 
as was the differences between the accuracy of the assays for the different 
composite endpoints. 
Using the 10% CV cut-offs, the Roche assay produced average sensitivities and 
specificities for 0h (65.0%, 95% CI 55.9 – 73.4 and 55.8%, 95% CI 51.4 – 60.2, 
respectively), which did not increase at 3h (65.9%, 95% CI 56.8 – 74.2 and 53.1%, 
95% CI 48.7 – 57.5, respectively). The NPVs for 0h and 3h were higher (87.0%, 95% 
CI 83.8 – 89.6 and 86.7%, 95% CI 83.4 – 89.4, respectively) suggesting a high 
proportion of patients below the cut-off could be ruled out of 30-day MACE. By 
using the same cut-off, the AV1 prognosis had higher sensitivity (0h: 89.3%, 95% CI 
78.1 – 96.0 and 3h: 83.3 (71.5 – 91.7), which suggests that the rule out of AMI-
associated events is higher than non-AMI associated events and the cause of the 
rise of the cTn could be caused by another ischaemic condition. The NPV for AV1 
was higher at 98.2% (95% CI, 96.2 – 99.1) and 97.2% (95% CI, 95.2 – 98.4) for 0h and 
3h, respectively, again suggesting more confidence in AV1 rule out. AV2 prognosis 
shows a reduction in sensitivity to composite MACE levels (0h: 59.3, 95% CI 38.8 – 
77.6 and 3h: 55.6%, 95% CI 35.3 – 74.5) and the same occurred with specificity 
(50.3%, 95% CI 46.0 – 54.5 and 52.2%, 95% CI 48.0 – 56.5, respectively). 
Interestingly, the NPV remained high at 96.2% (95% CI, 94.2 – 97.6) and 96.1% (95% 
CI, 94.1 – 97.4), respectively, which may point to the separation of more similar 
conditions for prognosis to achieve better accuracy. 
As with the diagnostic analyses, the Singulex assay displayed high sensitivities and 
NPVs with very low specificities and PPVs due to its low cut-off. For composite 
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MACE, the sensitivities for 0h, 3h and max values were all high (96.3%, 95% CI 91.6 
– 98.8, 97.8%, 95% CI 93.6 – 100.0 and 98.5%, 95% CI 94.7 – 99.8, respectively) as 
were the NPVs for 3h and max values, which were 94.6% (95% CI, 84.6 – 98.2) and 
93.6% (95% CI, 77.8 – 98.4) but was very low for 0h at 8.6% (95% CI, 7.8 – 9.4). This 
could mean for accurate prognosis of composite MACE, it is necessary to increase 
the interval to 3h to increase confidence in rule out when using the Singulex assay. 
This could be down to the variation seen at the low levels measured by Singulex 
and at the chosen cut-off. 
For AV1 prognosis, the sensitivities were high and was found to be highest for max 
values (0h: 98.1, 95% CI 89.9 – 100.0, 3h: 96.2%, 95% CI 86.8 – 99.5 and max values: 
100.0%, 95% CI 94.0 – 100), which also demonstrated 100% NPV. Therefore, by 
using the Singulex assay over 3h, all patients under the cut-off could be ruled out of 
30-day AV1. As with the Roche assay, the sensitivities of AV2 (all 96.3%, 95% CI 81.0 
– 99.9) were higher than composite MACE but lower than AV1, again showing that 
prognosis could be split by conditions to increase accuracy for different conditions. 
The iSTAT assay followed the same pattern as with diagnosis with high specificities 
and low sensitivities. For composite MACE, the highest specificity was found for 0h 
(97.1%, 95% CI 95.2 – 98.4) but only marginally as the difference between 0h and 
3h and max values was marginal (95.8%, 95% CI 93.7 – 97.4 and 95.4%, 95% CI 93.2 
– 97.1, respectively). However, the PPVs were average (64.1%, 95% CI 48.9 – 76.9, 
59.2%, 95% CI 45.9 – 71.2 and 55.1%, 95% CI 42.0 – 67.5, respectively) suggesting a 
limit value of rule in for composite MACE at this cut-off. NPVs were also high 
(82.5%, 95% CI 81.2 – 83.8, 82.9%, 95% CI 81.5 – 84.3 and 82.6%, 95% CI 81.1 – 
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83.9, respectively) but the sensitivity (20.2%, 95% CI 13.5 – 28.3, 23.4%, 95% CI 16.3 
– 31.8 and 21.8%, 95% CI 14.9 – 30.1, respectively) would limit the amount of 
patients correctly identified (14%). AV2 displayed very low sensitivities and PPVs (all 
< 10%) but high specificity (0h: 93.6%, 95% CI 91.2 – 95.5 and 3h and max values: 
92.1%, 95% CI 89.6 – 94.2) and NPVs (0h: 95.6%, 95% CI 95.3 – 96.0 and 3h and max 
values: 95.7%, 95% CI 95.2 – 96.2). This would allow confidence in the rule in of AV2 
condition within 30 days but the low NPV would again limit the number of patients 
correctly identified. 
Rapid rule out for a 3-month follow-up period is possible with NSTEMI patients 
within 3h. When comparing 4 hs-cTn assays and 3 s-cTn assays, all assays had 99.0% 
– 100% NPVs at 0h, for late presenters (> 6h after symptom onset), which only 
marginally increased when the interval was increased to 3h and no late presenters 
who were rule out died during the 3 month follow-up. Although this study observed 
only late presenters, it could provide a different avenue of prognosis for late 
presenters and rapid rule out of those under the cut-off. This study is similar to the 
current analyses and stratification by time since symptom onset could have 
improved prognostic accuracy. However, patients’ accounts of symptoms can be 
unreliable as the symptoms of AMI can manifest in many different ways and 
therefore caution should be applied. 
A large cohort of 65,696 patients evaluated the accuracy of a hs-TnT assay between 
2006-2013 (226). The cohort included all those who experienced chest pain 
(exclusion criteria notwithstanding) not only NSTEMI and assessed the accuracy of 
the assay upon the discharged patients to focus on 30-day MACE. The patients were 
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split into groups that had been immediate discharged and those who had been 
admitted but later discharged. The hs-TnT assay discharged fewer patients than the 
conventional cTnT assay (30-day MACE incidence 0.60% vs 0.90%, p < 0.001) 
showing not only greater analytical sensitivity but greater clinical sensitivity. The 
univariate analysis on the group that was discharged after an initial admission had a 
much higher HR than those who were immediately discharged (2.18 vs 0.69, 
respectively). This would be due to the number and severity of symptoms of those 
who were kept in would be more indicative of AMI and more likely to develop 
MACE within 30-days (227). 
Aldous et al (228) reported risk of death, non-fatal AMI and HF according to a hs-
TnT and cTnT over one year. The hs-cTnT was superior in predicting death and HF 
(HR 5.4 and 27.8) but not for non-fatal MI (HR 4.0). The more analytically sensitive 
hs-TnT assay was shown to be more prognostically accurate possibly because even 
small rises in cTn can predict poor long-term outcomes and the cTnT missed 
patients who fell below the cTnT assay’s 99th percentile cut-off. 
8.2.7 Prediction of 30-day MACE with cTn Δabsolute, %Δbaseline and %Δmean  
There was a majority of males in the cohort (60.6%) but proportionally the number 
of males experiencing MACE was less than expected, although not significantly so (p 
= 0.242). This concurs with other studies that show females over-experience MACE 
in comparison to males. 
By using Δabsolute cut-off at 10% CV, the Roche assay did not yield clinically useful 
prognostic accuracy for any of the composite outcomes. For this variable, the 
highest sensitivity was found for composite MACE at 30.7% (95% CI, 22.7 – 39.6), 
203 
 
and also yielded the highest specificity (92.3%, 95% CI 89.7 – 94.4). The %Δbaseline 
and %Δmean had the highest sensitivity for AV2 (both 63.0%, 95% CI 42.4 – 80.6) and 
highest specificity (76.7%, 95% CI 72.3 – 80.7 and 44.2%, 95% CI 39.4 – 49.2, 
respectively). The difference in specificity between %Δbaseline and %Δmean may arise 
from the large magnitudes of change that %Δbaseline can calculate in comparison to 
%Δmean as the %Δmean results can only reach 200%. This way the %Δmean will 
moderate outliers far more than %Δbaseline but may also result in the identification of 
fewer patients with AV2 outcomes. 
%Δbaseline and %Δmean were most accurate the Singulex assay especially the AV1 and 
2 groups. The sensitivity for 30-day composite MACE for Δabsolute, %Δbaseline and 
%Δmean were all This is strengthened by the NPVs that are also at 100% suggesting 
that all negative tests are true negative tests allowing confident rule out. By using 
max values in to predict AV1 by the Singulex assay, the sensitivity and NPVs are also 
both 100%. The Singulex assay also showed 100% sensitivity and NPV for 30-day 
AV2 prognosis, but only for %Δ. Again, the specificities are very low (5.7%, 95% CI 
4.0 – 8.0 and 5.2%, 95% CI 3.5 – 7.4 for %Δbaseline and %Δmean, respectively) but in a 
rule out diagnosis, this is not a significant concern. It is unusual that the %Δ 
outperformed Δabsolute in a NSTEMI cohort as Δabsolute outperforms %Δ at lower 
concentrations. However, according to the Singulex assay, the 30-day composite 
MACE cohort did have a wide range of cTn baseline concentrations with a mean of 
340 pg/ml, which is greater than the threshold at which the prognostic accuracy of 
Δabsolute is greater than %Δ (190). 
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The very low specificities comes from the fact that the Singulex is so variable that 
the low cut-offs are successful in identifying those without AMI but will also include 
many who are of moderate risk. The large variation in its performance means that 
whether a patient is put into high or low risk groups is almost random, as the 
crosstabs show. The survival analyses agree with this, as there is no significant 
difference between 30-day events between patients above and below the cut-offs. 
It is very useful for ruling patients out but it is random when compared with the 
final adjudicated diagnosis or 30-day MACE outcomes. 
The analytical sensitivity of the iSTAT assay has again shown higher specificities and 
lower sensitivities than the other two assays. This was shown more when 
composite MACE and AV2 were measured by Δabsolute (19.4%, 95% CI 12.8 – 27.4 
and 4.0%, 95% CI 0.1 – 20.4, respectively). However, the Δabsolute specificities for 
composite MACE, AV1 and AV2 were higher (96.5%, 95% CI 94.4 – 97.9, 96.2%, 95% 
CI 94.2 – 97.6 and 93.2%, 95% CI 90.8 – 95.2, respectively) and with optimisation 
the specificity and NPVs could reach 100%. This would require an increase in the 
Δabsolute cut-off and with only 40 patients (5.5% of cohort) above the current cut-off 
of 100 pg/ml, it would only recognise only the highest risk of patients but these 
patients are of greatest risk. The low PPVs (composite MACE at 58.5%; AV1 at 
48.8%; AV2 at 2.6%) also call in question how accurate the prognosis would be and 
for a 30-day prognosis this would cause unnecessary admissions. When using %Δ a 
higher cut-off will yield a greater delta in absolute terms and therefore specificity 
will be higher owning to the larger cTn change, especially at lower cTn baseline and 
mean values. 
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The %Δbaseline and %Δmean sensitivities were more uniform than the Roche assay but 
did not perform better (composite MACE at 56.0%, 95% CI 46.1 – 65.5 and 56.8%, 
95% CI 47.1 – 66.3; AV1 at 55.4%, 95% CI 41.5 – 68.7 and 71.4%, 95% CI 57.8 – 82.7; 
AV2 at 52.0%, 95% CI 31.3 – 72.2 for both, all respectively). The disparity between 
the %Δbaseline and %Δmean AV1 sensitivities could be due to the same reason as with 
the Roche assay, which is the mitigating of outliers by the %Δmean. 
The outcome that had the highest sensitivity, specificity, NPV and PPV and was 
most accurate across all assays was the AV1 composite outcome. This is because 
the conditions included in this composite outcome, all-cause mortality, AMI, 
revascularisation, PCI, CABG and stenosis are ACS-associated conditions, instead of 
AV2, which included cardiac arrest, arrhythmia and acute heart failure. 
Hazard ratios were conducted to assess which risk factors was most associated with 
30-day composite, which included age, sex, prior MI, prior angina, prior PCI, prior 
CABG, hypertension, hyperlipidaemia, chronic kidney disease, smoker and the non-
kinetic cut-off and deltas for each of the assays. Only prior angina and Singulex 
Δabsolute were significantly associated with 30-day composite MACE (HR: 0.462, p = 
0.022; HR: 2.466, p = 0.006, respectively). The reduced risk of patients with prior 
angina at 30 days is due to patients managing their condition. Of the 193 patients 
with prior stable angina, 21 (11%) were not receiving treatment related to their 
condition (includes aspirin, oral nitrate, statins, ACE inhibitors, beta blockers, Ca2+ 
blockers, Nicorandil). Patients with other risk factors would also be receiving 
treatment for the conditions, which would also cause the HR to fall below 1, none 
of which were significant. It is interesting to note that with increasing age there was 
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a slight but insignificant reduction in risk at 30 days but this is also because with age 
treatments that would reduce risk of MACE increase. 
Average time to event for composite MACE was performed for each of the assays 
for 0h and Δabsolute. These analyses showed very small variation between high and 
low groups for all assays, ranging from 29.68 – 30.00 days. Only the Singulex assay 
showed a significant difference between high and low cTn groups in which the high 
cTn group had less time to event than the low cTn group (29.68 days, 95% CI, 29.46 
– 29.90 and 29.95 days, 95% CI, 29.91 – 30.00, respectively; p = 0.003), as would be 
expected. However, due to the low number of events across the cohort (6 in total), 
it would be difficult to represent how accurate each assay is at predicting average 
time to event and cumulative event rate. 
Apple et al (210) used %Δ of 10%, 20% and 30% on a cohort of 397 for 60-day MACE 
and found highest cumulative event rate was with patients whose second cTn 
sample was > 0.034 µg/L (49.2%) and in patients whose %Δ was increased by > 30% 
(60.5%) and both were independent predictors of MACE. Non-kinetic values 
showed the strongest prognostic accuracy in this paper but combined the 6h > 
0.034 µg/L + ΔcTnI > 30% was the most prognostically accurate with 69.4% of 
cohort having an event at 60-days.  
In a study using a longer sample-sample interval of 24h, %Δ were set at +20%, +50% 
and +100% and showed higher proportional rates of a composite of AMI and death 
at 6 months (229). In the cTnI > 0.07 µg/L group 3.1% had events and this increased 
for cTnI > 0.07 µg/L + ≥ 20% %Δ to 14.4% of patients above threshold had an event. 
However, this did not increase with cTnI > 0.07 µg/L + ≥ 100% %Δ was 14.5%. Even 
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though the %Δ had increased, the effect on prognostic accuracy had not. The ≥ 20% 
did positively associate with AMI events over ten years (log rank p < 0.001), 
showing that even moderate rises of cTnI show poor long-term outcomes. 
In another long-term study associating cTn deltas with outcomes, Kaplan-Meier 
analysis showed only patients in the highest tertile (Δabsolute >104 ng/L) were 
significantly associated with worse outcomes after 30-days and those in the lowest 
tertile (Δabsolute <5.4 ng/L) were not (230). This concurs with the current analysis 
where only the Δabsolute Singulex was significantly predictive for 30-day composite 
MACE (HR = 2.466) Over one year, any detectable cTn was associated with poorer 
long-term outcomes with hazard ratios increasing as cTn deltas increased (%Δ 
<43%; %Δ >728%) but the HR for Δabsolute was greater than for %Δ (2.95 and 1.89, 
respectively). 
The difference in plaque morphology can lead to a difference in how AMI manifests 
Ruptured coronary plaques and multiple thrombi are more associated with early 
events after presentation and chronic atherosclerosis is more associated with later 
events after presentation (231). Imaging techniques could be incorporated for 
better prognostic accuracy for patients and would further reduce unnecessary 
hospitalisations. Early PCI improves outcomes but more likely to need another 
revascularisation at 6 months (88). 
8.2.8 Prediction of 30-day MACE using baseline cTn in predictor composites with cTn 
deltas, acute ischaemia, and H-FABP diagnosis for AMI diagnosis for cardiac-
associated conditions 
As with the composite predictor for diagnosis, the same method was applied but 
for 30-day composite MACE to assess this novel composite for accuracy across the 3 
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assays. As with the diagnosis accuracy of these composites, the Singulex assay had 
high sensitivities, the iSTAT assay had high specificities and the Roche assay had 
more consistent results but with some composites showing high rule out capability. 
The average predictive accuracy for the Roche assay for cTn + ECG (sensitivity: 
64.1%, 95% CI 55.6 – 72.0, specificity: 52.8%, 95% CI 48.6 – 56.9, PPV: 24.9%, 95% CI 
22.2 – 27.8 and NPV: 85.8%, 95% CI 82.7 – 88.3) did not improve with cTn + Δabsolute 
but cTn + %Δbaseline did improve with regards to rule out capability with sensitivity 
and NPV both at 100.0%. All cTn + ECG + deltas expressed 100% sensitivity and NPV 
also but the addition of H-FABP had a detrimental effect on sensitivities for Δabsolute, 
%Δbaseline and %Δmean (68.3%, 95% CI 60.0 – 75.9, 99.3%, 95% CI 96.1 – 100.0 and 
75.4%, 95% CI 67.4 – 82.2, respectively). This could be due to H-FABP being a short-
term predictor according to rapid release into the system. The specificity of 
composites including %Δbaseline was markedly less than %Δmean (cTn + %Δbaseline 0.4%, 
95% CI 0.0 – 1.3 and cTn + %Δmean 35.9%, 95% CI 32.0 – 40.0). This could be down to 
the mitigating factor of the %Δmean only allowing values to reach 200%, which 
%Δbaseline does not have and small increases in absolute terms could be large as a 
percentage misprognosing patients. 
For the Singulex assay, the cTn + ECG sensitivity was high (95.8%, 95% CI 91.0 – 
98.4) and the specificity low (10.3%, 95% CI 8.0 – 13.1) and the introduction of 
deltas to make cTn + delta composites did not improve sensitivity but had an effect 
on %Δbaseline and %Δmean specificity (1.6%, 95% CI 0.7 – 3.0 and 3.0%, 95% CI 1.7 – 
4.7, respectively). This could be due to the effect of percentages exaggerating 
differences at lower concentrations, at which the Singulex assay can measure. The 
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combination of the low cTn cut-off and low %Δbaseline and %Δmean cut-offs enhance 
this more than the specificity of cTn + Δabsolute (9.4%, 95% CI 7.2 – 12.1), which is 
very low but was not as effected as the %Δ. All cTn + ECG + deltas showed perfect 
rule out capability with 100% sensitivity and NPV, with consistently low specificity 
and PPVs once more. The addition of H-FABP reduced the sensitivities (97.2%, 95% 
CI 92.9 – 99.2, 98.6%, 95% CI 95.0 – 99.8 and 98.6%, 95% CI 95.0 – 99.8, 
respectively) and NPVs (93.0%, 95% CI 83.0 – 97.3, 84.6%, 95% CI 55.2 – 96.1 and 
90.5%, 95% CI 69.1 – 97.6, respectively). The + H-FABP results are greater than the 
Roche assay results shown above but the reduction in rule out capability for 30 day 
MACE could also be due to the rapid release and decrease in the serum of H-FABP. 
For the iSTAT assay, the specificities were mostly higher than the sensitivities with 
consistent NPVs either side of 85%. The addition of each variable to the composite 
had a negative effect on specificity, e.g. for Δabsolute, cTn + Δabsolute was 95.7% (95% CI 
93.7 – 97.3), cTn + ECG + Δabsolute was 90.2% (95% CI, 87.3 – 92.6) and cTn + ECG + 
Δabsolute + H-FABP was 79.8% (95% CI, 76.1 – 83.1). The opposite was true for 
sensitivity with it increasing with additional variables, e.g. for Δabsolute was 23.0% 
(95% CI, 16.2 – 31.0), 32.6% (95% CI, 24.8 – 41.2) and 41.5% (95% CI, 33.1 – 50.3), 
respectively. For a high cut-off assay, this is consistent with the data because added 
variables will increase false positives missed by cTn, as seen with the PPVs that 
decreased accordingly. 
The Singulex assay performed best when considering the rule out of patients from 
30-day MACE. As said previously, the poor specificity is not a large concern if a 
patient can be ruled out quickly and effectively. The Roche assay performed as well 
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for the cTn + ECG + delta as the Singulex assay showing a strong prognostic 
accuracy not only for the assays but also for the predictor composite itself. Further 
studies could assess the prognostic utility of this composite as a possible simple 
early rule out for 30-day MACE. However, more complex, tailored algorithms would 
be more accurate to this end. 
One such algorithm is the MACS rule, which used univariate logistic regression to 
identify predictors for AMI and MACE. The rule combines hs-cTnT, h-FABP, ECG 
ischaemia, observed sweating, vomiting, systolic blood pressure < 100 mmHg, 
worsening angina and pain radiating to right arm or shoulder in a multivariate 
logistic model (232). The rule produced AUC of 0.95 for predicting MACE at 30 days 
and could rule out all patients in the very low risk group that made up 35.5% of the 
cohort from 30-day AMI with only 1 patient experiencing MACE in the same group. 
This lead to an overall sensitivity of 99.4% and NPV of 99.6% for MACE and 100% 
for both for AMI. A further study with an automated assay for h-FABP increased the 
number of patients who could be ruled out of 30-day AMI with 100% sensitivity to 
40.5% of cohort with a 1.1% incidence of 30-day MACE (233). However, these 
analyses include STEMI and NSTEMI patients and therefore the percentage of 
patients who would be considered for rule out would be higher than a cohort of 
NSTEMI only patients. Yet, the use of continuous data in the form of hs-TnT and h-
FABP provides more information than categorical data alone and which could point 
towards its very high AUC. As NSTEMI diagnosis can be problematic, the use of 
continuous and not categorical data could be very useful in the further 
improvement in NSTEMI diagnostic accuracy. 
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8.2.9 Limitations 
Adjudication of outcomes was done with standard cTn assays and not those 
featured in the analyses and this could lead to mis-classification bias when using the 
assays in practise. Validation studies would need to be done to assess their 
performances in active clinical practice. Secondly, many patients did not have two 
samples taken, especially for the point of care iSTAT device, and these exclusions 
could lead to selection bias. The outcome measures for diagnosis were binary, AMI 
and no AMI, and does not include the myriad of ACS available. In future, the cohort 
could be subdivided further by cTn measurements to determine which ACS the 
patients is experiencing. However, even with ultra- or hyper-sensitive-cTn assays, 
subdividing by cTn alone may not be able to categorise patients effectively or more 
emphasis on rule in diagnoses may be needed for this end. 
The short 30-day prediction time lead to a limited number of events, which effected 
the Kaplan-Meier analysis and differences between high and low cTn groups was 
minimal. The follow-up data was incomplete, and had few events regardless adding 
to apparent inconsistencies in the data. Inconsistency could also have arisen from 
sample collection and storage; the samples were used by multiple groups in a busy 
environment that could have lead to sample degradation. The busy environment 
may have lead to incomplete data on duration of chest pain and therefore provided 
misleading information concerning TSSO and discrepancies seen across the 0h-3h 
time period. 
8.2.10 Future work 
Large %Δ cut-offs at low concentrations and small %Δ cut-offs at high 
concentrations are due to the effect of biological variation. At low concentrations, 
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the effect of biological variation is large and is much less at higher concentrations 
(234). This can be used clinically as cut-offs can be changed depending on the 
baseline cTn to make diagnoses and MACE predictions more accurate. Low %Δ cut-
offs at high concentrations could be used to quickly rule out patients who have 
chronically high cTn levels because only a very low %Δ would be observed in those 
patients due to their raised basal cTn level. However, this could be used as a rule in 
tool for patients who are already at risk of AMI arriving to the ED with raised cTn, 
which may not raise much higher. Without a significant rising or falling pattern it 
might be difficult to diagnose, especially in the uncommon instance of reinfarction. 
In addition, variation across time has been shown to increase and decrease (234, 
235) further complicating its use in diagnosis. 
In the same way that different assays have different specifications, the individual 
variation between and within patients (235) will also have implications on how 
effective the specific diagnosis cut-off or algorithm will be on different patients or 
groups of patients. 
A very small %Δ could be seen as individual, biological, analytical or even circadian 
(236) variation and not to do with myocardial ischaemia. However, higher 
concentrations experience a plateau of %CV and therefore consistency above 300 
pg/ml. The above analyses include only NSTEMI patients, which does not 
experience such high levels of cTn as STEMI but cTn means for NSTEMI are found 
within this range (160) especially if sampling is done post-24h symptom onset (209). 
Pretorius and Ungerer (190) observed this phenomenon and tried to overcome the 
different %CV and analytical characteristics of different assays to produce a 
213 
 
universal cut-off for NSTEMI by using z-values. The cut-off was determined from the 
z-value, which takes into the account the analytical and biological variation found in 
the assay and the reference population of patients by this equation (190): 
𝑧 =  
𝛥𝑎𝑏𝑠𝑜𝑙𝑢𝑡𝑒
√2𝑆𝐷𝐴𝑛𝑎𝑙𝑦𝑡𝑖𝑐𝑎𝑙
2 +2𝑆𝐷𝐵𝑖𝑜𝑙𝑜𝑔𝑖𝑐𝑎𝑙
2
  
This is based on the reference change value (RCV) equation: 
𝑅𝐶𝑉 = √2𝑆𝐷𝐴𝑛𝑎𝑙𝑦𝑡𝑖𝑐𝑎𝑙
2 +  2𝑆𝐷𝐵𝑖𝑜𝑙𝑜𝑔𝑖𝑐𝑎𝑙
2   
Using RCVs could be important for groups of patients who have chronically elevated 
cTn as a raised baseline cTn would not be specific to AMI and a standardised rising 
and falling pattern must be observed for MACE prediction to be accurate. In a group 
of haemodialysis patients, RCV cut-offs were determined at +37% and -30% for hs-
cTnI and +25% and -20% for hs-cTnT and patients exceeding the RCVs had HR = 1.9 
and = 1.7 for all-cause mortality (237). Specifically for sudden cardiac death, hs-cTnI 
RCVs > +37% and -30% showed an adjusted HR = 2.6. 
Not only do RCVs allow another route for diagnosis and MACE prediction but also 
they are useful in directly comparing analytical specifications of different assays and 
not through diagnostic tests. This would allow comparing concentrations at which 
10% CVs, 99th percentiles and LoDs easier to compare making comparisons of 
diagnostic test more effective. In addition, by using RCVs, the cut-off is personalised 
to each patient creating a more tailored and specific diagnosis. The variations 
between patients will be different and therefore assigning reference population 
data will cause infrequent false negatives due to this difference. By taking into 
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account, a patient will very low intrapersonal variation may be wrongly adjudicated 
as AMI-free as the cTn delta was not high enough for a rule in diagnosis. By 
adjusting for this difference, a margin of error is removed and ACS diagnoses 
become closer to personalised medicine. In addition, RCV are not affected by how 
results are distributed whereas cTn Δabsolute and %Δ are more effective at opposing 
ends of the cTn baseline range giving RCVs more scope across all cTn 
concentrations. 
8.3 Conclusion 
The aim of these analyses was to produce a new clinical decision algorithm that 
included mCRP. However, the chemically complex nature of mCRP along with a 
non-commercial antibody made creating a reliable immunoassay problematic and 
too variable for clinical use. Its involvement in the degradation of the fibrous cap of 
atheromas suggests it would be a useful biomarker for rapid rule out or rule in. 
Alternatively, mCRP may be more of use in short-term MACE prediction as its role in 
degrading the fibrous cap is integral to and precedes MACE. However, it dissociates 
locally around sites of activated endothelium and therefore the systemic 
concentration will be low, which could require a very sensitive method of detection 
to discern between pathological and non-pathological rises in mCRP, as occurred 
with AMI diagnosis and cTn. 
Although cTn is a product of ACS and does not precede events unlike mCRP, the use 
of the ultra-hs-cTnI Singulex analyser did produce perfect rule out at presentation 
for AMI with 21% of patients below the specified cut-off. This was much higher than 
the current Roche assay in use at the MRI and could allow more patients to be ruled 
out of AMI more quickly with a single test. However, validation in a clinical study 
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could wait until a precision profile was expanded to include the concentrations at 
which the assay displays its analytical sensitivities. This would increase clinicians’ 
confidence concerning repeatability of the assay and in turn the safety of the 
patients. 
The point of care iSTAT assay showed promising rule in capability, which is 
necessary to quickly identify patients who are at high risk and require immediate 
assistance. Its performance in the predictor composite did not consistently enhance 
rule out accuracy, unlike the Roche or Singulex assays. However, by using the iSTAT 
to identify high-risk patients, it could be used alongside other iSTAT cartridges, such 
as the h-FABP to identify high-risk patients even earlier. Using an assortment of 
tools to positively diagnose patients consolidates more and varied data resulting in 
more accurate diagnoses. 
Furthermore, by categorising patients into risk groups based on the baseline cTn 
concentration and tailoring delta cut-offs to each individual group, diagnostic 
accuracy increases. Additional tailoring can be done with the use of RCVs, which 
provides each patient with a personalised cut-off. Although this may cause difficulty 
by taking time to calculate the RCVs, this could be automated for ease in busy EDs. 
This form of personalised medicine effectively negates the variation that causes 
uncertainties in diagnoses to provide clinicians with a more confident diagnosis for 
that particular patient and not solely based on reference populations. 
The Gold Standard of ACS diagnosis is cTn due to its cardiac specificity and with 
ever more sensitive cTn assays, it will remain as the most clinically useful 
biomarker. This does not suggest that cTn should be used alone, by combining 
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different diagnostic tools and biomarkers ACS diagnosis could become more 
personalised and therefore more accurate. 
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INTENDED USE
The Sgx Clarity™ cTnl Assay is an in vitro immunoassay test that quantitatively measures cardiac troponin (cTnl) in EDTA plasma using the
Sgx Clarity System. The Sgx Clarity cTnI Assay is indicated to be used in conjunction with clinical evaluation for ruling out cardiac ischemia
in patients suspected of having coronary artery disease.
DEVICE DESCRIPTION
The Sgx Clarity cTnI Assay is composed of the following individual components (all sold separately): 
- Sgx Clarity cTnI Reagent Pack 
- Sgx Clarity cTnI Calibrator Kit 
- Sgx Clarity System Elution Buffer 
- Sgx Clarity System Wash Buffer Concentrate.
SUMMARY AND EXPLANATION OF THE TEST 
Coronary artery disease (CAD) is one of the leading causes of death worldwide.1 Early detection of CAD and stress-induced cardiac
ischemia is critical to global efforts towards reducing the CAD public health burden. Cardiac stress testing is currently the mainstay of
noninvasive CAD diagnostics.2 Nuclear stress testing with imaging, such as myocardial perfusion imaging single emission tomography
(MPI-SPECT), has limitations including high costs, limited availability, and exposure to contrast agents and radiation. 2-4 Therefore, there is
a need for simple, safe, and widely available alternative tools to detect stress-induced cardiac ischemia with a degree of accuracy that
would enable rule-out of patients from such imaging tests. In addition to reducing healthcare costs, an equivalent alternative rule-out tool
would reduce patient time in medical facilities and the number of specialist referrals needed.
Cardiac troponins I and T (cTnT) have a central role in the diagnosis and management of patients with suspected acute coronary
syndrome (ACS).5,6 Previous studies have demonstrated an association between cTnI levels and stress-induced cardiac ischemia.7,8 The
association between cardiac troponin and stress-induced ischemia was further established in the BASEL VIII study using a high-sensitivity
cTnI Research Use Only (RUO) assay from Singulex in patients with suspected CAD being evaluated with MPI-SPECT—overall, the
Singulex cTnI assay (RUO) demonstrated strong diagnostic accuracy, in particular for the rule-out of cardiac ischemia, and therefore the
rule-out of standard stress-imaging procedures.9 A separate subset of the EDTA plasma cohort from the BASEL VIII study was used to
validate the Sgx Clarity cTnI Assay for its intended use and determine the diagnostic test characteristics at multiple cTnI concentrations. 
TEST PRINCIPLE
The Sgx Clarity cTnI Assay is an ultra-sensitive immunoassay that uses single photon fluorescence detection for the quantitation of cardiac
troponin I (cTnI) in EDTA plasma samples. The sample is transferred by the Sgx Clarity System to an Sgx Clarity Reaction Vessel (RV), into
which cTnI-specific antibody-coated paramagnetic microparticles (capture reagent) and fluorescently labeled cTnI-specific antibodies
(detection reagent) are then added. The reactants are then incubated at 37 °C in the Reaction Vessel. During incubation, cTnI present in
the sample binds to both the capture antibodies and the detection antibodies, forming an immune complex. Unbound material in the
reaction mixture is washed away during the subsequent wash steps. Elution buffer is then added to dissociate the immune complexes
(bound analyte and detection antibodies) from the paramagnetic microparticles and release fluorescently-labeled antibodies during the
second incubation step of the protocol. After dissociation, the mixture is exposed to a magnetic field in order to separate the paramagnetic
microparticles from the dissociated labeled antibodies. The resulting eluate, containing the dissociated detection antibodies, is transferred
to an Sgx Clarity Detection Vessel (DV) where the labeled molecules are detected and counted. The signal count results are then compared
to a calibration-adjusted Master Curve and converted into a cTnI concentration. 
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Sgx Clarity™ cTnI Assay Instructions for Use
OTHER RESOURCES
• For lot-specific information, refer to the package insert or reagent label associated with each reagent. 
• For detailed instructions on how to operate the Sgx Clarity System, refer to the Sgx Clarity System Operator’s Manual. To download
electronic copies of the operator’s manual, please visit singulex.com/IFUs. To request additional printed copies of the Sgx Clarity System
Operator’s Manual or these Instructions For Use, call +800 135 79 135.
REAGENTS
Assay Reagents
System Reagents
REAGENT STORAGE AND STABILITY
Store reagents as follows for use on the Sgx Clarity System. For lot-specific information, consult the package insert or reagent label for each
reagent. All unopened reagents are stable when stored as directed until labeled expiration date.
For instructions related to usage on the Sgx Clarity System, refer to the Sgx Clarity System Operator’s Manual.
Reagent Description Associated Notices REF
Capture Reagent A HEPES-buffered solution containing anti-troponin I mouse 
monoclonal antibody-coated paramagnetic microparticles with 
protein stabilizers and sodium azide as a preservative. 
None DX-CTNKIT-001
Sgx Clarity cTnI 
Reagent Pack 
Detection Reagent A HEPES-buffered solution containing fluorescently-labeled anti-
troponin I mouse monoclonal antibodies with protein stabilizers 
and sodium azide as a preservative.
None DX-CTNKIT-001
Sgx Clarity cTnI 
Reagent Pack 
Sgx Clarity cTnI 
Calibrators
Human Serum and Plasma protein matrix containing buffers, 
antibiotics, and stabilizers adjusted to known cTnI concentrations 
with native human cTnI.   
DX-CTNCAL-001
Sgx Clarity cTnI 
Calibrator Kit 
Sgx Clarity cTnI 
Controls (optional)
Human Serum and Plasma protein matrix containing buffers, 
antibiotics, and stabilizers adjusted to known cTnI concentrations 
with native human cTnI.  
DX-CTNCTR-001, 
002, 003, 004
Sgx Clarity cTnI 
Controls (Levels 1-4)
Reagent Description Associated Notices REF
Sgx Clarity System 
Elution Buffer
Aqueous solution with a glycine buffer system. DX-CLRELB-001
Sgx Clarity System 
Elution Buffer 
Sgx Clarity System 
Wash Buffer 
Concentrate
Borate buffer solution containing ProClin 950 as a preservative. None DX-CLRWAS-001
Sgx Clarity System 
Wash Buffer 
Concentrate
Reagent Store upright at... Open Stability
Sgx Clarity cTnI Reagent 
Pack:
Capture Reagent 
and 
Detection Reagent
56 hours at room temperature following first use or until the labeled expiration date, 
whichever comes first. (See "Sgx Clarity cTnI Reagent Pack Stability and Calibration 
Interval".)
Note: Unless specified otherwise, “room temperature” is defined as (15–30 °C).
Sgx Clarity System 
Elution Buffer
NA: Single use reagent.
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PRECAUTIONS 
• For In Vitro Diagnostic Use.
• Use routine laboratory precautions and do not pipette by mouth.
• Do not eat, drink, or smoke in the laboratory work area, and wash hands thoroughly after use. 
• WARNING - Sgx Clarity cTnI Calibrators (3 levels) and Sgx Clarity cTnI Controls (4 levels; optional) contain methanol and are subject to
the following Hazard and Precautionary statements:
- H303, May be harmful if swallowed
- H311, May be harmful in contact with skin
- H331, May be harmful if inhaled
- P264, Wash hands thoroughly after handling
- P270, Do not eat, drink, or smoke while using this product
- P280, Wear protective gloves/protective clothing/eye protection/face protection
- P261, Avoid breathing mist/vapors/spray
- P271, Use only in a well-ventilated area
Hazard Responses:
- P301 + P312, if swallowed, call a Poison Center or doctor/physician if you feel unwell
- P330, Rinse mouth
- P302+P352, IF ON SKIN: Gently wash with plenty of soap and water
- P312, Call a POISON CENTER or doctor/physician if you feel unwell
- P363, Wash contaminated clothing before reuse
- P304+P340, IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
- P311, Call a POISON CENTER or doctor/physician
• WARNING - Sgx Clarity cTnI Calibrators and Sgx Clarity cTnI Controls (if used) contain human blood products and should be considered
potentially infectious—take the same precautions as are used with patient specimens. 
• Sgx Clarity cTnI Reagent Packs, Sgx Clarity cTnI Controls, and Sgx Clarity cTnI Calibrators contain sodium azide, which can react with
copper and lead plumbing to form explosive metal azides. If disposal into a drain is in compliance with local requirements, flush
reagents with a large volume of water to prevent buildup of azides.
• Disposal – Dispose of biohazardous materials according to the practices of your institution. Discard all materials in a safe and
acceptable manner, and in compliance with all governmental requirements.
• The Safety Data Sheet (SDS) for each reagent is available upon request.
Sgx Clarity System Wash 
Buffer Concentrate
Concentrated: Until the labeled expiration date.
Prepared (diluted): 7 days following preparation or until the labeled expiration date of the 
Wash Buffer Concentrate, whichever comes first.
Sgx Clarity cTnI Calibrators 
(3 levels)
NA: Single use reagent.
Sgx Clarity cTnI Controls 
(Singulex / 4 levels)
30 days or until the labeled expiration date, whichever comes first.
Note: The Sgx Clarity System does not track open stability of Sgx Clarity cTnI Controls. It is 
the responsibility of site personnel to track this following first use. 
Reagent Store upright at... Open Stability
06-0019-01 4 of 16
Sgx Clarity™ cTnI Assay Instructions for Use
MATERIALS 
Materials Provided by Singulex
*Sgx Clarity cTnI Reagent Packs contain enough volume to run at least 92 tests under most operating conditions, but the
actual number of tests derived from any given pack will fluctuate according to variable evaporation rates and total open
time. If processed at the acceptable upper temperature limit for the entire open stability period, the actual number of tests
derived may be as few as 72. 
Materials Required But Not Provided by Singulex
Optional Materials
Material Quantity/Capacity REF or PN
Sgx Clarity cTnI Reagent Pack 1 pack (92 test capacity*) DX-CTNKIT-001
Sgx Clarity Detection Vessels Box 25 DVs DX-CLRDVS-001
Sgx Clarity Reaction Vessels Box 120 RVs DX-CLRRVS-001
Sgx Clarity System Elution Buffer 20 × 30 mL DX-CLRELB-001
Sgx Clarity System Wash Buffer Concentrate 1 × 1 L DX-CLRWAS-001
Sgx Clarity cTnI Calibrator Kit (lot matched) Level 1 (1 × 0.75 mL)
Level 2 (1 × 1.20 mL)
Level 3 (1 × 0.75 mL)
DX-CTNCAL-001
Sgx Clarity Spare Reagent Caps 250 DX-CLRCSM-001 
Sgx Clarity Waste Blisters 40 (20 large and 20 small) DX-CLRCSM-002
Spare Bottles for RV Buffer 12 DX-CLRCSM-003
13 mm × 75 mm Low Volume Sample Cup Holders 1,000 DX-CLRCSM-004
Low Volume Sample Cup (0.5 mL) 1,000 DX-CLRCSM-005
Disposable Tips (DiTi), 1000 μL 2,304 30064861
Disposable Tips (DiTi), 350μL 7,680 30083400
7.5 mL Disposable Graduated Transfer pipets 500 16001-188
Super Sani-Cloth Germicidal Disposable Wipes 1 pack (160 sheets) Q55172
Presaturated Wipes 1 pack (30 sheets) PS-919
Microcide SQ 1 Gallon MICROCIDE
Material Quantity REF or PN
Deionized water Not applicable Not applicable
Material Quantity Vendor / Description REF or PN
Sgx Clarity cTnI Control Level 1  6 × 3.0 mL Singulex DX-CTNCTR-001
Sgx Clarity cTnI Control Level 2  6 × 3.0 mL Singulex DX-CTNCTR-002
Sgx Clarity cTnI Control Level 3 6 × 3.0 mL Singulex DX-CTNCTR-003
Sgx Clarity cTnI Control Level 4  6 × 3.0 mL Singulex DX-CTNCTR-004
Phosphate Buffered Saline, no 
additives (for dilution, if 
required)
1 × 500 mL Thermo Fisher / Gibco PBS, pH 7.2 20012027
1 × 500 mL Thermo Fisher / Gibco PBS, pH 7.4 10010023
100 tablets Diagnostic BioSystems / pH 7.4 DMRE404-01
Centifruge filter, 500 μL capacity 100 VWR 82031-360
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PROCEDURAL NOTES
Specimen Collection and Handling
• EDTA plasma is the intended sample type for this assay.
• Follow the manufacturer’s processing instructions for plasma collection tubes.
• Collect blood samples observing Standard Precautions for venipuncture. 
• To avoid cross-contamination, use caution when handling patient specimens. The use of disposable pipettes or pipette tips is
recommended.
• Keep sample tubes capped at all times when not in use.
• Tightly cap and refrigerate sample tubes at 2–8 °C.
• Equilibrate samples to room temperature prior to processing on the Sgx Clarity System.
• Inspect all specimens for bubbles. If present, remove bubbles prior to analysis, being careful not to remove too much specimen volume. 
• Centrifuged specimens with a lipid layer on the top must be transferred to a Low Volume Sample Cup or secondary tube for processing
on the Sgx Clarity System. Care must be taken to transfer only the clarified specimen without the lipemic material.
• Frozen Sample Handling:
- Freeze samples ≤ -70 °C for long term storage, with maximum of 3 freeze/thaw cycles.
- Mix thoroughly by gentle inversion after thawing until samples are visibly homogenous, without layering or stratification. 
- Frozen samples must be fully thawed and centrifuged at 11,300 × g for 10 minutes before analysis. 
- Following centrifugation, prepare the supernatant and transfer as follows:
• For low volume (≤ 0.5 mL) samples: Without disturbing the pellet, transfer the supernatant to a Low Volume Sample Cup and load 
onto the Sgx Clarity System in a 13 × 75 mm Low Volume Sample Cup Holder per the instructions provided in the Sgx Clarity 
System Operator’s Manual.
• For larger volume samples (> 0.5 mL): Without disturbing the pellet, transfer the supernatant to an appropriately-sized tube. 
Pipette up and down 10 times  within the tube to mix thoroughly, then transfer 300 μL to a Low Volume Sample Cup and load onto 
the Sgx Clarity System per the instructions provided in the Sgx Clarity System Operator’s Manual.
Or:
• As needed: If supernatant retains visible particulate matter following centrifugation, samples may require filtration. In this case, 
transfer the supernatant to a VWR centrifuge filter (see “Optional Materials” on page 4) and centrifuge at 
13,900 g for 10 min prior to transferring sample to Low Volume Sample Cup or tube as noted above.
- Before placing samples onto the system, ensure that the samples are:
• Free of particulate matter.
• Free of bubbles.
• Stability
The Sgx Clarity cTnI Assay has shown stability for EDTA plasma samples at room temperature (20–25 °C) for up to 24 hours, refrigerated
(2–8 °C) for up to 120 hours, and 12 months at ≤ -70 °C with up to 3 freeze/thaw cycles. 
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Reagent Preparation
Sgx Clarity cTnI Reagent Pack Stability and Calibration Interval
• Sgx Clarity cTnI Reagent Pack stability: 
- Open stability for cTnI Reagent Packs is 56 hours from first scan on the Sgx Clarity System, and assumes that cTnI Reagent Packs 
are immediately capped and returned to storage when not in use.
- Discard Sgx Clarity cTnI Reagent Pack at the end of the stability interval. Stability is tracked in the Sgx Vision Software—see the Sgx 
Clarity System Operator’s Manual for details. 
• Calibration interval: 7 days
- A new calibration is required:
• When changing lot numbers of Sgx Clarity cTnI Reagent Packs.
• When quality control results are repeatedly out of range.
• When calibration interval is expired.
- For full details regarding the calibration concept and instructions for calibrating cTnI Reagent Packs, refer to the Sgx Clarity System 
Operator’s Manual. 
Master Standard Curve
Sgx Clarity cTnI Reagent Packs require a new lot-specific Master Curve with each new reagent pack lot. The Master Curve is provided in
the Sgx Clarity cTnI Reagent Pack Package Insert, and is entered during reagent calibration per the instructions in the Sgx Clarity System
Operator’s Manual.
Reagent Preparation
Sgx Clarity cTnI 
Reagent Pack:
Capture Reagent 
and 
Detection Reagent
• Keep Sgx Clarity cTnI Reagent Pack vials capped when not in use.
• Once reagent vial caps have been removed for use of the reagent pack on the Sgx Clarity System, replace them with new Sgx
Clarity Spare Reagent Caps before returning the reagent pack to storage.
• Do not combine leftover volume from one Sgx Clarity cTnI Reagent Pack with another.
• Prior to loading reagents onto the Sgx Clarity System:
- Remove from storage and allow to equilibrate to room temperature for 60 minutes. 
- Mix the reagent pack by hand by gentle inversion at least 10 times prior to loading. 
- Open each reagent vial and dispose of reagent caps (new reagent caps must be used upon returning the reagent pack to 
storage).
- Remove bubbles from the surface with a disposable transfer pipette as follows:
• Use separate disposable pipettes for each reagent vial.
• Be careful not to aspirate the liquid reagent.
Note: Do not store Sgx Clarity cTnI Reagent Packs on the benchtop or on the Sgx Clarity System—always cap and return to 
storage at 2–8 °C when not in use.
Sgx Clarity System 
Elution Buffer
• Remove from storage and allow to equilibrate to room temperature for 30 minutes.
Sgx Clarity System 
Wash Buffer 
Concentrate
• To prepare a working solution, dilute Wash Buffer Concentrate 10X with deionized water (1 part Sgx Clarity Wash Buffer
Concentrate / 9 parts deionized water), then mix thoroughly.
Caution: Failure to dilute Wash Buffer Concentrate as noted above prior to use on the Sgx Clarity System may impact assay 
results. 
Sgx Clarity cTnI 
Assay Calibrators (3 
levels)
• Remove from storage and allow to equilibrate to room temperature for 30 minutes.
• Once at room temperature, mix by gentle inversion (10 times minimum).
• Keep tubes capped when not in use.
Sgx Clarity cTnI 
Controls 
(Singulex / 4 levels)
• Remove from storage and allow to equilibrate to room temperature for 30 minutes.
• Once at room temperature, mix by gentle inversion (10 times minimum).
• Keep tubes capped when not in use.
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Calibration
Prepare and load Sgx Clarity cTnI Calibrators onto the Sgx Clarity System per the instructions provided in the Sgx Clarity System Operator’s
Manual. Note: Sgx Clarity cTnI Calibrators are lot-matched with Sgx Clarity cTnI Reagent Pack lots, as noted in their respective package
inserts. Sgx Clarity cTnI Reagent Packs may only be calibrated on the Sgx Clarity System using the matched Sgx Clarity cTnI Calibrator lot.
• Handling Sgx Clarity cTnI Calibrators:
- Sgx Clarity cTnI Calibrators are stable when stored unopened at 2–8 °C until the expiration date.
- Keep calibrator tubes capped when not in use.
- Store in upright position.
Note: Always use a new Sgx Clarity cTnI Reagent Pack (never opened/loaded on the Sgx Clarity System) to establish reagent lot calibration.
See the Sgx Clarity System Operator’s Manual for detailed calibration instructions.
Quality Control
• Singulex recommends the use of quality control materials provided by Singulex, or other commercially available quality control material
with at least four levels. An acceptable level of performance is achieved when the control values obtained are within the acceptable
control range, as defined by an appropriate internal laboratory quality control scheme. 
• In addition to site requirements, required control levels and frequency of quality control runs may be dictated by local government
regulations or accreditation requirements.
• Prior to use, control lots must be configured by an administrator-level user within the Sgx Vision Software. For detailed instructions on
configuring control lots, refer to the Sgx Clarity System Operator’s Manual. 
• Required Control Volume
- Required control volume is dependent on the number of replicates and the additional volume required for the Sgx Clarity System to 
initiate aspiration (dead space volume): 
- Dispense 300 μL (if run in singlicate) or 400 μL (if run in duplicate) of each control level to a Low Volume Sample Cup and load onto 
the Sgx Clarity System per the instructions provided in the Sgx Clarity System Operator’s Manual 
• Configure and load all QC samples per the instructions provided in the Sgx Clarity System Operator’s Manual. 
• If the quality control results do not fall within the expected values provided by the manufacturer, or if they are not within the laboratory’s
established values, do not report patient results and take the following actions:
- Verify that the materials are not expired.
- Verify that the required maintenance was performed on the Sgx Clarity System. 
- Verify that the assay was performed according to these Instructions For Use.
- Rerun the assay with fresh controls.
- Perform a re-calibration and retest controls if a rerun of fresh controls fails.
- If necessary, contact Singulex Technical Support.
Sample Volume
This assay requires 100 μL of sample for a single test. This volume does not include the unusable volume in the sample container or
primary tube (i.e. dead space volume). For the total sample volume required for the Sgx Clarity System (volume that must be present
within the tube to ensure accurate pipetting), refer to the Sgx Clarity System Operator’s Manual. 
Number of Control Replicates Low Volume Sample Cup* Dead 
Space Volume 
Sample Processing Volume Total Control Volume 
1 200 μL 100 μL 300 μL 
2 200 μL 200 μL 400 μL 
*0.5 mL Nalgene™ Vial 
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Sample Dilution
• Patient samples with troponin I levels reported as greater than 25,000 pg/mL must be diluted and retested to obtain numerical results if
a numerical result is required.
- If the sample result is beyond the reportable range of the Sgx Clarity cTnI Assay, perform a sample dilution using Phosphate Buffered 
Saline (PBS not included—refer to "Optional Materials" for recommended diluents).
- An initial dilution of 1/10 is recommended (1 part sample to 9 parts PBS). 
- Enter the dilution factor upon loading onto the Sgx Clarity System per instructions provided in the Sgx Clarity System Operator’s 
Manual.
• If a dilution factor is entered when scheduling the test, the Sgx Clarity System automatically calculates the result.
Assay Procedure
• All Sgx Clarity cTnI Assay processing steps are automated on the Sgx Clarity System. Prepare samples and reagents according to the
instructions provided in these instructions for use, then load onto the Sgx Clarity System and initiate assay processing per instructions
provided in the Sgx Clarity System Operator’s Manual. 
ANALYTICAL PARAMETERS
• The Sgx Clarity System reports the troponin I results in pg/mL. 
• The Sgx Clarity cTnI Assay quantitative range is 0.14 pg/mL – 25,000 pg/mL.
LIMITATIONS
• Although the Sgx Clarity cTnI Reagents have been formulated to minimize heterophilic interference, heterophilic antibodies in human
plasma may react with reagent immunoglobulins, interfering with in vitro diagnostics immunoassays.
• Patients routinely exposed to animals, or to animal serum or plasma products, may be prone to this type of assay interference and
anomalous values may be observed when testing samples from these individuals.
• Samples from patients receiving preparations of mouse monoclonal antibodies for therapy or diagnosis may contain Human Anti-Mouse
Antibodies (HAMA). These samples may show either falsely elevated or falsely depressed values when tested, even though the assay
has been formulated to minimize interference from HAMA.
• The ultra-sensitive performance of this assay may, in rare instances, result in potential sensitivity to some environmental contaminants.
Precautions have been taken in the design of the instrument and the assay to reduce this risk, however assay results that are not
consistent with other clinical observations may require a retest to confirm the initial result.  Results should always be assessed in
conjunction with the patient’s medical history, clinical examination, and other findings.
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PERFORMANCE CHARACTERISTICS
Data provided in this section were generated using the Sgx Clarity System. Assay results obtained in individual laboratories may vary from
data presented here.
Precision/Reproducibility 
Precision of the Sgx Clarity cTnI Assay was tested following a two-part precision study informed by Chapters 3 and 4 of the CLSI EP05-A3
guideline for Evaluation of Precision of Quantitative Measurement Procedures. For the first part of the study (Table 1), 2 operators at one
CLIA-certified laboratory tested 2 replicates per panel member of a 10-member panel on one Sgx Clarity System daily for 20 days using 3
different lots of Sgx Clarity cTnI Assay reagents. For the second part of the study (Table 2), 2 operators at each of 3 CLIA-certified
laboratories tested 1 lot of Sgx Clarity cTnI assay reagents for 5 days with 3 replicates per panel member of a 10-member panel on a single
Sgx Clarity System. The 10-member panel had members ranging from 1 pg/mL to 10,000 pg/mL. 
Table 1. Precision Estimates for 20-day, Multi-Lot, Single-Site Study 
Panel Member 
(pg/mL)
Lot Mean N Day-to-Day Repeatability
SD %CV SD %CV
1 A 1.03 79 0.04 4.07 0.09 8.94
B 0.98 78 0.02 2.05 0.08 7.98
C 0.96 78 0.03 2.84 0.1 10
5 A 5.51 80 0.25 4.58 0.37 6.8
B 5.28 80 0.25 4.74 0.3 5.64
C 5.06 79 0.22 4.26 0.29 5.8
10 A 10.99 80 0.54 4.89 0.6 5.45
B 10.57 80 0.26 2.48 0.47 4.45
C 10.47 80 0.46 4.39 0.53 5.02
15 A 17.21 80 0 0 1.19 6.91
B 16.69 79 0.24 1.45 0.69 4.15
C 16.35 79 0.38 2.3 0.78 4.79
20 A 21.99 79 1.05 4.78 0.97 4.43
B 21.15 80 0.47 2.21 1.02 4.84
C 20.7 80 0.59 2.83 1 4.84
100 A 107.98 79 4.4 4.07 4.94 4.57
B 96.68 80 2.13 2.21 3.73 3.86
C 100.62 80 4.46 4.43 4.35 4.33
200 A 239.63 79 13.36 5.57 20.95 8.74
B 224.56 80 6.25 2.78 15.53 6.92
C 218.9 79 11.3 5.16 15.3 6.99
500 A 572.13 79 21.85 3.82 22.92 4.01
B 527.07 80 8.96 1.7 16.67 3.16
C 543.72 80 23.49 4.32 24.03 4.42
1000 A 1090.64 80 47.97 4.4 41.92 3.84
B 988.95 79 17.64 1.78 34.88 3.53
C 1046.89 80 44.33 4.23 50.99 4.87
10,000 A 11115.92 79 410.46 3.69 545.35 4.91
B 9867.38 80 165.71 1.68 324.73 3.29
C 10828.73 80 325.05 3 372.64 3.44
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Table 2. Precision Estimates for 5-Day, Single-Lot, Multi-Site Study 
Panel Member 
(pg/mL)
Site Mean Repeatability Within Laboratory Reproducibility
SD CV(%) SD CV(%) SD CV(%)
1 1 1 0.09 9 0.1 10         
2 1.15 0.1 9 0.12 10         
3 1.12 0.11 9.4 0.11 10         
All Sites 1.09 0.1 9.2 0.11 10 0.13 12
5 1 5.39 0.28 5.3 0.34 6.3         
2 5.98 0.38 6.3 0.45 7.5         
3 6.21 0.54 8.7 0.55 8.8         
All Sites 5.86 0.42 7.1 0.45 7.7 0.61 10
10 1 10.7 0.52 4.9 0.6 5.6         
2 11.88 0.68 5.7 0.77 6.5         
3 11.52 0.42 3.7 0.52 4.5         
All Sites 11.36 0.55 4.8 0.64 5.6 0.87 7.6
15 1 16.94 0.93 5.5 0.97 5.7         
2 17.95 0.98 5.4 0.98 5.4         
3 17.96 1.03 5.7 1.22 6.8         
All Sites 17.62 0.99 5.6 1.06 6 1.18 6.7
20 1 21.44 1.2 5.6 1.36 6.3         
2 22.52 1.02 4.5 1.18 5.3         
3 22.18 1.46 6.6 1.7 7.7         
All Sites 22.04 1.25 5.7 1.43 6.5 1.49 6.7
100 1 96.13 4.08 4.2 5.84 6.1         
2 96.97 6.33 6.5 6.41 6.6         
3 97.57 4.89 5 5.27 5.4         
All Sites 96.89 5.22 5.4 5.77 6 5.77 6
200 1 224.62 16.3 7.3 17.3 7.7         
2 233.23 16.4 7 16.9 7.3         
3 221.05 15 6.8 15.7 7.1         
All Sites 226.3 16 7.1 16.6 7.4 17.43 7.7
500 1 524.12 27.6 5.3 34.2 6.5         
2 546.24 21.1 3.9 23.2 4.2         
3 549.34 21 3.8 22.2 4         
All Sites 539.79 23.7 4.4 27.1 5 29.49 5.5
1000 1 992.14 40.6 4.1 44.8 4.5         
2 1013.8 68.9 6.8 82.4 8.1         
3 1008.4 41.4 4.1 42.3 4.2         
All Sites 1004.8 52.7 5.2 59 5.9 59.02 5.9
10000 1 9851 554 5.6 554 5.6         
2 9953.2 358 3.6 418 4.2         
3 10048 499 5 683 6.8         
All Sites 9950.9 488 4.9 552 5.5 551.9 5.5
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Linearity/Reportable Range
Linearity of the Sgx Clarity cTnI Assay run on the Sgx Clarity System was evaluated in accordance with CLSI EP6-A guideline using one
reagent lot and one Sgx Clarity System testing EDTA plasma samples spiked with native cardiac troponin I analyte. The study reported here
evaluated linearity using 11 sample dilutions of varying analyte concentrations spanning the range from 0.08 to 25,000 pg/mL. Four (4)
replicates of each of 11 dilutions were tested and analyzed. For the range from 0.08 to 25,000 ng/mL, the 2nd and 3rd order polynomial fits
were no better than a linear fit to within 10% nonlinearity. Therefore, the acceptable linearity includes the reportable range from 0.14 to
25,000 pg/mL cTnI for the Sgx Clarity cTnI Assay. 
Hook Effect: The Sgx Clarity cTnI Assay demonstrated that there was no high dose hook effect up to 1000 ng/mL.
Expected Values/Traceability
• The Sgx Clarity cTnI Assay is traceable to the NIST Standard SRM2921.
• The Sgx Clarity cTnI Calibrators and Sgx Clarity cTnI Controls are prepared from commercially-available human cardiac troponin
complex. Sgx Clarity cTnI Calibrators and Sgx Clarity cTnI Controls are value assigned against a cTnI Master Standard Curve, which is
traceable to NIST SRM2921.
Sensitivity/Detection Limit [LoD,LoB,LoQ]
The limit of blank (LoB) and limit of detection (LoD) studies were performed following the recommendations in EP17-A2. Testing was
performed over 3 days using 2 reagent lots, 1 instrument, and 2 calibration cycles.
To calculate the LoB, 4 blank samples were measured in replicates of 5 on each day of testing over 3 days for each reagent lot. To estimate
the LoD, 4 low cTnI positive EDTA plasma samples were measured in replicates of 5 on each day of testing over 3 days for each reagent
lot. Using a non-parametric model, the LoB was calculated to be 0.02 pg/mL and the LoD was calculated to be 0.08 pg/mL.
To estimate the LoQ, 10 EDTA plasma samples containing low levels of cTnI analyte were measured in replicates of 4 over 3 days on 1
instrument and 2 reagent lots. The LoQ was calculated using a precision profile/functional sensitivity approach, whereby the LoQ at 20%
CV was calculated to be 0.14 pg/mL. The 10% functional sensitivity was calculated to be 0.53 pg/mL.
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Analytical Specificity
• Potentially Interfering Substances
The following potentially interfering exogenous compounds, at the following concentrations (Table 3), did not interfere with Sgx cTnI Assay
performance on the Sgx Clarity System (i.e., did not result in bias >10%).
Table 3. Exogenous Interference Substances That Do Not Interfere with the Sgx Clarity cTnI Assay
• HAMA: Studies conducted indicate that the Sgx Clarity cTnI Assay formulation reduces the effects of interference from heterophilic antibodies.
The following potentially interfering endogenous substances, at the concentrations listed below, did not interfere with Sgx Clarity cTnI
Assay performance on the Sgx Clarity System (i.e., did not result in bias >10%).
Potentially Interfering Substance Interfering Substance Interferent Concentration
Acetaminophen 1134 μmol/L
Acetylsalicyclic acid 2.54 μmol/L
Amlodipine besylate 245 nmol/L
Ampicillin 152 μmol/L
Ascorbic acid 342 μmol/L
Atenolol 37.6 μmol/L
Caffeine 308 μmol/L
Captopril 23 μmol/L
Chloramphenicol 155 μmol/L
Digoxin 7.8 nmol/L
Diltiazem hydrochloride 15 μmol/L
Dopamine hydrochloride 5.87 μmol/L
Enalaprilat 0.86 μmol/L
Furosemide 181 μmol/L
Hydrochlorothiazide 20.2 μmol/L
Indomethacin 100 μmol/L
Lisinopril 0.74 μmol/L
Nifedipine 1156 nmol/L
Quinidine 37 μmol/L
Ramipril 28.8 μmol/L
Spironolactone 1.44 μmol/L
Theophylline 222 μmol/L
Verapamil hydrochloride 4.4 μmol/L
Warfarin 32.5 μmol/L
Table 4. Summary of Endogenous Interference Substances That Do Not Interfere with the Sgx Clarity cTnI Assay
Potentially Interfering Substance Interfering Substance Interferent Concentration
Biotin 290 ng/mL
Cholesterol 13 mmol/L
Unconjugated bilirubin 342 μmol/L
Conjugated bilirubin 342 μmol/L
Triglycerides (Intralipid) 37 mmol/L
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The following are included as limitations:
• Samples showing visible signs of hemolysis may cause interference. Falsely depressed results were obtained when using samples with
hemoglobin concentrations >5 g/L, the lowest concentration of hemoglobin tested. The specific amount of hemoglobin that can be
present without causing a >10% bias will be determined in subsequent studies.
• Samples with high protein concentrations resulting in increased sample viscosity may cause interference. Falsely depressed results are
obtained when using samples with bovine serum albumin concentrations >30 g/L, the lowest concentration of albumin tested. The
specific amount of albumin that can be present without causing a >10% bias will be determined in subsequent studies.
Cross-Reactivity
The Sgx Clarity cTnI Assay has no significant cross-reactivity (<1%) to cardiac TnI (cTnI) when cross-reactants listed in Table 5 were tested
at 1000 ng/ml. 
Reference Range 
Singulex conducted a reference range study based on guidance from Clinical and Laboratory Standards Institute (CLSI) document
EP28-A3c. Donor samples were collected from 5 sites in the United States to establish the 99th percentile upper reference limit (URL) in a
population of apparently healthy adults with no known disease of the cardiovascular system or chronic disease. Patients were excluded
from the reference range if they had a history of CVD, angina complaints, heart failure, renal disease, diabetes, skeletal muscular disease,
rheumatoid arthritis, vascular disease, chronic inflammatory disease, immediate family history of CVD, cancer, thyroid disease, chronic or
systematic disease, recent CVD hospitalization, stroke, or an abnormal blood test result for NTproBNP or Creatinine. Extreme athletes and
pregnant women were also excluded.
Result from this study demonstrated the 99th percentile upper reference limit (URL) to be < 8.67 pg/mL. 
Table 5. Cross-Reactivity
Cross-Reactant Tested Cross-Reactant Source % Cross-Reactivity
Sample 1 (≈2.5pg/mL)
% Cross-Reactivity
Sample 2 (≈50pg/mL)
Skeletal Troponin T-1 Recombinant Protein 0.00% 0.00%
Skeletal Troponin T-3 Recombinant Protein 0.00% 0.00%
Cardiac Troponin C Purified Protein 0.00% 0.00%
Skeletal Troponin I Purified Protein 0.00% 0.00%
Cardiac Troponin T Purified Protein 0.21% 0.21%
Cardiac Myosin Heavy 
Chain
Purified Protein 0.00% 0.00%
Cardiac Myosin Light 
Chain
Purified Protein 0.08% 0.08%
Cardiac Tropomyosin Purified Protein 0.02% 0.02%
Table 6. 99th Percentile Upper Reference Limit of a Healthy Population
N Age Range (years) 99th Percentile
536 18-84  < 8.67 pg/mL
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Clinical Results - Rule-Out of Cardiac Ischemia
Using samples obtained from the Basel VIII cohort (Biochemical and Electrocardiographic Signatures in the Detection of Exercise-induced
Myocardial Ischemia, NCT01838148), a study was performed to assess the diagnostic test characteristics of the Sgx Clarity cTnI Assay for
ruling out myocardial ischemia in patients with suspected coronary artery disease (CAD). 
Five hundred and fifty-five (555) consecutive patients with suspected stress-induced myocardial ischemia and without previously known
CAD were tested with myocardial perfusion imaging utilizing single-photon emission computed tomography (MPI-SPECT). Clinical
judgment assessing the probability of stress-induced myocardial ischemia was performed by the treating cardiologist on a visual analogue
scale (VAS; range: 0%–100%) before (pre-stress VAS) and after (post-stress VAS) MPI-SPECT. Venous blood was collected prior to stress
MPI-SPECT testing, and cardiac troponin I (cTnI) concentrations were measured in EDTA plasma using the Sgx Clarity cTnI Assay. 
Diagnosis of stress-induced myocardial ischemia was adjudicated by two board-certified cardiologists based on interpretation of MPI-
SPECT images combined with information obtained from elective coronary angiography, when available. The observed prevalence of
myocardial ischemia was 19%.
The negative predictive value (NPV), positive predictive value (PPV), sensitivity, and specificity for multiple cTnI cutoff concentrations are
summarized in Table 7. 
Abbreviations used: cTnI (cardiac troponin I); pre-VAS (clinical judgment before stress testing quantified on a visual analogue
scale); CI (confidence interval). 
The area under the receiver operating curve (AuROC) predicting stress-induced myocardial ischemia was determined for pre-, and post-
stress test clinical judgment (VAS), pre-stress cTnI, and the combination of log-transformed pre-stress cTnI and VAS (Table 8).
aP values for comparison with the combination of pre-stress VAS. 
bP values for comparison with post-stress VAS.
Abbreviations used: AuROC (area under the receiver operating curve); CI (confidence interval); pre-VAS (clinical judgment
before stress testing quantified on a visual analogue scale); post-VAS (clinical judgment after stress testing quantified on
a visual analogue scale); log cTnI (log transformed cardiac troponin I). 
Table 7. Cardiac Troponin I Measurement Using the Sgx Clarity cTnI Assay: Diagnostic Characteristics at Pre-Specified Cutoff Concentrations
Sgx Clarity cTnI Assay 
cutoffs (pg/mL)
Pre-VAS criteria Incidence of 
criteria, n (%)
Sensitivity
(95% CI)
Specificity
(95% CI)
NPV
(95% CI)
PPV
(95% CI)
< 3.0 N/A 479 (86) 30 (22-39) 90 (87-93) 85 (81-88) 41 (30-52)
< 2.0 N/A 422 (76) 44 (35-54) 81 (77-84) 86 (83-89) 35 (27-43)
< 1.0 N/A 243 (44) 76 (67-83) 48 (44-53) 90 (85-93) 25 (21-30)
< 0.5 N/A 68 (12) 94 (88-97) 14 (11-17) 91 (82-96) 20 (17-24)
< 1.0 < 30% 105 (19) 95 (89-98) 22 (19-26) 95 (89-98) 22 (18-26)
< 0.5 < 30% 45 (8) 97 (92-99) 9 (7-12) 93 (82-98) 20 (17-24)
Table 8. AUROC for Predicting Stress-Induced Myocardial Ischemia in 555 Patients Using Clinical Judgment (VAS) and cTnI Measurements with the Sgx 
Clarity cTnI Assay.
AuROC 95% CI P Valuea P Valueb
Pre-stress VAS% 0.684 0.628-0.741 - 0.996
Post-Stress VAS% 0.704 0.644-0.764 0.996 -
cTnI 0.680 0.622-0.739 0.9170 0.5235
Pre-stress VAS + log cTnI 0.728 0.675-0.782 0.0160 0.2973
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Intended Use
The i-STAT® cardiac troponin I (cTnI) test is an in vitro diagnostic test for the quantitative measurement of 
cardiac troponin I (cTnI) in whole blood or plasma.  Measurements of cardiac troponin I are used in the 
diagnosis and treatment of myocardial infarction and as an aid in the risk stratification of patients with acute 
coronary syndromes with respect to their relative risk of mortality.
Method Explanation
The i-STAT cTnI test cartridge uses a two-site enzyme-linked immunosorbant assay (ELISA) method. 
Antibodies specific for human cardiac troponin I (cTnI) are located on an electrochemical sensor fabricated 
on a silicon chip.  Also deposited in another location on the sensor silicon chip is an antibody/alkaline 
phosphatase enzyme conjugate specific to a separate portion of the cTnI molecule.  The whole blood or 
plasma sample is brought into contact with the sensors allowing the enzyme conjugate to dissolve into 
the sample.  The cTnI within the sample becomes labeled with alkaline phosphatase and is captured onto 
the surface of the electrochemical sensor during an incubation period of approximately seven minutes. 
The sample, as well as excess enzyme conjugate, is washed off the sensors.  Within the wash fluid is a 
substrate for the alkaline phosphatase enzyme.  The enzyme bound to the antibody/antigen/antibody 
sandwich cleaves the substrate releasing an electrochemically detectable product.  The electrochemical 
(amperometric) sensor measures this enzyme product which is proportional to the concentration of cTnI 
within the sample.
Contents
Each i-STAT cTnI cartridge provides a sample inlet, sensors to detect the cTnI as described above, and all 
the necessary reagents needed to perform the test.  The cartridge contains a buffer and preservatives.  A list 
of reactive ingredients is indicated below:
Reactive Ingredient Biological Source Minimum Quantity
Antibody/Alkaline Phosphatase Conjugate Caprine IgG :  Bovine Intestine 0.003 μg
IgG Caprine IgG :  Murine IgG 8 μg : 8 μg
Sodium Aminophenyl Phosphate N/A 0.9 mg
Heparin Porcine Intestine 0.45 IU
IgM Murine IgM 0.3 μg
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Metrological Traceability
The i-STAT System test for cardiac troponin-I (cTnI) measures cardiac troponin-I amount-of-substance 
concentration in plasma or the plasma fraction of whole blood (dimension ng mL-1) for in vitro diagnostic 
use.  Cardiac troponin-I values assigned to i-STAT’s controls and calibration verification materials are 
traceable to i-STAT’s working calibrator prepared from human cardiac troponin-ITC complex (Hy-Test 
Ltd., Turku, Finland, catalogue #8T62).  i-STAT System controls and calibration verification materials are 
validated for use only with the i-STAT System and assigned values may not be commutable with other 
methods.  Further information regarding metrological traceability is available from Abbott Point of Care 
Inc.
Reportable Range
The i-STAT cTnI test will report 0.00 to 50.00 ng/mL (μg/L).  Samples above the reportable range will yield 
“>50.00 ng/mL” on the analyzer display screen.  However, the performance characteristics of the i-STAT 
cTnI measurement have not been established for cTnI values above 35.00 ng/mL (μg/L). 
Reference Range
Whole blood and plasma samples from 162 apparently healthy donors were assayed in duplicate using 
three different lots of i-STAT cTnI cartridges.  The 0 to 97.5% range of results spanned 0.00 ng/mL (μg/L) 
to 0.03 ng/mL (μg/L).  The 0 to 99% range of results spanned 0.00 ng/mL (μg/L) to 0.08 ng/mL (μg/L).
Note: Each facility should establish its own reference range using the i-STAT cTnI assay.
Clinical Significance
Biochemical cardiac markers, including cTnI, are useful for both the diagnosis of myocardial infarction and 
the risk stratification that can help guide the choice of therapeutic options.
For optimal diagnostic usefulness, a cardiac marker should be specific for cardiac tissue, should be rapidly 
released into the bloodstream with a direct proportional relationship between the extent of myocardial injury 
and the measured level of the marker, and should persist in blood for a sufficient length of time to provide 
a convenient diagnostic time window.1 The cardiac-specific troponins, troponin I (cTnI) and troponin T 
(cTnT) are considered the biochemical markers of choice in the evaluation of acute coronary syndromes 
(ACS) including ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable 
angina.2,3  Elevated levels of cardiac-specific troponins convey prognostic information beyond that supplied 
by the patients clinical signs and symptoms, the ECG at presentation, and the pre-discharge exercise test.1 
Antman et al. reported that patients with elevated levels of cTnI had a statistically significant increase in 
mortality (p< 0.001).4 Other studies have shown increases in other non-fatal cardiac events such as non-
fatal MI, congestive heart failure, and urgent revascularization with increasing levels of cTnI.5,6,7
The ability for cTnI to be measured at low concentrations allows therapeutic intervention to be considered at 
any elevation above the normal range. Patients that present with no ST-elevation on their ECG but who have 
even slight elevation in cTnI or cTnT may receive a greater treatment benefit from certain drugs such as GP 
IIb/IIIa inhibitors or low molecular weight heparin.8,9,10
A Global Task Force with joint leadership from the European Society of Cardiology (ESC), the American 
College of Cardiology Foundation (ACCF), the American Heart Association (AHA) and the World Heart 
Federation (WHF) refined past criteria of myocardial infarction with a universal definition of myocardial 
infarction that supports the use of cTnI as a preferred biomarker for myocardial injury.  The universal 
definition of MI according to this task force is defined as a typical rise and gradual fall of cardiac biomarkers 
(preferably troponin) with at least one value above the 99th percentile of the upper reference limit (URL) 
together with evidence of myocardial ischemia with at least one of the following: ischemic symptoms, 
pathological Q waves on electrocardiogram (ECG), ischemic ECG changes, or imaging evidence of new 
loss of viable myocardium or new regional wall motion abnormality.2  An elevated troponin value alone is 
not sufficient to diagnose a myocardial infarction. Rather, the patient’s clinical presentation (history, physical 
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exam) and ECG should be used in conjunction with troponin in the diagnostic evaluation of suspected 
myocardial infarction.3 A serial sampling protocol is recommended to facilitate the identification of temporal 
changes in troponin levels characteristic of MI.2,3,11 
Since cTnI is not unequivocably detectable by commercial assays in samples from healthy persons, 
measurements beyond the upper limit of the reference range have a significant probability of being 
associated with ischemia or necrosis;12 this probability increases with the measured troponin concentration. 
Nonetheless, by definition, results beyond the reference range will occur in a normal population in healthy 
individuals in the absence of myocardial necrosis, i.e., a result beyond the 99th percentile does not confirm 
the presence of troponin with absolute certainty. Each institution should determine the reference range and 
decision levels appropriate to its specific patient population and clinical practice.
Acute myocardial injury is evidenced by temporal changes in troponin levels while consistent elevations 
of troponin may be suggestive of other chronic cardiac or non-cardiac conditions. There are many clinical 
conditions that can lead to an elevated troponin level without ischemic coronary artery disease. Such 
conditions include blunt trauma, myocarditis, congestive heart failure, left ventricular hypertrophy etc.13,14 
These clinical conditions should be considered when interpreting results. The use of serial sampling with 
a consistent troponin methodology can identify temporal troponin changes, as well as provide additional 
information that can assist in the clinical diagnosis for those patients with low-level results.  Where there are 
inconsistencies in the clinical information or where diagnostic criteria are not fully satisfied, the possibility of 
biased results should be recognized – see Test Limitations. 
Performance Characteristics
Precision data were collected in multiple sites as follows:  Duplicates of each control were tested daily for a 
period of 20 days, resulting in a total of 40 replicates.  The average statistics are presented below.
Method comparison data were collected using CLSI guideline EP9-A2.15 Venous blood samples were 
collected in heparinized evacuated tubes and analyzed in duplicate on the i-STAT System.  A portion of the 
specimen was centrifuged and the separated plasma was analyzed in duplicate on the comparative method 
within 1 hour of collection.
Deming regression analysis16 was performed on the first replicate of each sample.  In the method 
comparison table, n is the number of specimens in the first data set, Sxx and Syy refer to estimates of 
imprecision based on the duplicates of the comparative and the i-STAT methods respectively.  Sy.x is the 
standard error of the estimate, and r is the correlation coefficient.*
Method comparisons will vary from site to site due to differences in sample handling, comparative method 
calibration and other site specific variables.
Interference studies were based on CLSI guideline EP7.17
*The usual warning relating to the use of regression analysis is summarized here as a reminder.  For any analyte, “if the data is a narrow range, the 
estimate of the regression parameters are relatively imprecise and may be biased.  Therefore, predictions made from estimates may be invalid”.13 The 
correlation coefficient, r, can be used as a guide to assess the adequacy of the comparative method range in overcoming the problem.  As a guide, the 
range of data can be considered adequate if r>0.975.
Precision Data (ng/mL)
Control Mean SD %CV
Level 1 0.53 0.04 7.8
Level 2 2.17 0.18 8.5
Level 3 31.82 2.42 7.6
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Method Comparison (ng/mL)
Dade Behring 
Stratus® CS
n 189
Sxx 0.28
Syy 0.31
Slope 0.883
Int’t 0.029
Sy.x 1.40
Xmin 0.00
Xmax 46.27
r 0.975
Analytical and Functional Sensitivities
The analytical sensitivity of the cTnI method is 0.02 ng/mL, which is the lowest cTnI level that can be 
distinguished from zero.  The analytical sensitivity is defined as the concentration at two standard deviations 
from a sample at 0.00 ng/mL.  
Another characteristic of an analytical measurement is the functional sensitivity, which is defined as the cTnI 
level at which the test method displays a particular percent coefficient of variation (%CV).  Estimates of the 
20% and 10% functional sensitivity for the cTnI method were determined from whole blood measurements. 
The 20% and 10% functional sensitivities for the cTnI method are 0.07 ng/mL and 0.10 ng/mL, respectively 
(see graph below).
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Analytical Specificity
The cTnI method is specific for cardiac troponin I.  The following muscle proteins were tested and found to 
have an insignificant effect on the measured cTnI.
Crossreactant Concentration Percent Crossreactivity
Troponin C (cardiac) 1000 ng/mL <0.002%
Troponin T (cardiac) 1000 ng/mL 0.65%
Troponin I (skeletal) 1000 ng/mL <0.002%
Troponin T (skeletal) 1000 ng/mL <0.002%
Recovery
The dilution linearity of the i-STAT cTnI test was investigated using heparinized whole blood and plasma 
samples derived from 3 separate donors.  For each donor, the original cTnI negative sample and a cTnI 
spiked sample were prepared.  This process yielded three cTnI positive whole blood samples that were then 
assayed in duplicate for each of three separate i-STAT cTnI cartridge lots.  These whole blood samples were 
then diluted using an equal mass of the original unspiked whole blood and assayed in duplicate.   From this 
whole blood data, the cTnI recovery was calculated.
The plasma derived from these three donors was combined in equal masses and all pairwise combinations. 
These combinations were then assayed in duplicate for each of three separate i-STAT cTnI cartridge lots. 
The cTnI recovery for each pair was calculated using the average of the 6 results.  The % recoveries are 
listed in the Tables below.
Whole blood
Sample Concentration Diluted Concentration % Recovery
A 2.05 1.04 101%
B 6.31 3.14 100%
C 27.04 14.05 104%
Plasma
Sample Concentration Diluted Concentration % Recovery
A 2.41 ----- -----
B 7.50 ----- -----
C 29.35 ----- -----
A+B ----- 4.69 95%
B+C ----- 18.90 103%
A+C ----- 16.89 106%
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Test Limitations
The frequency of suppressed results is affected by atmospheric pressure.   Suppressed result rates may 
increase with higher elevations (decreased barometric pressure) and may become persistent if testing is 
performed at more than 7500 feet above sea level.  Where unavailability of results is unacceptable, i-STAT 
recommends having an alternate test method available. 
Samples from patients who have been exposed to animals or who have received therapeutic or diagnostic 
procedures employing immunoglobulins or reagents derived from immunoglobulins may contain antibodies, 
e.g., HAMA or other heterophile antibodies, which may interfere with immunoassays and produce erroneous 
results.18-24 The generation of potentially interfering antibodies in response to bacterial infections has been 
reported.16 While this product contains reagents that minimize the effect of these interferents and QC 
algorithms designed to detect their effects, the possibility of interference causing erroneous results should 
be evaluated carefully in cases where there are inconsistencies in the clinical information. Results from the 
i-STAT cTnI assay should be considered in the context of the entirety of the available clinical information. 
Medical decisions should not be based on a single i-STAT measurement.14  
Cardiac troponin may not appear in circulation for 4-6 hours following the onset of symptoms of MI. 
Consequently, a single negative result is insufficient to rule out MI.  The use of a serial sampling protocol is 
recommended practice.11
The results of different troponin assays are not generally comparable: cTnI and cTnT are distinct molecules 
and results are not interchangeable, nor comparable. In addition, significant variation in absolute troponin 
values may be observed for a given patient specimen with different analytic methods.13
Partially clotted samples can result in elevated cTnI results above the reference range, as well as quality 
check code errors.  To prevent this from occurring, upon drawing the whole blood sample into a heparinized 
collection tube, the sample should be inverted gently at least 10 times to ensure even dissolution of the 
heparin anticoagulant.
Grossly hemolyzed samples can cause a decreased alkaline phosphatase activity, resulting in decreased 
detection of cTnI, increased assay backgrounds, and/or quality check codes.
Hematocrits in the range of 0-65% PCV have been demonstrated not to affect results. Samples with 
hematocrit levels above this range have demonstrated increases in the test imprecision and quality check 
codes.
The analyzer must remain on a level surface with the display facing up during testing. Motion of the analyzer 
during testing can increase the frequency of suppressed results or quality check codes.  A level surface 
includes running the handheld in the downloader/recharger.
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Interference Testing
The following substances were found to have no significant effect (less than 10%) on the cTnI method, 
when added to a plasma pool containing approximately 2 ng/mL of cardiac troponin I, at the concentrations 
indicated:
Compound Test Level  (μmol/L unless otherwise indicated)
Acetaminophen 1660
Allopurinol 294
Ascorbic Acid 227
Acetyl Salicylic Acid 3330
Atenolol 37.6
Caffeine 308
Captopril 23
Chloramphenicol 155
Diclofenac 169
Digoxin 6.15
Dopamine 5.87
Enalaprilat 0.86
Erythromycin 81.6
Furosemide 181
Sodium Heparin* 36 U/mL
Ibuprofen 2425
Isosorbide dinitrate 636
Methyldopa 71
Nicotine 6.2
Nifedipine 1.156
Phenytoin 198
Propranolol 7.71
Salicylic Acid 4340
Theophylline 222
Verapamil 4.4
Warfarin 64.9
*Heparin at 90 U/mL was found to decrease the cTnI level by approximately 20%.
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